Programme book

OCTOBER 5-8

www.ever.be

EVER 2016

NICE

Science for Sight

EUPO course in conjunction with EVER

22 CME
Find a list of countries where XEN is available at the Allergan stand.

Adverse events should be reported to your local regulatory authority and Allergan office. XEN is not commercially available in France.
Dear EVER members, colleagues and friends,

2016 heralds an exciting and animated month of October as EVER and EUPO (the European Professors of Ophthalmology group) come together for a grand event. This meeting is not to be missed!

As in previous years, EVER offers a varied menu of fundamental fare and house specialties. These include board preparation sessions, clinical courses, topic-specific symposia, state-of-the-art research platforms, keynote lectures and a broad palette of scientific posters. The “extra” in 2016 will be the EUPO courses dedicated to neuro-ophthalmology and strabismus. These are CME accredited courses which will run in parallel with the EVER scientific program during Friday and Saturday (October 7-8). EUPO courses are intended to assist the preparation of young ophthalmologists for the European Board of Ophthalmology examination and also serve as excellent refresher courses for any practicing ophthalmologist.

I am delighted to announce that EVER offers open general admission to EUPO courses for all EVER meeting registrants (without an increase in registration fee from the previous year!). Likewise, EUPO attendees will have open access to the EVER program on those 2 shared days. And as EVER and EUPO boast a strong international faculty, this is a win-win situation for all!

At EVER, we strive for growth, advancement and improvement in ophthalmology and visual science. This may sound like the oft-heard rally cry of “more, bigger and better” which, in practice, often translates to harried, stressed and rushed. Rest assured that EVER is none of that. The beautiful relaxed atmosphere of the French Riviera is once again home to the EVER meeting. Over 4 sunny days in Nice, after the scientific day, enjoy a stroll through the fresh market, take a dip in the Mediterranean waters and savor tasty gourmet dishes on an open terrace.

So join me at EVER-EUPO 2016. It will be a stimulating experience!

Aki KAWASAKI
President EVER 2016
L’innovation en Ophtalmologie va bien au-delà des médicaments

Téléchargez l’Application Retina Base pour tablettes tactiles sur l’App Store® ou le Google Play® et découvrez plus de 120 cas cliniques de pathologies rétiniennes rédigés par des experts, disponibles en Français et en Anglais.

- Naviguez à travers l’organisation planétaire des pathologies et cas cliniques.
- Recherchez facilement les clichés grâce au moteur de recherche intuitif et filtrez les résultats par mot-clé, technique d’imagerie et auteur.
- Recevez les notifications dès que de nouveaux cas sont disponibles.

Rendez-vous sur www.viaopta.fr pour découvrir ou redécouvrir tous les services ViaOpta™ dédiés à l’ophtalmologie
Word from the president ................................................................. 1
About EVER .................................................................................. 4
Composition of the board 2016 ..................................................... 8
Congress information ..................................................................... 10
Grants and prizes ........................................................................ 14
Floorplan ....................................................................................... 16
Partners of EVER ........................................................................ 18
About the programme book .......................................................... 20
Scientific sections 2016 ................................................................. 21
Industry Sponsored Symposia ...................................................... 22
Courses ......................................................................................... 23

Wednesday, October 5 .................................................................. 25
Noon session .................................................................................. 26
First afternoon session ................................................................. 30
Opening Ceremony ........................................................................ 35
Second afternoon session ............................................................. 36
European Ophthalmology Heritage Lecture - Luc MISSOTTEN .......... 40
Keynote Lecture - Robert MACLAREN ......................................... 41
Welcome reception ....................................................................... 43

Thursday, October 6 .................................................................... 45
First morning session .................................................................... 46
EVER-Acta lecture - John GREENWOOD ...................................... 51
Second morning session ............................................................... 52
Lunchtime session - CIS ............................................................... 56
Keynote Lecture - Shigeru KINOSHITA ........................................ 59
First afternoon session ................................................................. 60
Poster session 1 ............................................................................ 65
Second afternoon session ............................................................. 74
Evening session ........................................................................... 79

Friday, October 7 .......................................................................... 81
First morning session .................................................................... 82
Keynote Lecture - Marcela VOTRUBA ......................................... 87
Second morning session ............................................................... 88
First afternoon session ................................................................. 92
Poster session 2 ............................................................................ 97
Second afternoon session ............................................................. 106
Section Business Meetings ......................................................... 107
Second afternoon session ............................................................. 108
General Assembly ........................................................................ 113

Saturday, October 8 ................................................................. 115
First morning session .................................................................... 116
Ophthalmic Research Lecture - Marie-José TASSIGNON .............. 119
Second morning session ............................................................... 120
Poster session 3 ............................................................................ 121
First afternoon session ................................................................. 130
Prize award ceremony and Closing Remarks .................................... 133

EUPO Course programme overview ............................................ 134-135

Presenting first authors .................................................................. 147
Presenting all authors .................................................................... 153
Authors by Country ....................................................................... 163
Congress time schedule ............................................................... 164-165
Sponsors ........................................................................................ back cover
The European Association for Vision and Eye Research, EVER, is a non-profit organisation. The aims of the association are to encourage research and the dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information. EVER is the leading ophthalmological research association in Europe which covers all areas of ophthalmology and the visual sciences. It provides an umbrella for other ophthalmological societies to meet during its annual congress and is an excellent place for networking.

Membership

EVER currently has members from 50 countries all over the world and represented by 11 scientific sections. Membership is open to individuals of any nationality, engaging in or with an interest in ophthalmic and vision research. Applications for membership - available on www.ever.be - may be submitted at any time, membership is on calendar year basis and starts on January 1. Every member must select one of the 11 scientific sections that best represents his or her primary area of interest.

The benefits of EVER membership are:

- significantly reduced registration fees for annual meeting
- submission of abstracts at annual meeting
- organizing Special Interest Symposia (SIS) and Courses
- free electronic subscription to the EVER journal, Acta Ophthalmologica (IF 2.844)
- voting rights for the election of the Board Members
- travel grants and poster prizes
- quarterly E-Newsletter

Elections 2016

In 2016 new representatives of the scientific sections

- IM Immunology / Microbiology
- PBP Physiology / Biochemistry / Pharmacology

will be elected through electronic voting. Voting 2016 will close on October 6, midnight. The result of the elections will be announced at the General Assembly on Friday, October 7, 18:00 -18:30.

Website: www.ever.be

On this website, you can

- obtain up-to-date information about the scientific programme and the EVER 2016 meeting and view the status (session, hour, place) of your presentation
- pay on-line and print your invoice
- access general information about EVER
- access Acta Ophthalmologica, the EVER journal
- cast your vote for officers
- print CME certificate after each congress you attended
### Speakers’ affiliation to scientific sections

<table>
<thead>
<tr>
<th>Section</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>G (Glaucoma)</td>
<td>16%</td>
</tr>
<tr>
<td>RV (Retina / Vitreous)</td>
<td>15%</td>
</tr>
<tr>
<td>COS (Cornea / Ocular Surface)</td>
<td>14%</td>
</tr>
<tr>
<td>NSPH (Neuro-ophthalmology / Strabismology / Paediatric / History)</td>
<td>8%</td>
</tr>
<tr>
<td>PBP (Physiology / Biochemistry / Pharmacology)</td>
<td>8%</td>
</tr>
<tr>
<td>MBGE (Molecular Biology / Genetics / Epidemiology)</td>
<td>8%</td>
</tr>
<tr>
<td>ACB (Anatomy / Cell Biology)</td>
<td>7%</td>
</tr>
<tr>
<td>PO (Pathology / Oncology)</td>
<td>7%</td>
</tr>
<tr>
<td>LC (Lens / Cataract)</td>
<td>6%</td>
</tr>
<tr>
<td>IM (Immunology / Microbiology)</td>
<td>6%</td>
</tr>
<tr>
<td>EOVS (Electrophysiology, physiological Optics, Vision Sciences)</td>
<td>4%</td>
</tr>
</tbody>
</table>

---

**About EVER, European Association for Vision and Eye Research**
EVER is the leading ophthalmological research association in Europe which covers all areas of ophthalmology and the visual sciences. One of the main activities of EVER is the organizing of a high quality research meeting every October at a location chosen for its access and its agreeable autumn climate. EVER collaborates closely with other societies and encourages them to convene annually with EVER.

In 2010, the EVER Foundation was created to raise money to organize EVER Research Fellowships to offer to young ophthalmologists or young vision scientists, especially from Eastern Europe or from developing countries outside Europe, the opportunity to gain experience in laboratory techniques and scientific research in leading European Departments for Vision and Eye Research. The duration of the fellowship is limited to 6 months.

Fellowships 2016:
1. Dr. Mahajan DEEPTI, India, host institute: Vision Lab, Cardiff Centre for Vision Sciences, Cardiff University, UK
2. Dr. Narine ADZHEMIAN, Russia - host institute: Medical University of Vienna, Austria

Fellowships 2015:
1. Dr. Sepehr FEIZI, Iran - host institute: Queens Medical Centre, Nottingham, UK
2. Dr. Sabina SAPETA, Poland - host institute: Medical University of Vienna, Austria

Fellowships 2014:
1. Dr. Ganne PRATYUSHA, India - host institute: Vision Lab, Cardiff Centre for Vision Sciences, Cardiff University, UK
2. Dr. Mohamed Shafik Mohamed ELALFY, Egypt - host institute: Queens Medical Centre, Nottingham, UK

Fellowships 2013:
1. Dr. Reka ALBERT, Hungary - host institute: Queens Medical Centre, Nottingham, UK
2. Dr. Minika JASIELSKA, Poland - host institute: Department of Experimental Ophthalmology at the Charite University Medicine in Berlin, Germany

Acta Ophthalmologica is the official scientific publication of the European Association for Vision and Eye Research (EVER) and of the five Nordic ophthalmological societies. Acta Ophthalmologica publishes clinical and experimental original articles, reviews, editorials, educational photo essays (Diagnosis and Therapy in Ophthalmology), case reports and case series, letters to the editor and doctoral theses. (IF 2.844)
Executive committee

Aki KAWASAKI
President

Bart P LEROY
Past President

Catherine CREUZOT
Secretary General

Andrew DICK
President Elect

Steffen HEEGAARD
Treasurer

Laurence DESJARDINS
Vice President

Marcela VOTRUBA
Programme Secretary

Gerhard GARHÖFER
Vice President

Leopold SCHMETTERER
EVER liaison

EVER office by Mecodi

Marlene VERLAECKT
Executive Officer

Lies VAN EYCKEN
Executive Assistant

Mieke AKKERS
Executive Assistant

Kapucijnenvoer 33, 3000 Leuven, Belgium - ever@ever.be

Website and onsite support

COVR
IT solutions for scientific and medical associations

www.mecodi.eu

www.covr.be
## Composition of the board 2016

### Section chairs

<table>
<thead>
<tr>
<th>Name</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kai KAARNIRANTA</td>
<td>Anatomy / Cell Biology</td>
</tr>
<tr>
<td>Thomas FUCHSLUGER</td>
<td>Cornea / Ocular Surface</td>
</tr>
<tr>
<td>Miguel CASTELO-BRANCO</td>
<td>Electrophysiology, physiological Optics, Vision Sciences</td>
</tr>
<tr>
<td>Alain BRON</td>
<td>Glaucoma</td>
</tr>
<tr>
<td>Andrew DICK</td>
<td>Immunology / Microbiology</td>
</tr>
<tr>
<td>Rafael BARRAQUER</td>
<td>Lens / Cataract</td>
</tr>
<tr>
<td>Jochen GRAW</td>
<td>Molecular Biology / Genetics / Epidemiology</td>
</tr>
<tr>
<td>Dominique BREMOND-GIGNAC</td>
<td>Neuro-ophthalmology / Strabismology / Paediatric / History</td>
</tr>
<tr>
<td>Frédéric MOURIAUX</td>
<td>Pathology / Oncology</td>
</tr>
<tr>
<td>Gerhard GARHÖFER</td>
<td>Physiology / Biochemistry / Pharmacology</td>
</tr>
<tr>
<td>Peter WIEDEMANN</td>
<td>Retina / Vitreous</td>
</tr>
</tbody>
</table>

### EVER representatives in Acta Board

<table>
<thead>
<tr>
<th>Name</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>Constantin POURNARAS</td>
<td></td>
</tr>
<tr>
<td>Leopold SCHMETTERER</td>
<td></td>
</tr>
</tbody>
</table>

### Senior advisory committee

<table>
<thead>
<tr>
<th>Name</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jean-Jacques DE LAEY</td>
<td></td>
</tr>
<tr>
<td>Jost JONAS</td>
<td></td>
</tr>
<tr>
<td>Graham HOLDER</td>
<td></td>
</tr>
<tr>
<td>Einar STEFANSSON</td>
<td></td>
</tr>
</tbody>
</table>

### Representatives

<table>
<thead>
<tr>
<th>Name</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bozena ROMANOWSKA-DIXON</td>
<td>Representative East Europe</td>
</tr>
<tr>
<td>Stephanie BAILLIF</td>
<td>Local representative France</td>
</tr>
</tbody>
</table>
Congress information

Venue

EVER 2016 will be held at the Acropolis Convention Center in Nice, France
⇒ www.nice-acropolis.com
The scientific programme of the EVER congress starts on Wednesday, October 5 at 11:30 and concludes on Saturday, October 8 at 15:00.

Registration

Everyone attending the scientific sessions - whether or not an EVER member - must register and pay the registration fee. Onsite registration starts on Wednesday, Oct 5, 9:00.
Please note that:
• being or becoming an EVER member – or having an abstract accepted – does not imply that you are registered
• if you register as a member-in-training, you need to prove your traineeship with a document signed by the Head of your Department
• if you register as an Eye-care, Technician or Nurse, you need to prove your status

Registration fees on-site

<table>
<thead>
<tr>
<th></th>
<th>EUR</th>
<th>EUR</th>
</tr>
</thead>
<tbody>
<tr>
<td>EVER member / Course invited speakers</td>
<td>455</td>
<td>390</td>
</tr>
<tr>
<td>Member-in-training</td>
<td>250</td>
<td>200</td>
</tr>
<tr>
<td>Non-member</td>
<td>800</td>
<td>645</td>
</tr>
<tr>
<td>Non-member-in-training</td>
<td>400</td>
<td>310</td>
</tr>
<tr>
<td>Eye-Care / Technician / Nurse</td>
<td>200</td>
<td>180</td>
</tr>
</tbody>
</table>

* Citizens of these listed countries only: Albania, Algeria, Armenia, Belarus, Bosnia and Herzegovina, Congo, Egypt, Georgia, Iran, Libya, Macedonia, Moldova, Montenegro, Morocco, Ouzbekistan, Pakistan, Serbia, Tunesia, Ukraine

Welcome reception

The Welcome reception is open for all participants and exhibitors.

• Wednesday 19:30 - 21:30 in the Exhibition area, Acropolis Convention Center

Coffee / tea / refreshments

Included in the registration fee are the coffee / tea and soft drinks offered throughout the whole meeting. In addition coffee & croissants will be served early morning.

Internet access

Wi-Fi internet access is available in the Convention Center.
Photographs

It is strictly forbidden to take photographs or videos of the presentations in all lecture halls. The hostess will ask you to leave the lecture hall immediately and your name will be noted.

No-shows

Please note that any first author, whose paper or poster has been accepted, will be prohibited from presenting papers at EVER for the next two years if a valid reason is not sent to the EVER office in writing.

CME - Continued Medical Education credits

The European Accreditation Council for Continuing Medical Education Institution of the UEMS, EACCME has granted 22 European CME credits (ECMEC) to the EVER 2016 congress on Oct 5 - 8 in Nice, France. CME credit certificates can be printed from the EVER website after the congress.

Liability

The organisers cannot accept liability for personal accidents, loss of or damage to private property of participants and accompanying persons either during, or directly arising from the Meeting. Participants must make their own arrangements with respect to health and travel insurance.

EVER 2016 Congress App

All congress information in a nutshell:
- About EVER
- Floorplan and sponsors
- My congress bag

- My schedule
- News Feeds
- Notes
- Session rating
- etc.
Publication of the abstracts

The abstracts of the EVER 2016 congress are published on-line in a special issue of Acta Ophthalmologica, the EVER journal. Access for members-only through EVER homepage.

Section Business Meetings

EVER Section Business Meetings of the scientific sections
Friday, 16:00 - 16:30

- ACB .................................................. Gallieni 4
- COS .............................................. Rhodes 2
- EOVS .......................................... Rhodes 1
- G ..................................................... Rhodes 1
- IM ................................................. Gallieni 1 & 2
- LC ................................................ Gallieni 5
- MBGE ........................................... Gallieni 1 & 2
- NSHP ........................................... Rhodes 2
- PO ................................................. Rhodes 3
- PBP .............................................. Rhodes 3
- RV ................................................. Hermes

The sections
- COS - Cornea / Ocular Surface
- G - Glaucoma

will nominate at least 2 candidates for the succession of their representatives in the Board of EVER for elections in 2017.

Agenda see page 107

EVER General Assembly

Friday, 18:00 - 18:30 in room Hermes
Agenda see page 113

Prize award ceremony and conclusion of the congress

Saturday, 14:30 - 15:00 in room Hermes
Agenda see page 133

Women 4 EVER

Saturday, October 8 from 13:00 to 14:30 in Hermes

Women 4 EVER wishes to assist women in developing tools for career advancement and to foster gender equality in ophthalmology and visual science. We encourage mentorship, collaboration, and communication. In this informal and open session, we invite all interested members of EVER to come and meet colleagues, share experiences and ask for advice. It is also a venue where ideas about gender-based studies in ophthalmology may be developed. See page 130.
Meet the Experts

Thursday, October 6 from 16:00 - 17:00 in poster area

In an initiative to encourage dialogue amongst speakers and EVER members, we have launched a one hour session called “Meet the Experts”. This will be a table of 6-8 “guests” at a table headed by one of the EVER speakers.

The idea is to provide a casual yet personal venue where colleagues, in particular the younger faction, can share comments and ideas with an expert.

This initiative is scheduled on Thursday, October 6 from 16:00 - 17:00 in poster area. See page 73. Please sign in at the registration desk.

YOS for EVER - young ophthalmologist/scientist

Thursday, October 6 from 17:00 - 18:30 in Rhodes 2

EVER 2016 will introduce a new symposium entitled YOS for EVER. YOS is a well-recognized acronym for “young ophthalmologist” and as not only ophthalmologists attend EVER, YOS stands for “young ophthalmologist/scientist”. YOS for EVER represents the trainee and young specialist group within EVER. This is a networking assembly of students, residents, post-docs and junior scientists to focus on objectives and goals relevant to the early stages of career development. Such topics include board examinations, information exchange, research and/or educational programs, fellowship and job opportunities. The 2016 inaugural symposium will be organized by Gauti Jóhannesson, a young ophthalmologist/scientist and member of the organization committee for YOS sessions at the Nordic Ophthalmologic Congress. All interested parties are encouraged to attend as guidelines and objectives and representatives for this new subgroup will be discussed at this first meeting. Immediately following the symposium, there will be a reception with light food and beverages on site. See page 75.

EUPO course - European University Professors of Ophthalmology

Friday, October 7 and Saturday, October 8 in Rhodes 4.

Each year EUPO organises a 2 days course for residents in training.

This year, the course is on Neuro-ophthalmology (Friday, Oct 7) and Strabismus (Saturday, Oct 8) organized by Aki Kawasaki

The EUPO programme can be consulted in pages 134-135.
EVER section Travel Grants

We are pleased to announce that the following 14 members have received an EVER section Travel Grant of 750 EUR each:

- **ACB** - Daria AFANASYEVA - Russia
  1375 - Angiogenic potential of orbital adipose derived stromal cells

- **COS** - Mette CORRELL - Denmark
  1146 - Graft functionality after DSAEK surgeries in Denmark from 2006 to 2009

- **COS** - Wojciech CZAK - Poland
  2673 - Communication between the researcher and the researched. Designing an application based study regarding effects of air pollution on ocular surface diseases

- **EOVS** - Kevin Sean JENKINS - Australia
  3567 - Systematic Assessment of Clinical Methods to Diagnose and Monitor Diabetic Retinal Neuropathy

- **G** - Shiama BALENDRA - United Kingdom
  1162 - A Curry A Day Keeps Glaucoma Away? - A Curcumin Study

- **G** - Kendrick Co SHIH - China
  1163 - Transcorneal electrical stimulation prevents secondary retinal ganglion cell death after acute ocular hypertensive injury through modulation of microglia-mediated local inflammatory response

- **IM** - Dafina DRAGANOVA - Belgium
  3373 - Validation of an antiretinal antibody detection strategy for the diagnosis of autoimmune retinopathies

- **LC** - Xiaodi QIU - China
  2352 - Effects of histone acetylation on superoxide dismutase 1 gene expression in the pathogenesis of senile cataract

- **MBGE** - Andrea GARCÍA LLORCA - Iceland
  3585 - Autophagy is affected by Mitf in mouse primary RPE cells

- **NSPH** - Ségalène ROEMER - Switzerland
  1551 - Reduced post-illumination pupil response in patients with mild-moderate cataracts is associated with impaired sleep quality

- **PBP** - Olga KUDRYAVTSEVA - Denmark
  2381 - Ca2+ activity during ATP-induced tone changes in porcine retinal arterioles in vitro spreads along the processes of perivascular cells

- **PO** - Joni TURUNEN - Finland
  5087 - BAP1 germline mutations in uveal melanoma patients without family history of eye cancer

- **RV** - David CORDEIRO SOUSA - Portugal
  2685 - Hypoxia and retinal blood flow changes: a study using OCT-Angiography

- **RV** - Koen WILLEKENS - Belgium
  1566 - Robot assisted retinal vein cannulation in an in vivo porcine retinal vein occlusion model

The Travel Grant awards will be handed over during the Prize Award Ceremony on Saturday, 14:30 - 15:00 in room Hermes.
**EVER Poster Prizes**

Poster Prizes of 500 EUR will be awarded for the best posters across all sections. The winners will be chosen by the poster moderators and will be announced in the Prize Award Ceremony on Saturday, 14:30 - 15:00 in room Hermes. No prize will be given after the congress.
Exhibitors

<table>
<thead>
<tr>
<th>Number</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>102</td>
<td>Thea Pharma</td>
</tr>
<tr>
<td>109</td>
<td>Heidelberg Engineering</td>
</tr>
<tr>
<td>111</td>
<td>Charles River</td>
</tr>
<tr>
<td>116</td>
<td>Cambridge Research Systems Ltd</td>
</tr>
<tr>
<td>117</td>
<td>Diagnosys UK Ltd</td>
</tr>
<tr>
<td>104</td>
<td>ARVO</td>
</tr>
<tr>
<td>118</td>
<td>Novartis</td>
</tr>
<tr>
<td>101</td>
<td>Santhera Pharmaceuticals</td>
</tr>
<tr>
<td>110</td>
<td>Bioptigen</td>
</tr>
<tr>
<td>110</td>
<td>Bioptigen</td>
</tr>
<tr>
<td>112</td>
<td>Bayer</td>
</tr>
<tr>
<td>107</td>
<td>Metrovision</td>
</tr>
<tr>
<td>114</td>
<td>Allergan</td>
</tr>
<tr>
<td>115</td>
<td>Topcon</td>
</tr>
<tr>
<td>119</td>
<td>VITO</td>
</tr>
<tr>
<td>103</td>
<td>Wisepress</td>
</tr>
<tr>
<td>105</td>
<td>Horus Pharma</td>
</tr>
<tr>
<td>106</td>
<td>Iris Pharma</td>
</tr>
<tr>
<td>108</td>
<td>LKC Technologies</td>
</tr>
<tr>
<td>109</td>
<td>Heidelberg Engineering</td>
</tr>
<tr>
<td>117</td>
<td>Diagnosys UK Ltd</td>
</tr>
<tr>
<td>107</td>
<td>Metrovision</td>
</tr>
<tr>
<td>118</td>
<td>Novartis</td>
</tr>
<tr>
<td>120</td>
<td>NuVision</td>
</tr>
<tr>
<td>101</td>
<td>Santhera Pharmaceuticals</td>
</tr>
<tr>
<td>102</td>
<td>Thea Pharma</td>
</tr>
</tbody>
</table>
In many senses the counterpart of EVER in North America, the purposes of ARVO are to encourage and assist research, training, publication, and dissemination of knowledge in vision and ophthalmology. EVER and ARVO are collaborating in many fields, including an ARVO symposium held every year in EVER and an EVER symposium held in ARVO since 2005. See page 88.

The European Board was founded in 1992 to guarantee the highest standards of care in ophthalmology in the countries of the European Union by ensuring that the training is raised to the best possible level. It makes recommendations regarding the standards and syllabus for training ophthalmologists, assesses the content and quality of training by site visits and the annual EBO Diploma Examination, facilitates the exchange of trainees and teachers, and promotes CME in ophthalmology. EBO works under the Section of Ophthalmology of the European Union of Medical Specialists (UEMS). Since 2007, EBO has organized review courses open to all delegates during the EVER congress. See pages 27, 31.

EUPO is the organizer of the annual structured subspecialty course for residents in training in Europe since 1988. Most of the ophthalmology curriculum is covered over a 4 year period to allow residents to get an overview of theoretical knowledge during their residency rotation. EUPO courses are held in different places in Europe. The EUPO 2016 course on Neuro-ophthalmology and Strabismus is organized in conjunction with the EVER congress in Nice, France. EUPO course in Rhodes 4 on Friday, October 7 and on Saturday, October 8. Programme EUPO course on pages 134-135.

The FAN Club started as a friendly reunion of pioneers of Medical Retina, in the early days of fluorescein angiography and laser coagulation of the retina. The FAN received a semi-official status, being invited to organize a session of Medical Retina Case Presentations during large meetings in Ophthalmology. The Club runs itself without official status, there is no membership fee, and no registration fee for the meetings. Upcoming meetings are decided within the group, trying to change the location from country to country, and offering all members the opportunity to organize at least once a full day reunion in their hospital. Since 2012, FAN has organised joint meetings open to all delegates during the EVER congress. See page 108.
FRO
Belgian Fund for Research in Ophthalmology www.fro-online.org

The aim of the FRO association is to stimulate research in ophthalmology and in visual function by awarding grants to research projects carried out under order of Belgian institutions. The FRO candidates have presented their research work to an international jury during the EVER congress since 2002. See pages 118, 132.

GOA
Groupe Ophtalmo Allergo

In ocular surface pathologies the cooperation between clinical ophthalmology and allergology created the GOA. The GOA allowed the development of clinical research in ocular allergic disease. Vernal keratoconjunctivitis and atopic keratoconjunctivitis create severe ocular impairment that must be recognized and treated. See page 111.

OOG
The Ophthalmic Oncology Group www.oog.eu

OOG is an independent scientific workgroup devoted to basic and clinical ophthalmic oncology. It has convened with EVER since 1998. The aims of the OOG are to improve the practice of ophthalmic oncology in Europe, develop internet-based databases to share scientific information, organise multicenter studies and quality control studies, and meetings and other activities with the aim of improving the treatment of eye tumours and knowledge about them. OOG encourages all EVER delegates to take part in its sessions. See pages 109, 117 and 131.

Optic Nerve Meeting www.optic-nerve-online.com

Intended for basic scientists and clinicians to address important topics in translational research, including scientists in interdisciplinary areas such as neurology, neurodegenerations and autoimmunity. 2016 meeting: December 13-15, 2016 in Obergurgl, Austria. See page 92.
Sessions

**BM** Business Meeting  **JM** Joint Meeting

**C** Course  **KN** Keynote lecture

**CIS** Industry Sponsored Symposium  **SIS** Special Interest Symposium

**FP** Free Paper session  **SOC** Social

**GA** General Assembly  **POS** Poster session

**PS** Plenary session

Symbols

Ever section travel grant recipient

Rapid fire presentation

Conflict of interest disclosed

Scientific sections

**ACB** = Anatomy / Cell Biology

**COS** = Cornea / Ocular Surface

**EOVS** = Electrophysiology, Physiological Optics, Vision Sciences

**G** = Glaucoma

**IM** = Immunology / Microbiology

**LC** = Lens and Cataract

**MBGE** = Molecular Biology / Genetics / Epidemiology

**NSPH** = Neuro-ophthalmology/Strabismology / Paediatric Ophthalmology / History of Ophthalmology

**PBP** = Physiology / Biochemistry / Pharmacology

**PO** = Pathology / Oncology

**RV** = Retina / Vitreous Section programme secretaries
Programme Secretary, Marcela VOTRUBA

**EVER programme committee meeting in Leuven on June 11**

### 2016 Section programme secretaries + representatives*

<table>
<thead>
<tr>
<th>Section</th>
<th>Name</th>
<th>Representative</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACB</td>
<td>Anatomy/Cell Biology</td>
<td>Goran PETROVSKI</td>
</tr>
<tr>
<td>COS</td>
<td>Cornea/Ocular Surface</td>
<td>Jean-Jacques GICQUEL</td>
</tr>
<tr>
<td>EOV</td>
<td>Electrophysiology, Physiological Optics, Vision Sciences</td>
<td>Franziska RAUSCHER Rebekka HEITMAR</td>
</tr>
<tr>
<td>G</td>
<td>Glaucoma</td>
<td>Francesca CORDEIRO</td>
</tr>
<tr>
<td>IM</td>
<td>Immunology/Microbiology</td>
<td>Piergiorgio NERI Joachim VAN CALSTER</td>
</tr>
<tr>
<td>LC</td>
<td>Lens and Cataract</td>
<td>Stefan LÖFGREN</td>
</tr>
<tr>
<td>MBGE</td>
<td>Molecular Biology/Genetics/Epidemiology</td>
<td>Petra LISKOVA</td>
</tr>
<tr>
<td>NSPH</td>
<td>Neuro-ophthalmology/Strabismus/Paediatric Ophthalmology/History of Ophthalmology</td>
<td>Patrick YU-WAI-MAN</td>
</tr>
<tr>
<td>PBP</td>
<td>Physiology/Biochemistry/Pharmacology</td>
<td>Alexandre MOULIN</td>
</tr>
<tr>
<td>PO</td>
<td>Pathology/Oncology</td>
<td>Neville OSBORNE Gerhard GARHÖFER</td>
</tr>
<tr>
<td>RV</td>
<td>Retina/Vitreous</td>
<td>Stephanie BAILLIF Anita LEYS</td>
</tr>
</tbody>
</table>

* Senior members of the scientific committees.
Industry Sponsored Symposia throughout the EVER 2016 congress

Thursday, October 6

**Théa**

THÉA Pharma

12:40 - 13:40 | Rhodes 2

Demodex: innocent or guilty in blepharitis? ................................................................. 57

**Santhera Pharmaceuticals**

12:40 - 13:40 | Rhodes 1

Leber's hereditary optic neuropathy (LHON): latest advances in diagnosis, staging and patient management................................................................. 56
Courses throughout the EVER 2016 congress:

**Wednesday, October 5**

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Speaker</th>
<th>Level</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30</td>
<td>Rhodes 1</td>
<td></td>
<td>B</td>
<td>A clinician’s guide to visual electrophysiology: a road map for neuro-ophthalmology</td>
</tr>
<tr>
<td>11:30</td>
<td>Rhodes 2</td>
<td></td>
<td>I</td>
<td>EBO course: Intraocular inflammation and infection (part I)</td>
</tr>
<tr>
<td>11:30</td>
<td>Gallieni 4</td>
<td></td>
<td>I</td>
<td>Tear fluid proteome</td>
</tr>
<tr>
<td>14:00</td>
<td>Hermes</td>
<td></td>
<td>I</td>
<td>Management of Aphakia</td>
</tr>
<tr>
<td>14:00</td>
<td>Rhodes 2</td>
<td></td>
<td>I</td>
<td>EBO course: Intraocular inflammation and infection (part II)</td>
</tr>
<tr>
<td>14:00</td>
<td>Rhodes 4</td>
<td></td>
<td>A</td>
<td>Optical principles of state-of-the-art ophthalmic instrumentation</td>
</tr>
<tr>
<td>16:50</td>
<td>Gallieni 4</td>
<td></td>
<td>B</td>
<td>High-resolution imaging of the anterior eye segment</td>
</tr>
</tbody>
</table>

**Thursday, October 6**

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Speaker</th>
<th>Level</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>Rhodes 2</td>
<td></td>
<td>I</td>
<td>Corneal dystrophies - diagnosis and treatment</td>
</tr>
<tr>
<td>11:00</td>
<td>Rhodes 3</td>
<td></td>
<td>I</td>
<td>Mistakes in the diagnosis of fundus tumors</td>
</tr>
<tr>
<td>14:30</td>
<td>Rhodes 3</td>
<td></td>
<td>B</td>
<td>ABC in retina structure and function</td>
</tr>
<tr>
<td>14:30</td>
<td>Rhodes 4</td>
<td></td>
<td>I</td>
<td>Challenges in management of orbital tumors</td>
</tr>
<tr>
<td>14:30</td>
<td>Gallieni 1+2</td>
<td></td>
<td>A</td>
<td>Update in clinical features and genetics in microphthalmia</td>
</tr>
<tr>
<td>17:00</td>
<td>Rhodes 2</td>
<td></td>
<td>B</td>
<td>YOS for EVER - Young Ophthalmologist/Scientist</td>
</tr>
</tbody>
</table>

**Friday, October 7**

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Speaker</th>
<th>Level</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30</td>
<td>Gallieni 1+2</td>
<td></td>
<td>I</td>
<td>Ocular pulse amplitude - from pole to pole</td>
</tr>
</tbody>
</table>

**Saturday, October 8**

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Speaker</th>
<th>Level</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>Rhodes 2</td>
<td></td>
<td>I</td>
<td>Corneal infectious diseases</td>
</tr>
<tr>
<td>13:00</td>
<td>Rhodes 2</td>
<td></td>
<td>I</td>
<td>Maximising success in deep anterior lamellar keratoplasty</td>
</tr>
</tbody>
</table>
EVER 2016
Wednesday, Oct 5
Imaging of the human retina has in the recent years undergone tremendous changes. Whereas decades these techniques have only been used experimentally, the introduction of OCT-based technology has gained widespread clinical use. It is particularly OCT angiography that has revolutionized ocular vascular imaging. Most likely the technique will replace classical fluorescein and ICG angiography in the near future. In addition, several investigators have worked on quantification of ocular blood flow. The present SIG will give an overview on these developments from a clinical view, but will also provide an update on latest technology.

SCHMETTERER L, NAGAOKA T

1111 11:30  Role of Glial Cells in Regulating Retinal Blood Flow during Flicker-Induced Hyperemia and Systemic Hyperoxia-Induced Hypoxemia in Cats
       NAGAOKA T - Asahikawa

1112  11:48  Retinal Oximetry and Blood Flow

1113 12:06  OCT angiography: evaluation of the macular perfusion
       POURNARAS C - Genève

1114 12:24  Retinal Oxygen Extraction
       WERKMEISTER R, Aschinger G, Linzenmeier R, Schmetterer L - Vienna

1115 12:42  The oxygen saturation in retinal arterioles is predictive for the effect of intravitreal anti-VEGF treatment on diabetic macular edema
       BEKT - Århus C

EOVS - A clinician’s guide to visual electrophysiology:
a road map for neuro-ophthalmology

Beginner

Learning outcomes: at the end of the course the participant will be able to
· understand the purpose of the main visual electrophysiological tests (and their acronyms)
· recognise indications for visual electrophysiological tests
· inform patients of what they will experience
· understand the physiological principles underpinning each response
· recognise the response measurements and nomenclature associated with different tests
· interpret overall patterns of visual electrophysiological results to localise the site of visual pathway dysfunction
· prepare requests that optimise test selection and give context for result interpretation
· access ISCEV standards as a resource for test procedure and guidance

THOMPSON D, SMITH R

1121 11:30  The tests
       THOMPSON D - London

1122 11:48  The indications
       SMITH R - Aylesbury

1123 12:06  Retinal tests
       ROBSON A - London

1124 12:24  Visual Evoked Potentials
       LIASIS A - London

1125 12:42  In the neuro-ophthalmology clinic
       SMITH R - Aylesbury
**IM - EBO course: intraocular inflammation and infection (part I)**

The aim of this course is to review major topics of intraocular inflammation and infection. MCQs will be proposed online before the course to evaluate the basic knowledge of the participants. The test will be followed by 6 consecutive general presentations for the understanding of different uveitis features. The course will be interactive allowing general discussion and the participation of the audience. MCQs will be discussed during each presentation. At the end of this course, participants will be prepared for the MCQ part of the EBO examination in uveitis.

**BODAGHI B, HERBORT CP**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1131</td>
<td>11:30</td>
<td>Pathophysiology of uveitis</td>
<td>DICK A - Bristol</td>
</tr>
<tr>
<td>1132</td>
<td>11:45</td>
<td>Classification of uveitis</td>
<td>ANDROUDI S - Thessaloniki</td>
</tr>
<tr>
<td>1133</td>
<td>12:00</td>
<td>Signs and symptoms of uveitis</td>
<td>NERI P, Bisceglia P, Cesari C, Carrozzi G, Pirani V - Agugliano</td>
</tr>
<tr>
<td>1134</td>
<td>12:15</td>
<td>Laboratory work-up and specialized investigations</td>
<td>PLEYER U - Berlin</td>
</tr>
<tr>
<td>1135</td>
<td>12:30</td>
<td>Imaging in uveitis: techniques and indications</td>
<td>HERBORT C P - Lausanne</td>
</tr>
<tr>
<td>1136</td>
<td>12:45</td>
<td>Therapeutic management of uveitis</td>
<td>DICK A - Bristol</td>
</tr>
</tbody>
</table>

**COS - FP session - Corneal grafting**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1141</td>
<td>11:30</td>
<td>Immunosuppression with a subconjunctival implant releasing dexamethasone in a rabbit model of penetrating keratoplasty</td>
<td>CROUZET E, He Z, Perrache C, Basset T, Delavenne X, Peoc'h M, Gain P, Thuret G - Saint Priest en Jarez</td>
</tr>
<tr>
<td>1143</td>
<td>11:54</td>
<td>Mid-term clinical outcomes of collagen-phosphorylcholine cornea substitutes for therapeutic anterior lamellar keratoplasty</td>
<td>BUZNYK O, Islam M M, Iakymenko S, Pashechnikova N, Griffith M - Odessa</td>
</tr>
<tr>
<td>1144</td>
<td>12:06</td>
<td>Chondro-keratoprosthesis: an alternative to OOKP ?</td>
<td>HOFFART L, Guyot L - Marseille</td>
</tr>
</tbody>
</table>
LC - Controversies in cataract surgery pharmacology

The exciting evolution of best care practice in the use of pharmacological substances before, during, and after cataract surgery also creates controversies in the ophthalmic community. The dispersion of and adhesion to improved evidenced based treatments are hampered by local traditions, bureaucracy and national legislation. The speakers will present their take on past and current controversies in the use of pharmaceuticals relevant to cataract surgery.

LOFGREN S, GRZYBOWSKI A

1151 11:30 Controversies in the use of NSAIDs
PLEYER U - Berlin

1152 11:52 Controversies in the use of steroids
KUGELBERG M - Stockholm

1153 12:14 Controversies in the use of mydriatics
LABETOULLE M - Le Kremlin Bicêtre

1154 12:36 Controversies in the use of antibiotics
GRZYBOWSKI A - Olsztyn

FP - Advances in glaucoma

BRON A, NORMANDO EM

1161 11:30 Racial differences in the extracellular matrix of the lamina cribrosa and the peripapillary sclera
KIM Y, Park HY L - Seoul

1162 11:42 A curry a day keeps glaucoma away? - A curcumin study
BALENDR A S I, Davis B M, Guo L, Cordeiro M F - London

1163 11:54 Transcorneal electrical stimulation prevents secondary retinal ganglion cell death after acute ocular hypertensive injury through modulation of microglia-mediated local inflammatory response
SHIH K C, Fu L, Lo A CY, Lai J S M - Island South

1164 12:06 Normobaric hypoxia induces changes in mean ocular perfusion pressure
LEAL I, Cordeiro Sousa D, Moreira S, Dionsio P, Abegao Pinto L, Marques-Neves C - Lisbon

1165 12:18 Quantification of green fluorescent protein expression in mouse retinal ganglion cells following intravitreal injection of recombinant adeno-associated virus
KHATIB T, Osborne A, Widdowson P, Martin K - Cambridge

1166 12:24 Incidence and risk factors of elevated intraocular pressure following deep anterior lamellar keratoplasty
HUANG O, Mehta J, Htoon H, Tan D, Wong T - Singapore

1167 12:30 A vascular comparison between primary open-angle glaucoma and normal-tension glaucoma
VAN KEER K, Abegão Pinto L, Barbosa Breda J, Willekens K, Vandewalle E, Stalmans I - Leuven

1168 12:36 A link between Diabetes Mellitus and Glaucoma — Danish Nationwide Study
HORWITZ A, Petrovski B E, Petrovski G, Torp-Pedersen C, Kolko M - Copenhagen
Intermediate

ACB - Tear fluid proteome

Ocular surfaces are delicate structures of the anterior segment of the eye protected, nourished and lubricated by tear fluid. The system has its own regulatory mechanisms. Ocular surfaces are exposed environmental factors, topical ophthalmic drugs and affected by various ocular and systemic diseases. Inflammation and wound healing are vital processes involved in the defense mechanisms of the human body and pathogenesis of many eye diseases. It is also one of the most important factors in many ocular surgeries e.g. corneal, refractive and glaucoma surgery. Tear proteomics is a powerful tool to diagnose eye diseases and their risk factors. It is also a key to personalize the ocular therapies and health care processes. The course is focusing in the proteomics of the tear fluid and will give a practical overview of the technologies in this field.

UUSITALO H

<table>
<thead>
<tr>
<th>Code</th>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1171</td>
<td>11:30</td>
<td>When and why proteomic approach is needed?</td>
<td>UUSITALO H - Tampere</td>
<td></td>
</tr>
<tr>
<td>1172</td>
<td>12:00</td>
<td>Proteomics of tear fluid</td>
<td>BEUERMAN R - Singapore</td>
<td></td>
</tr>
<tr>
<td>1173</td>
<td>12:30</td>
<td>Practical examples of tear proteomic studies</td>
<td>HOLOPAINEN J - Helsinki</td>
<td></td>
</tr>
</tbody>
</table>
Management of aphakia still represents challenge as many options are available. Contact lenses correction will be detailed. Then, different intraocular lenses implantation will be presented, giving more details on advantages and inconveniences for each lens. Finally, complex reconstruction with aniridia implants will be discussed.

POURNARAS J, PAPPAS G

1311  14:00  Contact lenses
       PLAINIS S - Heraklion

1312  14:15  Anterior chamber lenses
       MOSCHOS M M - Athens

1313  14:30  Iris claw
       POURNARAS J A - La Conversion

1314  14:45  Sleral structured iol
       SIMCOCK P - Exeter

1315  15:00  Sclear embedded iol
       PAPPAS G - Heraklion

1316  15:15  Aniridia implants
       STAPPLER T - Liverpool

Glaucoma is one of the leading causes of irreversible blindness. It is therefore a major part in Ophthalmology education and a major focus of Ophthalmology residency programmes. The syllabus in these programmes usually involves providing the residents with a set of skills, ranging from surgical procedures or treatment decision-making, they should master by the end of their glaucoma rotations. However, there is a great diversity between training centers and there is not a clear definition of what constitutes the core values in glaucoma training for the general Ophthalmologists. Accordingly, a much needed debate is needed between all players involved, from residents, Directors of training and Institutional organizations such as a the European Glaucoma Society.

ABEGAO PINTO L, SUNARIC MEDEVAND G

1321  14:00  The view of the doctor in training
       SCOTT A - London

1322  14:18  The view of a director of training
       GARCIA-FEJOO J - Madrid

1323  14:36  The view of the EGS and the subspecialty exam
       SUNARIC MEDEVAND G - Geneva

1324  14:54  How can we improve?
       SUNARIC MEDEVAND G - Geneva

1325  15:12  What did we learn from this session?
       ABEGAO PINTO L - Lisbon
Wednesday, Oct 5 - First afternoon session

**14:00 - 15:30 | RHODES 2**

**IM - EBO course: intraocular inflammation and infection (part II)**

*Intermediate*

The first part on general aspects of uveitis will be followed by case presentations in different basic or more challenging situations. Important points will be discussed during each practical situation. The course will be interactive allowing general discussion and the participation of the audience. It will be intermediate and present entities that are frequently observed in routine. At the end of this course, participants will be prepared for the viva voce part of the EBO examination in uveitis.

**BODAGHI B , HERBORT CP**

1331 14:00  B27-associated uveitis, Fuchs uveitis

  **WILLERMAIN F - Bruxelles**

1332 14:18  Infectious uveitis

  **PLEYER U - Berlin**

1333 14:36  Behçet's disease, VKH, sarcoidosis

  **KHAIRALLAH M , Khochtali S , Abroug N - Monastir**

1334 14:54  Inflammatory choroiditis

  **HERBORT C P - Lausanne**

1335 15:12  Retinal vasculitis

  **ABU EL ASRAR A - Riyadh**

---

**14:00 - 15:30 | RHODES 3**

**PBP - FP session - Drug delivery and biomarkers for ocular disease**

**SCHMETTERER L , HARDARSON S**

1341 14:00  Trans-scleral delivery of novel anti-angiogenic small molecule inhibitors of SRPK1

  **BATSON J , Toop H D , Allen C , Rowlinson J , Babaei-Jadidi R , Gibbons B ,

1342 14:12  Toward rational design of gene carriers: a novel ex vivo model to study the vitreoretinal interface as a barrier

  **FEYNSHAERT K , Fradot V , Picaud S , De Smedt S , Remaut K - Ghent**

1343 14:24  Results of microinvasive cross-linking of rabbit posterior eye pole sclera

  **IOMDINA E N , Tarutta E , Semchishen V , Sianosyan A , Milash S - Moscow**

1344 14:36  Retinal α-synucleinopathy: taking a new look at Parkinson's disease.

  **DE GROEF L , Normando E M , Andresis L , Davis B , Lefevere E , Van den Haute C ,
  Baekelandt V , Cordeiro M F , Moons L - Leuven**

1345 14:48  Exploration of human tear proteome

  **TURCK N , Dor M , Eperon S , Salvisberg C , Fouda C , Hainard A , Guex-Crozier Y ,
  Hamédiñi M - Geneva**

1346 15:00  In the search of biomarkers for thyroid associated orbitopathy (TAO)

  **TURCK N , Kishazi E , Dor M , Eperon S , Gracía M D L A , Fouda C , Oberic A ,
  Hamédiñi M - Geneva**

1347 15:06  Variation of accommodative process and anterior chamber parameters in diabetic patients

  **COSTA L , Passos I , Pires G , Proença R , Amado D , Ferreira J - Lisbon**
EOVS - Optical principles of state-of-the-art ophthalmic instrumentation

This single-speaker course is aimed to provide an overview of the optical principles of various state-of-the-art ophthalmic instruments, such as scanning laser ophthalmoscopy, optical coherence tomography, including adaptive optics, to make it easy for the clinician and scientist to understand the underlying concepts of various devices, even if not familiar with the particular technology.

This course is designed for ophthalmologists in training or those in practice, aimed at addressing common optical pitfalls in general ophthalmology practice with easy-to-understand explanations enhanced by simple illustrations. Its goal is to make ophthalmic optics accessible and understandable with real-life, clinically relevant examples, such as why one should not switch myopes in their mid-life crises from wearing spectacles to contact lenses, or why aiming for a post-operative plano refraction with refractive or cataract surgery might not always yield the best vision or results.

IRSCH K

1351 14:00 Scanning Laser Ophthalmoscopy - Basic Optical Principles
IRSCH K - Paris

1352 14:30 Optical Coherence Tomography - Basic Optical Principles
IRSCH K - Paris

1353 15:00 Adaptive Optics - Basic Optical Principles
IRSCH K - Paris

MBGE - Epidemiology of eye diseases

To better understand mechanisms of development of ocular diseases, it is important to know their relationship to other diseases of the patients, to their genetic background, to their lifestyle, and to their whole environmental situation. The proportion of all these components is highly complex and cannot be resolved in small case-control studies. Therefore, large population-based cohorts are being developed at international and national levels to increase the power of such epidemiological studies. This Special Interest Symposium will share up-to-date information not only to stimulate discussions how to further improve epidemiological studies, but also to develop ideas for clinicians to include additional factors into their diagnostic and therapeutic considerations, and also for basic scientists to prove the molecular mechanisms behind epidemiological associations.

GRAU J

1361 14:00 The Global Vision Database – modeling the current and changing burden of eye disease
BOURNE R - Cambridge

1362 14:22 The E3 consortium – European Eye Epidemiology
DELCOURT C - Bordeaux

1363 14:44 The Montrachet Study
CREUZOT C, Bron A, Binquet C - Dijon

1364 15:06 Molecular Genetics in Ocular Epidemiology
DEN HOLLANDER A - Nijmegen
ACB - FP session - Cell biology and imaging of retina and orbit

**PETROVSKI G, KOLKO M**

1371 14:00 Hypoxia and inflammation in human retinal cells

*ARJAMAA O, Aaltonen V, Piippo N, Csont T, Petrovski G, Kaarniranta K, KIVELÄ A - Turku*

1372 14:12 Mitochondrial inhibition of retinal Müller cells alter glutamate homeostasis and their ability to sustain retinal ganglion cells

*SKYTT D M, Vohra R, Toft-Kehler A K, Gurubaran I S, Bergersen L H, Kolko M - Copenhagen*

1373 14:24 LACTATE: A valuable energy substrate in maintaining survival and function in the inner retina

*VOHRA R, Skytt D M, Bergersen L H, Kolko M - Copenhagen*

1374 14:36 Mechanisms behind the protein aggregation-related inflammasome activation in RPE cells

*KAUPPINEN A, Piippo N, Korhonen E, Hytti M, Kinnunen K, Kaarniranta K - Kuopio*

1375 14:48 Angiogenic potential of orbital adipose derived stromal cells

*AFANASYEVA D, Gushchina M, Borzenok S - Moscow*

1376 15:00 Description of the retinal vascular network by semi-automated computer software (SIVA) in the MONTRACHET study


1377 15:12 Manufacturing of an ocular prosthesis based on the 3D printed anophthalmic socket

*RUITERS S, Sun Y, De Jong S, Politis C, Mombaerts I - Leuven*
Wednesday, Oct 5 - Opening Ceremony

**15:40 - 16:30 | HERMES**

Opening Ceremony

**15:40** Welcome by the EVER President 2016
Aki KAWASAKI - Lausanne

**15:50** Word from the EVER President
Highlights of EVER
Update on EVER in EU-EYE
Leopold SCHMETTERER - Vienna

**16:00** EVER Past President lecture
Lessons from the Fascinating World of Bestrophinopathies
Bart LEROY - Ghent

*Introduction by Aki KAWASAKI*

End 16:30
16:50 - 18:20 | HERMES

**MBGE/RV - Advances in gene-based therapies for ocular disorders**

Gene-based therapies represents a very promising option for many inherited and acquired ocular disorders. The special interest symposium will focus on advances in gene therapy technologies, animal models that are a target for ocular gene therapy as well as current clinical gene therapy trials.

**LISKOVA P**

<table>
<thead>
<tr>
<th>Session No.</th>
<th>Time</th>
<th>Title</th>
<th>Authors, Institute</th>
</tr>
</thead>
<tbody>
<tr>
<td>1512</td>
<td>17:12</td>
<td>Animal models for ocular gene therapies</td>
<td>ARSENJEVICY, Kostic C - Lausanne</td>
</tr>
</tbody>
</table>

16:50 - 18:20 | RHODES 1

**G - FP session - New technologies in glaucoma**

**CORDEIRO MF, ROUSSEAU A**

<table>
<thead>
<tr>
<th>Session No.</th>
<th>Time</th>
<th>Title</th>
<th>Authors, Institute</th>
</tr>
</thead>
<tbody>
<tr>
<td>1521</td>
<td>16:50</td>
<td>Could 24-S-hydroxycholesterol play a role in Müller glial cell’s membrane dynamics in the rat</td>
<td>BRON A, Ferrero A, Gambert-Nicot S, Brétillon L, Acor N, Creuzot C - Dijon</td>
</tr>
<tr>
<td>1522</td>
<td>17:02</td>
<td>Reduced vascular response in patients with normal tension glaucoma in response to hypoxia</td>
<td>DALGAARD L M, Vibeak J, Jensen LT, Olsen N V, Kolko M - Copenhagen</td>
</tr>
<tr>
<td>1526</td>
<td>17:38</td>
<td>Primary Open Angle Glaucoma treated by High Intensity Focused Ultrasound (HIFU). Results at 18 months of a prospective pilot study on patients treated with the 2nd generation probe</td>
<td>ROULAND J F, Aptel F - Lille</td>
</tr>
<tr>
<td>1527</td>
<td>17:44</td>
<td>High-intensity focused ultrasound cyclocoagulation: a 6-month study</td>
<td>VANDEWALLE E, Somers A, Vermorgen K, Stalmans I - Leuven</td>
</tr>
<tr>
<td>1528</td>
<td>17:50</td>
<td>A comparison of visual field testing with a new automated perimeter, the Compass visual field analyser and the Humphrey visual field analyser</td>
<td>FENOLLAND J R, Bonnel S, Rosenberg R, Sendon D, Ghazal W, Giraud J M, Renard J P - Issy les Moulineaux</td>
</tr>
</tbody>
</table>
Intraocular inflammatory disorders encompass a broad spectrum of diseases that are a major cause of severe visual impairment. They may be specific to the eye or be part of a systemic problem or a combination of both. In fact, there is frequently a blurring of distinction between these categories. In addition, a pseudo-inflammatory eye disease can mimic the clinical findings and pattern of a real posterior uveitis. Very often misdiagnosis is the first and major problem of posterior uveitis management. The aim of this special interest symposium is to present the hottest topics in diagnostic challenges for posterior uveitis and the differentiation between real inflammation and pseudo-inflammation of posterior uveal tract.

NERI P, HERBORT CP

1531 16:50  Inflammatory versus non-uveitic serous/exudative retinal detachments  
Gupta V

1532 17:08  Central serous chorioretinopathy misdiagnosed as posterior uveitis  
Khairallah M, Kahloun R, Jelliti B - Monastir

1533 17:26  Central serous chorioretinopathy complicating inflammation suppressive treatment  
Herbort C P, Papadia M - Lausanne

1534 17:44  Primary vitreo-retinal lymphoma, an increasing pseudo-uveitis to be taken into account  
NERI P, Cesare M, Baruffa D, Pirani V - Agugliano

1535 18:02  Inflammatory versus non-uveitic posterior segment diseases in paediatric patients  
Bodaghi B - Paris

**FP**

16:50 - 18:20 | RHODES 3

**RV - FP session - Surgery I**

SOUBRANE G, BAILLIF S

1541 16:50  Visual function response to ocriplasmin for the treatment of vitreomacular traction: results from the oasis study  

1542 17:02  Functional and anatomical changes after standard and half dose verteporfin PDT in central serous chorioidopathy  

1543 17:14  The retinal macroglia in hypercholesterolemic rabbits: neuroprotective effect of a non-lipid-lowering statin dose  

1544 17:26  Therapeutic potential of non-viral mRNA delivery to Müller cells for neuroprotection  
Devolder J, Peynshaert K, De Smedt S, Remaut K - Ghent

1545 17:38  Anti-VEGF therapies for retinal vein occlusion: real-world outcomes of a Portuguese multi-center study  

1546 17:50  Incidence of macular oedema following pan-retinal photocoagulation using a multi-spot semi-automated pattern-scanning laser in one sit versus 4 monthly sits in mild proliferative diabetic retinopathy or pre-proliferative diabetic retinopathy  
Gabrielle P H, Massin P, Kodjikian L, Bron A, Creuzot C - Dijon
**BREMOND-GIGNAC D, BOSCHI A**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>1551</td>
<td>16:50</td>
<td>Reduced post-illumination pupil response in patients with mild-moderate cataracts is associated with impaired sleep quality</td>
<td>ROEMER S, Munch M, Ladaïque M, Hashemi K, Kawasaki A - Lausanne</td>
</tr>
<tr>
<td>1552</td>
<td>17:02</td>
<td>Consensus on guidelines for idebenone administration in Leber’s hereditary optic neuropathy (LHON)</td>
<td>CARELLI V, On behalf of the Consensus Study Group - Bologna</td>
</tr>
<tr>
<td>1554</td>
<td>17:26</td>
<td>Factors affecting the prognosis of visual acuity and visual fields in pituitary adenoma patients treated with endonasal endoscopic transsphenoidal surgery</td>
<td>LIINAMAA J, Luomaranta T, Raappana A, Saarela V - Oulu</td>
</tr>
<tr>
<td>1556</td>
<td>17:50</td>
<td>Visual outcomes of fractionated radiotherapy in optic nerve sheath meningioma</td>
<td>KHEIR V, Borruat F X - Lausanne</td>
</tr>
</tbody>
</table>

---

**LEYS A, HUSSAIN R**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>1562</td>
<td>17:02</td>
<td>Incidence and risk factors of cystoid macular edema after retinal detachment surgery</td>
<td>BERROD J P, El Kouhen N, Leroy B P, Conart J B - Vandoeuvre les Nancy</td>
</tr>
<tr>
<td>1563</td>
<td>17:14</td>
<td>Retinal toxicity of intraocular silicone oil. A retrospective study</td>
<td>ROCHA DE SOUSA A, Roca A, Barbosa-Breda J, Falcão-Reis F - Porto</td>
</tr>
<tr>
<td>1564</td>
<td>17:26</td>
<td>Heads-up eye surgery: pros and cons</td>
<td>LYTYYNCHUK L - Giessen</td>
</tr>
<tr>
<td>1565</td>
<td>17:38</td>
<td>Vitreous and subretinal VEGF levels in fresh rhegmatogenous retinal detachment</td>
<td>SOZEN-DELIL F I, Cekic O - Istanbul</td>
</tr>
</tbody>
</table>
In this course, we aim to introduce and review different optical technologies allowing the non-invasive imaging of the anterior eye segment with a resolution in the micrometer or sub-micrometer range. At first, ultrahigh-resolution optical coherence tomography based on a broadband Ti:Sapphire laser will be introduced. Its application for both imaging of different features of the healthy and diseased eye as well as the investigation of surgical treatment will be shown. In the second part, the concepts of confocal and non-linear microscopy and the underlying physical principles of different contrast mechanisms will be presented. Exemplary experimental results based on various non-linear signals showing the ability to image structure of the cornea down to the cellular level are content of the presentations. Finally, the two modalities – OCT and IVC – will be compared and their advantages and disadvantages for corneal imaging will be highlighted.

<table>
<thead>
<tr>
<th>Event</th>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1571</td>
<td>16:50</td>
<td>Introduction to Ultrahigh-Resolution OCT</td>
<td>WERKMEISTER R - Vienna</td>
</tr>
<tr>
<td>1572</td>
<td>17:05</td>
<td>OCT Imaging in Glaucoma and PEX</td>
<td>SAPETA S - Vienna</td>
</tr>
<tr>
<td>1573</td>
<td>17:20</td>
<td>Imaging of Corneal Lesions and Wound Healing</td>
<td>SCHMIDL D - Vienna</td>
</tr>
<tr>
<td>1574</td>
<td>17:35</td>
<td>Linear and nonlinear microscopy for AS imaging: principles and pathbreaking application</td>
<td>STACHS O - Rostock</td>
</tr>
<tr>
<td>1575</td>
<td>17:50</td>
<td>Nonlinear microscopy for quantification of riboflavin diffusion in the cornea</td>
<td>HEISTERKAMP A - Hannover</td>
</tr>
<tr>
<td>1576</td>
<td>18:05</td>
<td>OCT and IVC in Corneal Imaging</td>
<td>DUA H S - Nottingham</td>
</tr>
</tbody>
</table>
18:35 - 19:00 | HERMES
European Ophthalmology Heritage Lecture by Luc Missotten

Introduction by Marcela VOTRUBA

1611
Magnificat
Luc MISSOTTEN - Leuven

Summary:
We will present some evidence showing that the use of a magnifying glass started in Greece in the fifth century BC.

Award presentation of the EVER Certificate of Honour

Biography Luc MISSOTTEN:
Professor emeritus of the Catholic University of Leuven, Belgium, he is one of the founding fathers of EVER. As the eldest amongst the EVER members may recall, the European Community Ophthalmic Research Association (ECORA) was founded by Professor Manfred Spitznas at the request of EUPO (European University Professors in Ophthalmology) and its first meeting was held in Bonn. Very soon ECORA joined forces with the Association of Eye Research of which Missotten was a past president and a prominent member and with other research associations. The new identity was called Joint European Research Meeting in Ophthalmology (JERMOV) and it held its first meeting in Montpellier in 1995. The meeting was successful. However two years later, because of financial problems JERMOV ceased to exist. Professor Missotten then created a temporary structure which he called EVER for EVER and organized the 1997 meeting. New statutes were written and EVER was born. Luc Missotten was its first secretary-general, post he kept till 2002. He was vice-president of the International Society for Eye Research, chair of the Scientific Committee of the Netherlands Ophthalmic Research Institute and President of the European Ophthalmological Society (1996-2000).

He is Doctor honoris causa of the University of Mansoura (Egypt) and a honorary member of various ophthalmological societies.
Keynote Lecture by Robert Maclaren

Introduction by Bart LEROY

1711

Developing new treatments for inherited retinal degenerations

Robert MACLAREN - Oxford

Summary:
Retinal diseases are currently the leading causes of untreatable blindness in Europe. Most commonly, incurable blindness occurs when photoreceptors are lost and therapeutic strategies therefore aim to prevent photoreceptor cell death by genetic correction of single gene disorders. Once photoreceptors have degenerated, alternative strategies are required to regenerate the retina using biological approaches and subretinal electronic devices have also shown great promise in demonstrating that blindness may be potentially reversible. This lecture will provide an update on the application of scientific discovery in clinical trials for retinal degeneration and provide insight into the fascinating age of discovery that lies ahead.

Award presentation of the EVER Certificate of Honour

Biography Robert MACLAREN:
Robert McLaren is Professor of Ophthalmology at the University of Oxford and a retinal surgeon. His research interests focus on developing novel treatments for currently incurable retinal disease, particularly retinitis pigmentosa. His laboratory work has explored scientific concepts in retinal regeneration using developing neurons and photoreceptor transplantation. More recently he has been leading gene therapy clinical trials for choroideremia which are now ongoing in several EU countries, the USA and Canada. He is the academic founder of Nightstarx, a retinal gene therapy company based at the Wellcome Trust in London and he works closely with Retina Implant AG, in clinical trials of the electronic retinal implant.
Wednesday, Oct 5 - Welcome Reception

19:30 - 21:30 | EXHIBITION AREA

EVER Welcome Reception

Open to EVER participants and exhibitors
EVER 2016
Thursday, Oct 6
# EVER 2016

## Thursday, Oct 6 - First morning session

### HERMES

#### 8:30 - 10:00

**LYTVYNCHUK L, WIEDEMANN P**

<table>
<thead>
<tr>
<th>Session Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30</td>
<td>Vitrectomy in treatment naive diabetic macular edema</td>
<td>MICHALEWSKA Z, Michalewski J, Bednarski M, Nawrocki J - Lodz</td>
</tr>
<tr>
<td>8:48</td>
<td>Novel diagnostic tools in DRP - from science to clinical relevance</td>
<td>BRUNNER S - Vienna</td>
</tr>
<tr>
<td>9:06</td>
<td>OCT Angio imaging of the pathologic changes in PDR</td>
<td>GLITTENBERG C - Vienna</td>
</tr>
<tr>
<td>9:24</td>
<td>Treatment of hard exudates in CSME in PDR using Micropulse mode</td>
<td>SAKSONOV S, Teslenko A, Vitovska O - Kyiv</td>
</tr>
<tr>
<td>9:40</td>
<td>29G chandelier-assisted scleral buckling with new instruments</td>
<td>LYTINYCHUK L, Binder S - Lviv</td>
</tr>
</tbody>
</table>

### RHODES 1

#### 8:30 - 10:00

**G - You tube: different tubes for different glaucomas**

YouTube is a SIS about the main three surgical glaucoma techniques that use tubes. It is a short introductory symposium of the new and old tubes that nowadays are being used in clinics. The instructors introduce the different surgical techniques with videos and didactic images. "When and how", with special focus in the niche for these procedures, and their specific indications.

**DUCH S, MILLA E**

<table>
<thead>
<tr>
<th>Session Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30</td>
<td>YouTube: Different tubes for different glaucomas: XEN</td>
<td>ARCINIEGAS-PERASSO C A - Barcelona</td>
</tr>
<tr>
<td>8:52</td>
<td>YouTube: Different tubes for different glaucomas: Ex Press</td>
<td>MUNOZ M - Barcelona</td>
</tr>
<tr>
<td>9:14</td>
<td>YouTube: Different tubes for different glaucomas: Ahmed Valve</td>
<td>MILLA E - Barcelona</td>
</tr>
<tr>
<td>9:36</td>
<td>YouTube: Different tubes for different glaucomas: Non valved Tube&amp;Plate implants</td>
<td>DUCH S - Barcelona</td>
</tr>
</tbody>
</table>
Corneal dystrophies are the group of hereditary, slowly progressive disorders affecting all corneal layers.

In the past, histological examination was crucial in proper diagnosis of corneal dystrophies. In recent years, non-invasive optical imaging systems such as optical coherence tomography (OCT) and confocal microscopy (CM) along with genetic testing have become a new standard procedures in the diagnostic process. Advances in diagnosis and treatment of corneal dystrophies including genetic analysis and confocal microscopy findings were included in the IC3D classification in 2008 and 2015. During this course we would like to present the current classification, methods of diagnosis including genetic testing, confocal microscopy and optical coherence tomography, as well as different treatment options and its results.

**WYLEGALA E, DOBROWOLSKI D**

**2131** 8:30 Update on IC3D classification
NOWINSKA A - Bytom

**2132** 8:45 Confocal microscopy findings in corneal dystrophies
SMEDOWSKI A, Wylegala E - Katowice

**2133** 9:00 OCT in treatment planning
JANISZEWSKA D - Katowice

**2134** 9:15 Photorefractive keratectomy for corneal dystrophies
DOBROWOLSKI D - Katowice

**2135** 9:30 Surgical treatment of corneal dystrophies
WYLEGALA E - Katowice

**2136** 9:45 Corneal imaging after treatment in dystrophic eyes (OCT, CM)
DOBROWOLSKI D - Katowice

---

**HERRERO-VANRELL R, RUPENTHAL ID**

**2141** 8:30 Stimuli-responsive systems for tuneable ocular drug delivery
RUPENTHAL I D, Yasin N, Bisht R, Chen Y S, Jin J, Jaiswal J, Svirskis D - Auckland

**2142** 8:48 Multiloaded Microparticulate Drug Delivery Systems for the Treatment of Retinal Diseases

**2143** 9:06 Intravitreal mobility of nanoparticles: how to make a move toward successful ocular gene delivery?
REMAUT K, Devoldere J, Peynsaert K, Martens T, Engbersen J, Braeckmans K, De Smedt S - Gent

**2144** 9:24 Ocular drug delivery and pharmacokinetics: Influence of drug properties and delivery systems
KOMPELLA U B - Aurora

**2145** 9:42 Ocular pharmacokinetics assessed by in-vivo microdialysis
GARHÖFER G - Vienna
EVER 2016
Thursday, Oct 6 - First morning session

8:30 - 10:00 | RHODES 4
RV - FP session - Surgery III

**PRUENTE C, POURNARAS J**

2151 8:30  Retinal structural changes before and after idiopathic epiretinal membrane peeling - a study using OCT segmentation
   *SOUZA F, Pinto J, Marques-Neves C - Lisbon*

2152 8:42  Morphological, physiological and immunocytochemical evaluation in patients with idiopathic epiretinal membranes
   *MINIEWICZ J, Romanowska Dixon B, Petka O, Elas M, Sarna M, Kubicka-Trzaska A - Krakow*

2153 8:54  Mechanism of “Flap Closure” After the Inverted Internal Limiting Membrane Flap Technique
   *MICHALEWSKA Z, Boninska K, Michalewski J, Nawrocki J - Lodz*

2154 9:06  Accuracy of retinal layers optical coherence tomography automated segmentation before and after epiretinal peeling
   *MEDEIROS PINTO J, Caiado F, Marques-Neves C - Lisbon*

2155 9:18  Unexplained vision loss with intra-ocular silicone oil tamponade in situ; a case series
   *SILVESTER A, Cazabon S - West Kirby*

---

8:30 - 10:00 | GALLIENI 1+2
EOVS/MBGE - Doctor, I can’t see in the dark

The SIS will address the clinical problem of night blindness (nyctalopia). It will commence with the initial consultation and examination; what to look for and what questions to ask. It will then proceed to address the underlying causes of night blindness, both genetic and acquired, followed by a discussion of how electrophysiological testing can assist the diagnosis. The final presentation will discuss the effects on the patient of being night blind.

**HOLDER G**

2161 8:30  The initial consultation
   *SPILEERS W - Leuven*

2162 8:52  Causes of night blindness
   *LEROY B - Ghent*

2163 9:14  The electrophysiology of patients with nyctalopia
   *HOLDER G - London*

2164 9:36  What limits normal visual performance in the dark?
   *FITZKE FW - London*
EVER 2016

ACB - Proteostasis in the pathogenesis of age-related macular degeneration

Age-related macular degeneration (AMD) is a complex chronic neurodegenerative disease associated with many environmental, lifestyle, and genetic factors. Oxidative stress and the production of reactive oxygen species seem to play a pivotal role in AMD pathogenesis. During aging accumulation and aggregation of misfolded proteins can be recognized in retinal pigment epithelial (RPE) cells. This lead to the degeneration of RPE that is a hallmark of AMD. Molecular chaperones, proteasomes and lysosomes are key elements to refold misfolded proteins or degrade damaged proteins in the RPE cells. Autophagy, a part of lysosomal clearance system, has a cytoprotective role in diseases associated with protein aggregates. Failure in proteostasis may be one of the underlying mechanisms responsible for the cascade of events leading to AMD. This SIS covers the major cytoprotective and degradative pathways in the RPE and summarizes evidence of their involvement in AMD.

KAARNIRANTA K, UUSITALO H

2171 8:30  Age-related changes of cystatin C and effects on protein turnover in RPE cells
        PARAAN L - Liverpool

2172 8:52  Cytoprotective alpha crystallins in the regulation of RPE cell proteostasis
        KANNAN R - Los Angeles

2173 9:14  The marine n-3 PUFA DHA evokes cytoprotection by inducing autophagy and
        NFE2L2 in human retinal pigment epithelial cells
        BJORKOY G - Trondheim

2174 9:36  Nrf2- and PGC-1α-deficient mice: A novel animal model for disturbed proteostasis
        and RPE degeneration
        KAARNIRANTA K - Kuopio

LC - Lens and IOL - optics and accommodation

Our SIS will present new findings related to the optical properties of the crystalline lens and new evidence for a possible relation between cortical cataract and accommodation forces. Furthermore, we will attempt to explain the optical imaging properties of new multifocal intraocular lenses. Some of which show benefits that must be put into realistic technical and clinical contexts, beyond their commercial names. We will give an update on light-adjustable intraocular lenses and conclude showing new developments of accommodative intraocular lenses.

BARRAQUER R I, MICHAEL R

2181 8:30  Optical properties of the lens: An explanation for the zones of discontinuity
        PIERSCIONEK B, Bahrami M, Hoshino M, Regini J, Uesugi K, Yagi N - Kingston

2182 8:48  Cortical cataracts: The case for mechanical stress

2183 9:06  Optical imaging properties of multifocal IOL

2184 9:24  Light-Adjustable Lens: A non-invasive approach to adjust remaining refractive
        errors after cataract surgery
        HENGERER F, Conrad-Hengerer I - Frankfurt

2185 9:42  Accommodative IOLs: An update on recent developments
        VEGA-ESTRADA A, Alio J - Alicante
The pathogenic role of LRG1 in ocular neovascularisation: From discovery to targeted therapy

John GREENWOOD - London

Summary:
We have reported that the secreted glycoprotein, leucine-rich alpha-2-glycoprotein 1 (LRG1), promotes neovascularisation in various models of ocular disease (Wang et al., Nature 2014; 499: 306-311). LRG1 is up-regulated in many disease conditions and mediates its pro-angiogenic effect by modifying the TGFβ signalling network. Loss of LRG1, or blocking its biological activity, results in attenuation of neovascular complications in the rodent models of laser-induced choroidal neovascularisation and oxygen-induced retinopathy. Recently, we have observed that loss of LRG1 results in vessel normalisation, suggesting that in the pathological setting LRG1 corrupts the normal physiological angiogenic process. Early indications suggest that LRG1 interferes with vascular recruitment of pericytes resulting in failure of vessel maturation. These findings have important implications in diseases such as diabetic retinopathy where there is a need to promote a normal functioning vasculature. Consistent with the concept of LRG1 causing vascular dysfunction, we have additionally observed that loss of LRG1 reduces vascular permeability in ocular inflammation. Together these findings have led us to develop a humanised blocking antibody that will be taken into clinical trials for the treatment of wet age-related macular degeneration. In this seminar I will present our work on LRG1 in ocular disease and describe the development of an anti-LRG1 therapeutic for clinical use.

Biography John GREENWOOD:
Professor John Greenwood holds the Hugh Davson Chair of Biomedical Research at the Institute of Ophthalmology, University College London. He obtained his PhD in 1984 from the Institute of Psychiatry, University of London following studies on the pathobiology of the blood-brain barrier (BBB). After leaving the Institute of Psychiatry he took up a postdoctoral fellowship within the BBB research group at King’s College London. In 1990 he was awarded the Renee Hock Fellowship at the Institute of Ophthalmology to investigate the role of the blood-retinal barrier in inflammatory eye disease. In 1993, he was made Senior Lecturer and in 2000 was appointed Full Professor at the Institute of Ophthalmology. During the last 15 years he has been a member of the Institute Board of Management and for the last 8 years has been Head of the Department of Cell Biology. The Greenwood laboratory’s primary focus is the role the vasculature plays in the pathogenesis of diseases of the retina and brain. His work spans the spectrum from fundamental research through to clinical trials. Research into the role the vascular endothelium plays in the pathogenesis of retinal and brain inflammation is a core component of the laboratory. Such work has been at the forefront of identifying and characterising novel endothelial cell mechanisms that facilitate the recruitment of leukocytes to the retina and brain, a critical step in the pathogenesis of diseases such as posterior uveitis and multiple sclerosis. This work established the principle of outside-in signalling in CNS endothelial cells that support leukocyte transvascular migration and has influenced the decision to trial statin therapy for the treatment neuroinflammatory disease. More recently a major emphasis has been to investigate the biology underpinning vascular dysfunction in diseases such as diabetic retinopathy and wet age-related macular degeneration (AMD) and to discover new therapeutic targets. This work has resulted in the identification and characterisation of a novel pro-angiogenic factor called leucine-rich alpha-2-glycoprotein 1 (LRG1) and has led to the development of a therapeutic antibody targeting this protein. In 2018 this therapy will enter into clinical trials for the treatment of wet AMD. This work has been conducted in close collaboration with Professor Stephen Moss at the UCL Institute of Ophthalmology.
11:00 - 12:30 | HERMES

**IM - OCT in inflammatory ocular diseases: beneath and beyond the retina**

Optical coherence tomography (OCT) has revolutionized the understanding and management of different ophthalmological diseases, including ocular inflammation. Although the retina has been the subject of the most intense investigation, other ocular structures can also be analyzed by this elegant technique. Indeed, very early, OCT was used to study the cornea and the optic disk. More recently, recent methodological developments have given access to the choroid. The aim of this SIS is to provide an overview of the information that can be provided by OCT in analyzing ocular tissues distinct from the retina, in the context of inflammatory diseases.

**WILLERMAIN F , NERI P**

**2311** 11:00 From time domain to high resolution and angio-OCT: an historical perspective  
NERI P , Mariotti C , Pirani V , Bisceglia P , Giovannini A - Agugliano

**2312** 11:22 Anterior segment OCT in corneal diseases and surgery  

**2313** 11:44 OCT as a Novel useful tool in corneal transplantation  
THURET G , Gabison E , Guindolet D , Lepine T , Rolland J , Gain P - Saint Etienne

**2314** 12:06 Usefulness of OCT for imaging the choroid, the vitreous and the optic nerve during uveitis  
DENNISTON A - Birmingham

---

11:00 - 12:30 | RHODES 1

**G - Mathematical modelling in glaucoma**

Glaucomatous optic neuropathies (GON) share as a hallmark a progressive loss of RGCs and their axons with the presence of visual field defects, structural and molecular changes in the optic nerve head and other cellular responses throughout the retina. The advancement of image analysis technologies has allowed a more precise and objective study of the cellular and morphological changes associated with GON. The Special Interest Symposium will present recent studies focussing on mathematical and automatic methods to identify and quantify cellular and structural changes that appear on the retinal layers and on the optic nerve head following various types of retinal or optic nerve injury glaucoma models. The SIS will provide ample opportunity for interaction among scientists attending the conferences.

**VIDAL-SANZ M , CORDEIRO MF**

**2321** 11:00 Tridimensional studies on the adult rat optic nerve head  
PAZOS M , Yang H , Gardiner S , Cepurna W , Elaine J , Morrison J , Burgoyne C - Barcelona

**2322** 11:22 Counting microglial cells in the adult rodent retina  

**2323** 11:44 Algorithms looking for patterns of cell loss in glaucoma models  
DAVIS B - London

**2324** 12:06 Counting retinal neurons in the adult rat retina  
<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
</table>
| FP      | 11:00 - 12:30 | RHODES 2 | RV - FP session - Diabetes                                      | SOUBRANE G , DE LAEY JJ  
2331 11:00 Alterations of retinal vessel size after single injection of intravitreal anti-VEGF for diabetic macular edema  
AKPOLAT C , Kurt M , Cekic O - Istanbul  
2332 11:12 Uregulated expression of heparanase in the vitreous of patients with proliferative diabetic retinopathy originates from activated endothelial cells and leukocytes  
2333 11:24 In vivo measurement of increased vascular permeability after STZ induction of diabetes in rats by fluorescence angiography using the Micron IV  
ALLEN C , Bates D - Nottingham  
2334 11:36 Choroidal thickness in diabetic patients without diabetic retinopathy  
2335 11:48 Tomographic analysis of the retinal layers in diabetic macular edema treated with dexamethasone intravitreal implant  
MEDIEIROS PINTO J , Prates Canelas J , Rosa R , Coelho C , Vaz-Pereira S - Lisbon  
2336 11:54 Iluvien monotherapy for diabetic macular oedema in vitrectomised and non-vitrectomised eyes: one year data  
2337 12:00 Deep learning approach for diabetic retinopathy screening  
COLAS E , Besse A , Orgogozo A , Schmauch B , Meric N , Besse E - Paris  
2338 12:06 Diabetic maculopathy screening in England; are we seeing too much?  
BEGUM S , Macgregor C , Meredith P , Cansfield J , Meredith S - Portsmouth |
| C       | 11:00 - 12:30 | RHODES 3 | PO/RV - Mistakes in the diagnosis of fundus tumors          | DESJARDINS L , ZOGRAFOS L  
2341 11:00 Mistakes in the diagnosis of children intraocular tumors  
CASSOUX N - Paris  
2342 11:18 Suspicious choroidal naevi: when to observe , when to treat  
KIVELÄT - Helsinki  
2343 11:36 Difficulties in the diagnosis of achromic fundus lesions and hemorrhagic lesions  
DESJARDINS L - Paris  
2344 11:54 Problems in the diagnosis of intraocular lymphoma  
CASSOUX N - Paris  
2345 12:12 Indications and interpretation of various imaging techniques  
ZOGRAFOS L - Lausanne
Primary inherited optic neuropathies are a group of blinding genetic disorders in which optic atrophy secondary to loss of retinal ganglion cells is a clinical key feature. The commonest causes world-wide is mutation in mitochondrial DNA (causing Leber’s Hereditary Optic Neuropathy) and OPA1 mutations (causing Autosomal Dominant Optic Atrophy: ADOA). 60-80% of patients with autosomal dominant optic atrophy have mutations in the OPA1 gene. Inherited optic neuropathy is an ‘orphan’ disease. However, the disease prevalence is not so low (1: 20,000 to 35,000), and it is estimated that there are 5000 to 8000 distinct rare diseases, affecting 6-8% of the population of the European Union (27-36 million people). Recent trials of the drug idebenone, a co-enzyme Q10 analogue, in patients with the mitochondrial optic neuropathy, Leber’s hereditary optic neuropathy, have shown the first glimmer of hope for the treatment of this group of patients. At this exciting time this SIS will focus on disease mechanisms and potential avenues towards therapy.

VOTRUBA M, YU-WAI-MAN P

2361 11:00 The genetic pathophysiology of dominant optic atrophy

2362 11:18 Looking for a sensitive biomarker for genetically determined neurodegenerative diseases through the window of the eye

2363 11:36 OCT angiography in mitochondrial optic neuropathies
BARBONI P, Balducci N - Bologna

2364 11:54 Perturbed mitochondrial homeostasis in LHON: a new target for rescue strategy
CARELLI V - Bologna

2365 12:12 Personalised therapies for mitochondrial optic neuropathies - myth or reality?
YU-WAI-MAN P - Newcastle upon Tyne
Thursday, Oct 6 - Second morning session

SIS

11:00 - 12:30 | GALLIENI 4

ACB/COS - How I fell in love with scleral lenses - the attractive lens paradox

Scleral lenses represent a paradox in contact lens care: Even though they offer a great deal of advantages for patient and doctor in a so many scenarios of ocular surface dysfunction and disease - they are only used in a minority of cases. This may be due to the fact that Sclerals seem to represent the historic type of a large rigid ‘foreign body’ that rests on the sclera and vaults the cornea. However, modern lens materials & designs nowadays make Sclerals an easy to use and versatile tool for daily practise with ideal wearing comfort and medical safety in contrast to the vast majority of (mainly soft) cosmetic contact lenses that can often give rise to problems. Sclerals are a highly underestimated medical tool. Their tear-fluid filled lake over the cornea makes them an ideal tool for optical restoration of irregular corneas, particularly in keratokonus, for the prevention of further wounding, for the restoration of ocular surface integrity in dry eye disease of different type and as a measure to improve or even heal corneal recurrent erosions, ulcers, opacities and scars without the need to undergo surgery or even keratoplasty. Long term experience of ophthalmologists from around the world will be introduced in this SIS.

KNOP E, KNOP N

2371 11:00 The ocular surface anatomy under cover - its interaction with a scleral lens

KNOP E, Knop N - Berlin

2372 11:18 Keratokonus - the killing application for most contact lenses is the prototypical job for sclerals

NAU C, Schornack M - Minnesota

2373 11:36 It’s not just keratokonus - some general fitting techniques for scleral lenses in so many scenarios

CARRASQUILLO K G - Boston

2374 11:54 Moderate to severe dry eye - a promising indication for scleral lenses

DOAN S, Delcampe A - Paris

2375 12:12 Are scleral lenses safe for the meibomian gland?

MEKKI M B, Yahiaoui S, Titah O, Belaoudmou R, Taibi A, Bouguerfa R - Algiers

FP

11:00 - 12:30 | GALLIENI 5

PBP - FP session - Oxygen delivery and regulation of vascular tone

OSBORNE N, GARHÖFER G

2381 11:00 Ca2+ activity during ATP-induced tone changes in porcine retinal arterioles in vitro

spreads along the processes of perivascular cells

KUDRYAVTSEVA O, Bek T - Aarhus

2382 11:12 Vasodilation by cell membrane permeable but not impermeable carbonic anhydrase inhibitors of precontracted retinal arteries

EYSTEINSSONT T, Hardarson A O, Carta F, Supuran CT - Reykjavik

2383 11:24 Automatication and improved repeatability of retinal oximetry

HARDARSON S, Karlsson R A, Olafsdottir O B, Eliasdottir T, Bek T, Stefánsson E - Reykjavik

2384 11:36 Correlation between retinal and mixed venous oxygen saturation

VAN KEER K, Abegão Pinto L, Stalmans I, Vandewalle E - Leuven

2385 11:48 The effect of systemic tamsulosin hydrochloride on choroidal thickness and pupil diameter sizes

DOGAN M, Kutluksaman B, Keles I, Halat A O - Abyonkarahisar

2386 12:00 The assessment of Ocular Blood Flow with Laser Speckle Flowgraphy in healthy Caucasian


2387 12:06 Quantitative assessment of retinal permeability in the diabetic Akimba mouse: validation of a promising animal model for diabetic retinopathy

HU TT, Vanheukelom V, De Vriese A, Feyen J H M - Heverlee
Thursday, Oct 6 - Lunchtime session

Leber's hereditary optic neuropathy (LHON): latest advances in diagnosis, staging and patient management

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker and Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:40</td>
<td>Introduction</td>
<td>KLOPSTOCK T - Germany</td>
</tr>
<tr>
<td>12:45</td>
<td>Advances in identifying patients with LHON: Early diagnosis</td>
<td>LAGREZE W D - Germany</td>
</tr>
<tr>
<td>12:55</td>
<td>Advances in understanding of the disease: Pathogenic mechanisms for neuronal degeneration</td>
<td>TIRANTI V - Italy</td>
</tr>
<tr>
<td>13:05</td>
<td>Advances in understanding of the disease: Clinical staging</td>
<td>CARELLI V - Italy</td>
</tr>
<tr>
<td>13:15</td>
<td>Advances in patient care: Raxone a new treatment option for patients with LHON</td>
<td>KLOPSTOCK T - Germany</td>
</tr>
<tr>
<td>13:35</td>
<td>Co-Chairman’s summary and Q&amp;A</td>
<td>CARELLI V - Italy</td>
</tr>
</tbody>
</table>
### Rhodos 2: Thursday, Oct 6 - Lunchtime session

#### 12:40 - 13:40 | Rhodos 2

**Demodex: innocent or guilty in blepharitis?**

**James Te**
- **12:40** Introduction

**2431 12:45** Demodex background and epidemiology aspects  
  *Merayo-Lloves J - Spain*

**2432 13:00** Demodex: ocular implications  
  *Kaya S - Austria*

**2433 13:15** Management of Demodex in ophthalmology  
  *James Te - United Kingdom*

- **13:15** Conclusion
Introduction by Thomas FUCHSLUGER

Summary:
It is important for clinician scientists to acquire the advanced knowledge and novel technology needed to create completely new areas of translational research, ultimately aimed at application in the clinical setting. For instance, devastating ocular surface disorders such as Stevens-Johnson syndrome and chemical injury, aiming at the development of novel therapies for corneal endothelial dysfunction. Proved the clinical efficacy of medical injection for corneal endothelial dysfunction such as Fuchs endothelial corneal dystrophy. For this purpose, non-proliferative corneal endothelial cells from donated corneas can be induced to proliferate, without inducing cell state transition (CST). In clinical research started in December 2013, all the cases performed this procedure have already shown promising results. It is our hope that ophthalmology-related translational research, such as that described above, will receive official governmental approval based on accumulated data of the safety and efficacy of the procedures.

Award presentation of the EVER Certificate of Honour

Biography Shigeru KINOSHITA:
Dr. Shigeru Kinoshita, a clinician scientist, graduated from Osaka University Medical School in 1974, and has served as the Professor and Chair of Ophthalmology at Kyoto Prefectural University of Medicine since 1992. Because of his stepping down from the Chair of Ophthalmology in March 2015, he was elected the Professor and Chair of Frontier Medical Science and Technology for Ophthalmology at Kyoto Prefectural University of Medicine in April 2015. And, he has been continuously working as a distinguished clinician scientist.

In the early 1980s at Harvard Medical School, he, in collaboration with Dr. Richard A. Thoft, established the concept of centripetal movement of corneal epithelium, and his groundbreaking work has shed new light on the importance of limbal epithelium. His series of findings has had an enormous impact on this subject and has afforded much insight, ultimately contributing to the development of the corneal stem cell theory set forth by Tuen-Tien Sun. Based on these concepts, Dr. Kinoshita developed a new surgical procedure for in vivo corneal epithelial transplantation that has led to epithelial stem cell transplantation for ocular surface rehabilitation. Over the past 30 years, his primary interest has been focused on the translational research of new therapeutic modalities for severe corneal diseases. Following this path, his group has recently established the system of cultivated mucosal epithelial stem cell transplantation for severe ocular surface disorders such as Stevens-Johnson syndrome and chemical injury, and cultivated corneal endothelial cell transplantation for bullous keratopathy. His group also proved the clinical efficacy of Rho-associated protein kinase (ROCK)-inhibitor topical application for partial endothelial dysfunction, aiming at the development of novel therapies for corneal endothelial dysfunction.

Kinoshita is a recipient of the 1999 Alcon Research Institute Award, the 2008 Castroviejo Medal Lecturer of the Cornea Society, the 2009 ARVO Gold Fellow, the 2010 Claes H. Dohlman Conference Address of the TFOS, the 2010 Meibom Lecturer in Germany the Doyne Memorial Lecturer of the 2011 Oxford Ophthalmological Congress in United Kingdom, the 2011 ElseMay Bjorn Lecture in Finland, Schepens Eye Research Institute Almunus Award 2011, the Peter Herberg Lecture at IMCLC2012, the Richard Lindstrom Lecture, CLAO, ASCRS 2014, Charles D. Kelman Inovator Award, ASCRS 2015, and the Friedenwald Award Lecturer at the ARVO 2016. He served as an ARVO Program Committee Member in the Cornea Section between 1996 and 1999, the ARVO Trustee of the Cornea Section between 2006 and 2011, and the ARVO Vice President in 2010-2011.
The evolution of tertiary care ophthalmology is clearly towards the development of subspecialist with a very specific domain of competence. However, in several diseases the clinical presentation requires an experience in multiple subspecialties. The aim of this SIS is, based on clinical cases, to join different sections to understand how they differently approach the same disease.

CASPERS L, WILLERMAIN F

14:30 - 16:00 | HERMES

**IM/RV - Challenges and controversies in ophthalmology: When the patient overlap between different subspecialties**

Controversies between retinal dystrophies and uveitis - the point of view of the retina specialist. Does electrophysiology help?

**LEROY B, Holder G - Ghent**

Controversies between retinal dystrophies and uveitis - the point of view of the uveitis specialist. Does retinal antibody detection help?

**WILLERMAIN F, Draganova D, Leroy B P, Caspers L, Postelmans L, Corazza F - Bruxelles**

Controversies between lymphoma and uveitis - the point of view of the ophthalmologist

**TOUITOU V - Paris**

Controversies between lymphoma and uveitis - the point of view of the neuro-oncologist

**TOUITOU V, HOUILLIER C - Paris**

Controversies between how to handle uveitis and glaucoma. The point of view of the uveitis specialist

**KESTELYN P - Gent**

Controversies between how to handle uveitis and glaucoma. The point of view of the glaucoma specialist

**BRON A - Dijon**

**14:30 - 16:00 | RHODES 1**

**G/PBP - OCT spectralis in neurodegeneration - Young investigator presentations**

Experts from different fields will discuss the use of the spectralis in neurodegeneration including: Glaucoma, Alzheimer’s, Down’s, Parkinson’s, Multiple Sclerosis

CORDEIRO MF, NORMANDO EM

14:30 - 16:00 | RHODES

**G/PBP - OCT spectralis in neurodegeneration - Young investigator presentations**

OCT in AD


Retinal structure in Down’s syndrome; potential markers of Alzheimer’s disease

**WALPERT M, Normando E M, Cordeiro M F, Holland A - Cambridge**

Fluorescence lifetime imaging

**DYSLI C - Bern**

Auto fluorescence

**HERMANN P - Bonn**
Graves’ Orbitopathy is one of the most frequent inflammatory disorders of the orbit, but still with a puzzling pathogenesis. Diagnostic evaluation and management are also challenging.

New diagnostic approach, with a comprehensive differential diagnosis will be presented. The updated EUGOGO (European Group of Graves’ Orbitopathy) guidelines and medical management as the possibility of new molecules for the immunosuppression therapy will be discussed. Various pathogenesis hypotheses and their possible consequence on the GO management will also be considered.

**BOSCHI A, BALDESCHI L**

**2631** 14:30 Update in Graves’ Orbitopathy  
**LUDGATE M - Cardiff**

**2632** 14:52 Differential Diagnosis of Graves’ Orbitopathy  
**BALDESCHI L - Bruxelles**

**2633** 15:14 Euthyroid Graves’ Orbitopathy  
**BOSCHI A - Bruxelles**

**2634** 15:36 Update in medical management of Graves’ orbitopathy  
**SALVI M - Milan**

---

An understanding of the anatomy and physiology of the retina are essential in order to help in the diagnoses and treatment of various types of retinal diseases. Generally, only a limited amount of information is available in ophthalmic textbooks with the reader being unaware of more recent advances. The aim of this course is therefore to provide some more in-depth information on retinal structure and function to hopefully facilitate in an understanding in, for example, imaging diagnostic technologies like OCT and adaptive optics. Moreover, the newer available methods that include gene and stem cell treatments are aimed at preserving specific retinal cell-types and this requires knowledge related to the functional and morphological relationship between neurons, glial cells and the retinal vascular. In addition, an understanding of the relationship between retinal physiology and circadian rhythms cannot be ignored. The course should benefit clinicians, basic scientists and physiologists and will concentrate on retinal glial cells, the important relationship between photoreceptors and retinal pigment epithelial cells, the significance of ganglion melanopsin cells and the unique characteristics of the ON/OFF pathway of the retina.

**GRZYBOWSKI A, OSBORNE N**

**2641** 14:30 General structure and function of the retina  
**GRZYBOWSKI A - Olsztyn**

**2642** 14:48 Retinal vasculature structure and function  
**SCHMETTERER L - Vienna**

**2643** 15:06 The RPE/photoreceptor complex  
**OSBORNE N - Oxford**

**2644** 15:24 Retinal glial cells  
**OSBORNE N - Oxford**

**2645** 15:42 The ON/OFF system pathway of the retina  
**CASTELO-BRANCO M - Coimbra**
PO - Challenges in management of orbital tumors

The purpose of this course is to emphasize the diagnostic and surgical challenges in orbital tumors. Given the variety of structures confined to orbit, orbital tumors constitute a wide spectrum of lesions which pose numerous challenges for the clinician in terms of accurate diagnosis and management. A systematic approach is necessary to understand the pre-operative evaluation, classification, surgical planning and management of orbital tumors. In this course we will provide a general overview of diagnostic challenges including clinical features, imaging characteristics, pathological evaluation and surgical challenges in orbital tumors.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30</td>
<td>Clinical evaluation in orbital tumors</td>
<td>Clinical evaluation in orbital tumors</td>
<td>MOURIAUX F - Rennes</td>
<td></td>
</tr>
<tr>
<td>11:52</td>
<td>The art of orbital imaging</td>
<td>The art of orbital imaging</td>
<td>TUNC M - Ankara</td>
<td></td>
</tr>
<tr>
<td>12:14</td>
<td>Orbital pathology: Differential diagnostic challenges</td>
<td>Orbital pathology: Differential diagnostic challenges</td>
<td>HEEGAARD S - Copenhagen</td>
<td></td>
</tr>
<tr>
<td>12:36</td>
<td>Surgical management in orbital tumors</td>
<td>Surgical management in orbital tumors</td>
<td>BRISCOE D - Afula</td>
<td></td>
</tr>
</tbody>
</table>

NSPH - Update in clinical features and genetics in microphthalmia

Microphthalmia is a rare and panocular disease. This rare ocular disorder can occur as unilateral or bilateral. Anophthalmia is at the extreme of the malformative manifestations. Microphthalmia is a developmental and genetic ocular disease. Axial length is reduced with severe hyperopia and ocular globe anomalies are common. Genetic components are exposed with update of new genes. Syndromic manifestations in microphthalmia can be associated. Nanophthalmos is a specific form of microphthalmia and ocular complications must be known and anticipated. Exploration, imaging, medical and surgical care are specific and described to optimize the treatment of ocular complications.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:52</td>
<td>Nanophthalmos clinical features and specific outcome</td>
<td>Nanophthalmos clinical features and specific outcome</td>
<td>BREMOND-GIGNAC D - Paris</td>
<td></td>
</tr>
<tr>
<td>15:14</td>
<td>Optical coherence tomography findings of retinal folds in nanophthalmos</td>
<td>Optical coherence tomography findings of retinal folds in nanophthalmos</td>
<td>ATILLA H - Ankara</td>
<td></td>
</tr>
</tbody>
</table>
### FP 4: Ocular Surface Diseases Update

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>2671</td>
<td>14:30</td>
<td>Effectiveness of platelet-rich plasma treatment in patients with chronic corneal erosions, associated with Herpetic keratitis</td>
<td>LOSHKAREVA A, Maychuk D - Moscow</td>
<td></td>
</tr>
<tr>
<td>2672</td>
<td>14:42</td>
<td>Ocular surface involvement on GVHD patients</td>
<td>LAZREG S - Dar el Beida</td>
<td></td>
</tr>
<tr>
<td>2673</td>
<td>14:54</td>
<td>Communication between the researcher and the researched. Designing an application based study regarding effects of air pollution on ocular surface diseases</td>
<td>CZAK W, Nowakowski J, Mulak M, Laba A, Misiuk - Hojlo M - Wroclaw</td>
<td></td>
</tr>
<tr>
<td>2674</td>
<td>15:06</td>
<td>Correlations Fleischer deposits with topographic parameters at different deformations of the cornea</td>
<td>ANISIMOV S, Anisimova S, Mistrukov A - Moscow</td>
<td></td>
</tr>
<tr>
<td>2675</td>
<td>15:18</td>
<td>Severe ocular manifestations of rosacea in adult</td>
<td>HASSAIRI A, Limaiem R, Maamouri R, El Matri L - Tunis</td>
<td></td>
</tr>
<tr>
<td>2677</td>
<td>15:30</td>
<td>Surface chemistry of the interactions of cationic nanoemulsions with human meibum films</td>
<td>DAULL P, Yokoi N, Nencheva Y, Georgiev G A - Evry</td>
<td></td>
</tr>
</tbody>
</table>

### FP 5: Imaging

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>2681</td>
<td>14:30</td>
<td>Normal values for fundus perimetry with the MAIA microperimeter and short-term repeatability evaluation</td>
<td>BAUDIN F, Assad G, Meillon C, Koehrer P, Bron A, Creuzot C - Dijon</td>
<td></td>
</tr>
<tr>
<td>2682</td>
<td>14:42</td>
<td>High resolution adaptive optics retinal image analysis in early-stage central areolar choroidal dystrophy with a PRPH2 mutation</td>
<td>GOCHO K, Itoh N, Akeo K, Kameya S, Hayashi T, Takahashi H - Inzai</td>
<td></td>
</tr>
<tr>
<td>2683</td>
<td>14:54</td>
<td>Static and dynamic retinal vessel analyses in patients with stroke as compared to healthy control subjects</td>
<td>DE BOEVER P, Palkovits S, Pertl L, Fazekas F, Kneihsl M, Trozic I, Goswami N, Weger M - Mol</td>
<td></td>
</tr>
<tr>
<td>2684</td>
<td>15:06</td>
<td>Stereo OCT angiography in macular diseases</td>
<td>MAUGET-FAYSSE M, Wolff B, De Bat F, Vasseur V, Alonso A S - Paris</td>
<td></td>
</tr>
<tr>
<td>2686</td>
<td>15:30</td>
<td>Static retinal vessel analysis in routine optometric practice</td>
<td>FRENCH C, Heitmar R - Birmingham</td>
<td></td>
</tr>
<tr>
<td>2687</td>
<td>15:36</td>
<td>Trial study to automatically distinguish small haemorrhages in early diabetic retinopathy from image artefacts</td>
<td>SUZUKI N, Yamane K - Numazu</td>
<td></td>
</tr>
</tbody>
</table>
16:00 - 17:00 | POSTER AREA

**EOVS: Electrophysiology, physiological Optics, Vision Sciences**

**T001 - T013**

**LEROY B, HOLDER G**

**T001**
Normal Values for Amplitude of Accommodation among a Population of High School students in Iran

**T002**
Aberrations, accommodation and pseudoaccommodation in myopia and hyperopia
Tarutta E, Harutyunyan S, Khazdzhan A, Khodzhabekyan N - Moscow

**T004**
Difference between manifest and cycloplegic refraction in healthy non-presbyopic patients

**T005**
The Impact of efferent oculomotor signals on size and distance perception

**T006**
Early hydroxychloroquine retinal toxicity enhanced by multifocal electroretinogram and laser flare-cell meter
Cellini M, Sebastiani S, Campos E - Bologna

**T007**
Analysis of macular sensitivity using multifocal electroretinogram and microperimetry in Central Serous Chorioretinopathy patients after half-dose photodynamic therapy

**T008**
Combination of global electroretinogram and sd-oct in the etiology of infantile nystagmus
Bouladi M, Bouraoui R, Limaiem R, Chaker N, Mghaieth F, El Matri L - Tunis

**T009**
Onset-offset visual evoked potentials in the diagnosis of ocular albinism in infantile nystagmus
Bouladi M, Bouraoui R, Limaiem R, Chaker N, Mghaieth F, El Matri L - Tunis

**T010**
Are Currently Available Tests Satisfactory for Color Vision Assessment?
Isik M, Ozcerit AT, Erdurmus M, Inam O - Sakarya

**T011**
The Effect of Sports Participation on Quality of Life in Subjects with Low Vision
Ilhan B, Idil A, Ilhan I, Erkan Turan K - Ankara

**T012**
Unilateral Carcinoma-Associated Retinopathy: Diagnosis, Serology and Treatment
Roels D, Ueno S, Kondo M, Leroy B P - Ghent

**T013**
Systematic Assessment of Clinical Methods to Diagnose and Monitor Diabetic Retinal Neuropathy
Jenkins K S, Rowan A, Layton C - Brisbane
16:00 - 17:00 | POSTER AREA

G: Glaucoma

T014 - T064

PAZOS M , ABEGAO PINTO L

T014  Long-term results of up to 6 years of mitomycin-c augmented non-penetrating deep sclerectomy for pseudoexfoliation glaucoma
YAZGAN S , Ates H , Guven Yilmaz S , Celik T - Zonguldak

T015  Filtering Blebs After XEN Implantation and Trabeculectomy: A Clinical and In Vivo Confocal Microscopy Study

T016  Ab Intra Collagen Stent implantation as a treatment option for open angle glaucoma
CRISOSTOMO S , Cardigos J , Costa L M , Basilio A L , Anjos R , Cardoso M , Gomes T - Lisbon

T017  Trends in glaucoma surgical procedures in Portugal - a national database report 2000-2014
BARBOSA BREA D, Gonçalves-Pinho M, Vasco Santos J, Rocha Sousa A, Freitas A - Porto

T018  Incidence and risk factors of elevated intraocular pressure following deep anterior lamellar keratoplasty
HUANG O, Mehta J, Htoon H, Tan D, Wong T - Singapore

T019  New drainage construction in the surgical treatment of glaucoma
SULEIMAN E, Kiseleva O, Zhuravleva A - Moscow

T020  EyeOP1 as a novel non-invasive surgical treatment of glaucoma: an Italian multicenter study

T021  Retrospective review of pressure reducing effect of iStent and Trabectome procedures combined with cataract surgery
TOTH M, Bazeer S, Gazzard G - London

T022  Canaloplasty with Stegmann’s Canal Expander® for Open-angle Glaucoma
STANGOS A, Mameletzi E, Sunaric Megevand G - Geneva

T023  Ultrasound evaluation of Ahmed Glaucoma Valve: IOP versus tube patency
BONO V, Zeppa L, Costagliola C, Zeppa L - Avellino

T024  Macroscopic analysis of filtering bleb functionality after XEN Gel Stent implantation with Anterior Segment Optical Coherence Tomography
COSTA L, Cardigos J, Crisostomo S, Anjos R, Sa Cardoso M, Gomes T - Lisbon

T025  Trabeculectomy: long term visual field stability
BOBAT H, Lockwood A, Kirwan J F - Portsmouth

T026  Augmentation of corneal graft tissue with UV-riboflavin crosslinking: a pilot study in glaucoma drainage device patients
STONE D, Ahmad S, Craven R, Owaïdah O - Riyadh

T027  Case-finding for angle closure: the diagnostic value of simple tests for estimating limbal and central anterior chamber depth

T028  Integrated visual field and relative risk for quality of life loss
Thursday, Oct 6 - Poster session 1

G: Glaucoma

**T014 - T064**

**T029** | rf | Ultrasound treatment in patients with Primary Open-Angle Glaucoma with a second generation probe: Results of a Multicenter Clinical Trial
---|---|---
APTEL F, Rouland J F, Stalmans I, Denis P - Meylan

**T030** | rf | Transmission electron microscopy study of the collagen fibers of the trabecular meshwork in glaucoma patients
---|---|---

**T031** | rf | A link between diabetes mellitus and glaucoma — Danish Nationwide Study
---|---|---
HORWITZ A, Petrovski B E, Petrovski G, Torp-Pedersen C, Kolko M - Copenhagen

**T032** | rf | Hemodynamic changes in eyes with early primary open-angle glaucoma measured by transpalpebral rhoephtalmography
---|---|---

**T033** | rf | Primary Open Angle Glaucoma treated by High Intensity Focused Ultrasound (HIFU). Results at 18 months of a prospective pilot study on patients treated with the 2nd generation probe
---|---|---
ROULAND J F, Aptel F - Lille

**T034** | rf | Efficacy and patient tolerability of preservative-free latanoprost compared with preservative prostaglandin analogs in patients with ocular hypertension or glaucoma
---|---|---
EL AMEEN A, Vandermeer G, Pisella P J - Tours

**T035** | rf | Why risking the satisfaction and the compliance of your newly diagnosed glaucoma patient? The PASSY survey.
---|---|---
MUNOZ - NEGRETE F J, Erb C, Stalmans I, Lemij H - Madrid

**T036** | rf | High-intensity focused ultrasound cyclocoagulation: a 6-month study
---|---|---
VANDEWALLE E, Somers A, Vermorgen K, Stalmans I - Leuven

**T037** | rf | Introducing and measuring cornea and sclera deformability parameters on the basis of Schiotz tonometry: mathematical modeling and clinical evaluation in Primary Open Angle Glaucoma (POAG)
---|---|---
IOMDINA E N, Lyubimov G, Moiseeva I, Stein A, Kiseleva O, Archakov A - Moscow

**T038** | rf | 5-year Incidence of Lubricant Dependence in Medically and Surgically Treated Glaucoma Patients
---|---|---
IYER J, Lim F, Yang Z, Tong L, Wong T - Singapore

**T039** | rf | Effect of different lightning conditions on daily living activities of glaucoma patients
---|---|---

**T040** | rf | Follow-up of patients treated by prostaglandins eyedrops. Preliminary results from the FREE survey
---|---|---
GRABSKA-LIBEREK I - Warszawa

**T041** | rf | A descriptive subgroup analysis of within hospital glaucoma referral in a tertiary center in Portugal
---|---|---
LEAL I, Cordeiro Sousa D, Marques-Neves C, Abegao Pinto L - Lisbon

**T042** | rf | A comparison of visual field testing with a new automated perimeter, the Compass visual field analyser, and the Humphrey visual field analyser
---|---|---
16:00 - 17:00 | POSTER AREA

**G: Glaucoma**

**T014 - T064**

**T043**

Efficacy & safety comparison between Cosopt & Xolamol: Branded & generic fixed combination of 2% Dorzolamide / 0.5% Timolol

ALI ALJASIM L, Edward D, Khandekar R - Riyadh

**T044**

Early & delayed effect of using steroid following SLT, randomised controlled trial

ALI ALJASIM L, Owaidhah O - Riyadh

**T045**

Use of glaucoma medications in Portugal: a cross-sectional nationwide study

CORDERO SOUSA D, Leal I, Nascimento N, Abegao Pinto L - Lisbon

**T046**

Ultrafiltration rate in hemodialysis does not affect mean ocular perfusion pressure or intraocular pressure in end-stage renal disease


**T047**

Dexamethasone induced glaucoma as part of chemotherapy for lymphoblastic lymphoma and colorectal cancer


**T048**

Müller cells increase survival of retinal ganglion cells - a coculture model of primary retinal ganglion cells and primary Müller cells

TOFT-KEHLER A K, Skytt D, Brændstrup C, Gurubaran I, Kolko M - Copenhagen

**T049**

Quantification of green fluorescent protein expression in mouse retinal ganglion cells following intravitreal injection of recombinant adeno-associated virus

KHATIB T, Osborne A, Widdowson P, Martin K - Cambridge

**T050**

Age related changes in axon guidance cues in the optic chiasm

GOMES ALVES DA CONCEICAO R, Barber A C, Martin K R - Cambridge

**T051**

Increased intraocular pressure causes deficiency in the level of ELAVL1/HuR cytoplasmic fraction in the retina


**T052**

The predegenerated nerves extract enhances the endogenous neuroprotective system of Retinal Ganglion Cells by modulating of BDNF expression in rat glaucoma model

PIETRUCHA-DUTCZAK M, Smedowski A, Lewin-Kowalik J - Katowice

**T053**

Association of polymorphic variants of miRNA processing genes DGCR8 and XPOS with primary open-angle glaucoma risk in a Polish population


**T054**

Neuroprotective effects of EPA and DHA fatty acids in the DBA/2J hereditary glaucoma mouse model


**T055**

The vitreopapillary interface in healthy and glaucoma – The VPI study

WILLEKENS K, Pinto L A, Vandewalle E, Stalmans P, Stalmans I - Leuven

**T056**

Longitudinal changes in retinal nerve fiber layer thickness in a healthy caucasian population

POPA CHERECHEANU A, Barac C, Miu J, Roncea T, Nicolae A, Duta S, Pirvulescu R - Bucharest
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>T057</td>
<td>A vascular comparison between primary open-angle glaucoma and normal-tension glaucoma</td>
<td>VAN KEER K, Abegão Pinto L, Barbosa Breda J, Willekens K, Vandewalle E, Stalmans I - Leuven</td>
</tr>
<tr>
<td>T059</td>
<td>Lamina cribrosa displacement after trabeculectomy in pseudoexfoliation and primary open angle glaucoma</td>
<td>KADZIAUSKIENE A, Strelkauskaite E, Asoklis R, Lesinskas E, Schmetterer L - Vilnius</td>
</tr>
<tr>
<td>T060</td>
<td>Anterior segment parameters measured by ultrasound biomicroscopy in the subtypes of angle-closure</td>
<td>KIM YY, Yoo C, Cho SY, Lee T E - Seoul</td>
</tr>
<tr>
<td>T061</td>
<td>Comparison of the pattern of peripapillary retinal nerve fiber layer damage between open-angle glaucoma and anterior ischemic optic neuropathy</td>
<td>HEO DW, Kim K N, Lee Y H, Kim C S - Daejeon</td>
</tr>
<tr>
<td>T062</td>
<td>Clinical precision for follow-up of glaucoma with PIMD-2 Pi</td>
<td>SANDBERG MELIN C, Malmberg F, Söderberg P - Uppsala</td>
</tr>
<tr>
<td>T064</td>
<td>Macular ganglion cell layer abnormalities in Spectral Domain(SD)-OCT outside glaucomatous neuropathy</td>
<td>MENDES M, El Chehab H, Bouteleux V, Agard E, Russo A, Dot C - Lyon</td>
</tr>
</tbody>
</table>
T065 - T084

GEORGIADIS T, MOHAN R

T065
From perfect visual function to “legally” blind in one year: New mutations in progressive cone dystrophy

T066
Patterned macular dystrophy as the first sign of maternally-inherited diabetes and deafness (MIDD)
ESTEBAN O, Ascaso J, Peiro B, Martinez M, Almenara C, Perez I - Zaragoza

T067
Stargardt disease phenotype-genotype correlation – first results of a Lithuanian cohort study
STRUPAITE R, Cimbalistiene L, Ambrozaityte L, Utkus A, Asoklis R - Vilnius

T068
A Novel Homozygous c.1154+3_1151+6delAAGT mutation in CERKL Causes Autosomal Recessive Retinitis Pigmentosa with a Special Phenotype in a Consanguineous Tunisian Family

T069
Oguchi disease due to a novel mutation in the GRK1 gene
DE ZAYTJJD J, Zeitz C, Leroy B P - Ghent

T070
Pseudodominance in a Czech family with Usher syndrome type II
KOUSAL B, Dudakova L, Skalicka P, Bujakowska K, Liskova P - Praha

T071
OPA1 analysis in an international series of probands with bilateral optic atrophy
LISKOVA P, Tesarova M, Dudakova L, Stepanka S, Kolarova H, Honzik T, Seto S, Votruba M - Prague

T072
Two novel KERA mutations causing cornea plana in a Czech family and associated phenotypes
SKALICKA P, Dudakova L, Liskova P - Prague

T073
Metallothionein polymorphisms in a Northern Spanish population with Age-Related Macular Degeneration (AMD)

T074
Classification and heritability of macular pigment spatial profile phenotypes using two-wavelength fundus autofluorescence
HUNTJENS B, Ctori I, Mahroo O, Williams K, Hammond C - London

T075
The zinc-metallothionein redox system in human retina and RPE

T076
Retinal function and morphology in Mitf mutant mice
GARCIA LLORCA A, Gudmundsdottir Aspelund S, Ggmundsdottir M H, Steingrimsson E, Eysteinsson T - Reykjavik

T077
The role of LRG1 in vessel normalization

T078
Validation of the STARS risk assessment tool for age-related macular degeneration in an Algerian population
DELCOURT C, Lazreg S, Sanchez A, Bandello F, Nouri MT - Bordeaux

T079
Variations in normative foveal morphology SD-OCT data: A study of White, South Asian and Black ethnicities
CTORI I, Huntjens B - London
Diabetic retinopathy and hearing loss; Results from Korean National Health and Nutrition Survey (KHANES VI) (2010-2012)

The German AugUR study: a population-based prospective study to investigate chronic diseases in the elderly with focus on age-related macular degeneration (AMD)

Spectrum and outcomes of open globe injuries presenting to a tertiary Eye Centre in Singapore
GOH M J, Chaung J, Koh V, Sundar G - Singapore

Wooden projectile caused eye injuries in Finland - Helsinki eye trauma study
HAAVISTO A K, Sahraravand A, Leivo T, Holopainen J - Helsinki

The prevalence of refractive errors among underserved rural areas in Iran
YEKTA A A, Hashemi H, Khabazkhoob M, Ostadimoghaddam H, Malekifar A, Nabovati P - Mahhad
OSBORNE N, HARDARSON S

T085 Hyperhomocysteinemia caused chorioretinal vasculopathy in an animal model
LEE Y J, Ke CY, Lin P K - New Taipei City

T086 Changes in choroidal thickness and mean ocular perfusion pressure with hemodialysis

T087 Functional end-arterial circulation of the choroid assessed by using fat embolism and electric circuit simulation

T088 Assessment of chorioretinal blood flow and vessel diameter by laser speckle flowgraphy in three animal models
WEI X, Barathi A, Sai B B, Balne P K, Khandelwal N, Agrawal R - Singapore

T089 Retinal vessel parameters in obstructive sleep apnea
HEITMAR R, Turnbull C, Blann A, Stradling J - Birmingham

T090 Visualizing retinal vessel dynamics of young type 1 diabetic patients using self-organizing map

T091 Coats’ syndrome is associated with reduced pressure autoregulation in retinal arterioles
HERBORG A, Bek T, Petersen L - Aarhus C

T092 The assessment of Ocular Blood Flow with Laser Speckle Flowgraphy in healthy Caucasian

T093 Quantitative assessment of retinal permeability in the diabetic Akimba mouse: validation of a promising animal model for diabetic retinopathy
HU TT, Vanheukelom V, De Vriese A, Feyen J H M - Heverlee

T094 The venous oxygen saturation predicts the visual prognosis after anti-VEGF treatment of central retinal vein occlusion
JEPESEN S K, Bek T - Aarhus C

T095 Retinal venous oxygen saturation in healthy, atrophic and retinal vascular diseases

T096 Differential hypoxic response of human choroidal and retinal endothelial cells proposes tissue heterogeneity of ocular angiogenesis
MAMMADZADA P, Gudmundsson J, Kvatne A, Andre H - Stockholm

T097 Vessel Diameter Study: Intravitreal Versus Posterior Subtenon Triamcinolone Acetonide Injection For Diabetic Macular Edema
AKPOLAT C, Kurt M, Cekic O - Istanbul

T098 The preventive effects of the rhodiola rosea on ischemia-reperfusion injury in the RAT retina

T099 Experimental study of intraocular temperature distribution in the rabbit under various environmental conditions
Anatychuk L, Pasynchnikova N, ZADOROVNIY O, Kobylianskyi R, Nazaretyan R, Myrenko V - Odessa
16:00 - 17:00 | POSTER AREA

PBP - Physiology/Biochemistry/Pharmacology

T105 - T108

T100
The Anti-angiogenic Effects of Gold Nanoparticles on Experimental Choroidal Neovascularization in Mice
KANG S, Rho C R, Cho W K, Roh Y J - Daejeon

T101
RESVEGA in exudative age-related macular degeneration
KUBICZ A - Wroclaw

T102
rf
Variation of accommodative process and anterior chamber parameters in diabetic patients

T103
rf
In the search of biomarkers for thyroid associated orbitopathy (TAO)

T104
Mechanisms of ocriplasmin uptake by retinal cells

T105
Light-induced oxidative stress production in the rod outer segments
PANFOLI I, Calzia D, Heinig N, Schumann U, Degan P, Traverso C E, Funk R H W, Roehlecke C - Genova

T106
Upregulated expression of proteolytic enzymes in the cultured retinal pigment epithelial cells of minipig transgenic for the human mutated huntingtin
ARDANT, Kocurova G, Hrnciarova E, Motlik J - Libechov

T107
The effect of systemic alfuzosin hydrochloride on choroidal thickness and pupil diameter sizes
DOGAN M, Kutluksaman B, Karalar M - Afyonkarahisar

T108
A 5-minute time interval between two different dilating eyedrops increases their combined effect
SAGUET P, Charlot F, Mouriaux F, Lux A L, Beraud G, Denion E - Caen

16:00 - 17:00 | POSTER AREA
Meet the Experts

In an initiative to encourage dialogue amongst speakers and EVER members, we have launched a 45 minute session called “Meet the Experts”. This will be a table of 6-8 “guests” at a table headed by one of the EVER speakers. The idea is to provide a casual yet personal venue where colleagues, in particular the younger faction, can share comments and ideas with an expert.
EVER 2016
Thursday, Oct 6 - Second afternoon session

17:00 - 18:30 | HERMES

RV - Controversies in vitreoretinal practice

This symposium will provide three relevant issues in Vitreoretinal practice: the potential treatment options for symptomatic vitreous opacities, the prophylactic use of antibiotics in intravitreal injections, and finally, the current preferred therapeutic approach for the management of age-related macular degeneration (AMD) and diabetic retinopathy. The speakers will analyze these topics, presenting and discussing both pro and con positions.

GRZYBOWSKI A , ASCASO F

2711  17:00  Vitrectomy for vitreous floaters
       ASCASO F - Zaragoza

2712  17:18  Laser for vitreous floaters
       TASSIGNON M J - Edegem

2713  17:36  Antibiotics in intravitreal injections
       GRZYBOWSKI A - Olsztyn

2714  17:54  Treat & Extend vs PRN in AMD
       PRUENTE C - Binningen

2715  18:12  Treat and Extend vs PRN in Diabetic retinopathy
       POURNARAS C - Genève

17:00 - 18:30 | RHODES 1

G - Laser - the force reawakens. New concepts in established technology

Laser treatments are important and effective in the modern management of glaucoma. In this session we will explore recent advances in inflow and outflow laser treatment options. Has Selective Laser Trabeculoplasty delivered the pressure lowering it promised with a new generation of medication free patients? Does diode laser have a role in the antiVEGF era of rubeotic glaucoma management? How can YAG laser assist glaucoma drainage devices? This session will address all forms of laser treatments in glaucoma in an effort to maximise patient outcome and enhance your clinical practice.

CRAWLEY L , BLOOM P

2721  17:00  Laser Trabeculoplasty Is the glaucoma fraternity completely convinced?
       GAZZARD G - London

2722  17:22  Inside out Diode laser for rubeotic glaucoma in the anti VEGF era
       AHMED F - London

2723  17:44  YAG laser glaucoma treatments; iridotomies and beyond
       CRAWLEY L - London

2724  18:06  Endoscopic laser- a direct view on the direct view
       BLOOM P - London
EVER 2016 will introduce a new symposium entitled YOS for EVER. YOS is a well-recognized acronym for "young ophthalmologist" and as not only ophthalmologists attend EVER, YOS stands for "young ophthalmologist/scientist". YOS for EVER represents the trainee and young specialist group within EVER. This is a networking assembly of students, residents, post-docs and junior scientists to focus on objectives and goals relevant to the early stages of career development. Such topics include board examinations, information exchange, research and/or educational programs, fellowship and job opportunities. The 2016 inaugural symposium will be organized by Gauti Johannesson, a young ophthalmologist/scientist and member of the organization committee for YOS sessions at the Nordic Ophthalmologic Congress. All interested parties are encouraged to attend as guidelines and objectives and representatives for this new subgroup will be discussed at this first meeting. Immediately following the symposium, there will be a reception with light food and beverages for those attending this session.

### JOHANNESSON G

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>2731</td>
<td>Presentation skills for oral presentations</td>
<td>JOHANNESSON G - Umeå</td>
<td></td>
</tr>
<tr>
<td>2732</td>
<td>How to fast track your research career</td>
<td>BECHRAKIS N E - Innsbruck</td>
<td></td>
</tr>
<tr>
<td>2733</td>
<td>Tricks for the spotlight - handling media</td>
<td>SOMNER J - Cambridge</td>
<td></td>
</tr>
<tr>
<td>2734</td>
<td>How to succeed with grant applications?</td>
<td>DANIELSON P - Umeå</td>
<td></td>
</tr>
</tbody>
</table>

### NSPH - Hot topic in ocular surface in children

Manifestations of ocular surface in children may be severe causing visual impairment. Vernal keratoconjunctivitis, Atopic Keratoconjunctivitis, severe dry eye manifestations of systemic pathology are rare diseases. Physiopathology of these diseases is reviewed and developed. Severe ocular surface disease in children is a challenge. Understanding and treatment is the key point. The pathogenesis remains unclear and classical tear substitute or antiallergic therapy often unsuccessful. An overview of the innovating new molecules, diagnosis and treatment are summarized. Furthermore molecules’ action can explain how the disease can be improved.

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>2741</td>
<td>Topical cyclosporine-A in dry eye associated with chronic graft versus host disease</td>
<td>ATILLA H - Ankara</td>
<td></td>
</tr>
<tr>
<td>2742</td>
<td>Severe clinical features in Vernal Keratoconjunctivitis</td>
<td>LAZREG S - Dar el Beida</td>
<td></td>
</tr>
<tr>
<td>2743</td>
<td>Atopic Keratoconjunctivitis in children</td>
<td>CHIAMBARETTA F - Clermont Ferrand</td>
<td></td>
</tr>
<tr>
<td>2744</td>
<td>Topical cyclosporine-A in Vernal Keratoconjunctivitis, when how and how long</td>
<td>BREMOND-GIGNAC D - Paris</td>
<td></td>
</tr>
</tbody>
</table>
FP

17:00 - 18:30 | RHODES 4

PO - FP session - PO

MOURIAUX F, MOULIN A

2751 17:00 The role of anterior segment optical coherence tomography (AS-OCT) and ultrasound biomicroscopy (UBM) in conjunctival nevi
LAUWERS N, Janssens K, Mertens M, De Keizer R JW, De Groot V - Edegem

2752 17:06 Loss of 5 hydroxymethylcytosine in conjunctival melanoma
MOULIN A, Caseiro P, Schalenbourg A, Zografos L, Kaya G - Lausanne

2753 17:18 Outcomes after surgical resection of lower eyelid tumors and reconstruction using a septal chondromucosal graft and an upper eyelid skin flap

2754 17:30 Cyberknife treatment in adenoid cystic carcinoma of the lacrimal gland
TUNC M, Guney Y - Ankara

2755 17:42 4 Gy radiotherapy in 6 patients with orbit marginal zone lymphoma: A small case series
GRAEFF E - Basel

2756 17:54 Sequential bilateral optic nerve infiltration as the sole manifestation of relapsed T-cell lymphoblastic lymphoma: a case report

2757 18:00 Clinical and instrumental diagnostics in patients with orbital metastasis
SAAKYAN S - Moscow

2758 18:06 Grading iris color of post-mortem human eyes
MADIGAN M, Cionaca V, Sitiwin E, Ton HT - Sydney

SIS

17:00 - 18:30 | GALLIENI 1+2

MBGE/NSPH - Syndromic retinopathies

Syndromic retinopathies are complex disorders in which the retinal involvement is of is one of the key features of the disease also affecting other organs and tissues. The special interest symposium will provide an overview of the molecular genetic mechanisms underlying inherited syndromic retinopathies, advances in the field of genetic testing and present selected distinct clinical entities manifestating in children.

LISKOVA P

2761 17:00 Using iP cells to uncover cilia protein function and model disease
SCHWARZ N - London

2762 17:22 Searching for the molecular causes of syndromic inherited retinal degenerations
BUJAKOWSKA K - BostonMA

2763 17:44 Syndromic paediatric vitreoretinopathies
HENDERSON R - London

2764 18:06 Molecular genetic basis of Usher syndrome in the Czech population
LISKOVA P, Kousal B, Bujakowska K, Dudakova L - Prague
### ACB - Tear proteome, inflammation and wound healing

Ocular surfaces are delicate structures of the anterior segment of the eye protected, nourished and lubricated by tear fluid. Composition of the tear film is in essential role in the health of the anterior segment of the eye. The system has its own regulatory mechanisms. Ocular surfaces are exposed environmental factors, topical ophthalmic drugs and affected by various ocular and systemic diseases. Inflammation and wound healing are vital processes involved in the defense mechanisms of the human body and pathogenesis of many eye diseases. It is also one of the most important factors in many ocular surgeries e.g. corneal, refractive and glaucoma surgery. It consists of many overlapping processes like inflammation, fibroblast activation, ECM production and remodeling of the ECM and there are many mechanisms and mediators involved in it. Tear proteomics is a powerful tool to diagnose and detect mechanisms and drugable targets of the ophthalmic and systemic diseases. SIS is focusing in the proteomics and biomarkers of the tears and anterior surface of the eye in relation these diseases.

**UUSITALO H, BEUERMAN R**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2771</td>
<td>17:00</td>
<td>Inflammation: The good and the bad</td>
<td>CALONGE M, Herreras J M, Stern M E - Valladolid</td>
</tr>
<tr>
<td>2772</td>
<td>17:22</td>
<td>Quantifying Inflammation as a common component of eye disease</td>
<td>BEUERMAN R - Singapore</td>
</tr>
<tr>
<td>2773</td>
<td>17:44</td>
<td>Tear lipids in corneal stress and inflammation</td>
<td>HOLOPAIENEN J - Helsinki</td>
</tr>
<tr>
<td>2774</td>
<td>18:06</td>
<td>Tear fluid biomarkers, conjunctival inflammation in glaucoma</td>
<td>UUSITALO H - Tampere</td>
</tr>
</tbody>
</table>

### LC - Non-surgical cataract treatment

At present, cataract can only be treated with surgical removal of the non-transparent lens. There are no effective prophylactic or therapeutic treatments despite the many attempts to find a non-surgical cure for cataract. In this symposium we will receive an introduction on lens and eye transparency and non-transparency, in order to better understand the various types of cataract measures and end-points used by the other speakers. We will hear about pharmacological and photochemical interventions intended to reverse or decrease the degree of cataract or cataract-related parameters in various models.

**LOFGREN S, BARRAQUER RI**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2781</td>
<td>17:00</td>
<td>Transparency of the lens and the eye</td>
<td>PRIETO P - Murcia</td>
</tr>
<tr>
<td>2782</td>
<td>17:15</td>
<td>Effects of a thiol antioxidant in various cataract models</td>
<td>ERCAL N, Maddirala Y, Carey J, Tobwala S - Rolla</td>
</tr>
<tr>
<td>2784</td>
<td>17:51</td>
<td>Photochemical reversal of cataract</td>
<td>KESSEL L - Glostrup</td>
</tr>
<tr>
<td>2785</td>
<td>18:09</td>
<td>Pharmacological restoration of transparency in cataract</td>
<td>MAKLEY L, Andley U, Gestwicki J - San Francisco</td>
</tr>
<tr>
<td>Session</td>
<td>Time</td>
<td>Title</td>
<td>Speaker</td>
</tr>
<tr>
<td>---------</td>
<td>--------</td>
<td>-------------------------------------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>2831</td>
<td>18:30</td>
<td>The last key highlights on dry eye</td>
<td>SULLIVAN DA</td>
</tr>
<tr>
<td>2832</td>
<td>18:45</td>
<td>Interrelationship between dry eye and MGD</td>
<td>LAZREG</td>
</tr>
<tr>
<td>2833</td>
<td>19:00</td>
<td>Is dry eye more about the ocular surface than the tear film?</td>
<td>MESSMER EM</td>
</tr>
<tr>
<td>2834</td>
<td>19:15</td>
<td>How are ocular surface cells protected in stressful situations?</td>
<td>CHIAMBARETTA F</td>
</tr>
</tbody>
</table>
EVER 2016
Friday, Oct 7
Friday, Oct 7 - First morning session

8:30 - 10:00 | HERMES

**RV - Confrontation of OCT-angiography and fluoresceine angiography**

OCT angiography became an emerging imaging modality particularly useful for the diagnosis and management of the retinal vascular pathologies. It is particularly useful for the investigations of various macular ischemic microangiopathies as well as for the diagnosis and management of age-related macular degeneration. The aim of this session is to bring together experts in order to clarify confrontation aspects of OCT-Angiography and fluorescein angiography in those macular pathologies.

POURNARAS C, ZOGRAFOS L

3111 8:30 OCT-A physics, instruments and limits of clinical application
      COSCAS F - Creteil

3112 8:42 OCT-A in neovascular age related macular degeneration
      LUMBROSO B - Rome

3113 8:54 OCT angiography in Retinal Angiomaticous Proliferation
      SOUBRANE G - Paris

3114 9:06 Diabetic maculopathy: Confrontation of FA and OCT-A findings
      COSCAS G, Lupidi M, Fiore T, Cagini C, Coscas F - Creteil

3115 9:18 OCT-A and FA findings in ocular Drepanocytosis
      AMBRESIN A - Lausanne

3116 9:30 OCT-A versus FA guided focal laser, in macular ischemic microangiopathies
      POURNARAS C - Genève

3117 9:42 OCT-A and FA in irradiation induced microangiopathy
      ZOGRAFOS L - Lausanne

8:30 - 10:00 | RHODES 1

**G - New technologies in glaucoma surgery**

The surgical field of glaucoma is rapidly changing with the introduction of new devices and techniques. Is this the end for the old trabeculectomy? First, an overview will be provided of new techniques like the Xen gel stent implant, the ultrasound cyclocoagulation, and the iStent. Secondly, difficult cases will be presented and the panel will discuss the different treatment options and guide us through the mazes of the labyrinth of glaucoma treatment nowadays.

VANDEWALLE E, STALMANS I

3121 8:30 The role for the Xen gel stent implant in glaucoma treatment
      STALMANS I - Leuven

3122 8:48 High-intensity focused ultrasound treatment for open angle glaucoma
      APTEL F - Meylan

3123 9:06 Results for the Synergy trial: use of iStent in open angle glaucoma
      GARCIA-FEIJOO J, Voskanyan L, Martinez de la Casa J M - Madrid

3124 9:24 How to tackle these difficult cases
      ABEGAO PINTO L - Lisbon

3125 9:42 How to tackle these difficult cases
      VANDEWALLE E - Leuven
SIS 8:30 - 10:00 | RHODES 2

COS - Nanotechnology in ophthalmology

This SIS highlights nanotechnological approaches for therapies in cornea, retina and glaucoma.

KOMPELLA UB, GRIFFITH M

3131 8:30 Nanoparticles for ocular surface drug and gene delivery
KOMPELLA UB - Aurora

3132 8:48 Magnetized nanoparticles for transfection of the corneal endothelium

3133 9:06 Layer-by-layer coated nanoparticles for glaucoma therapy: Focusing on the transport and cellular uptake in the trabecular meshwork
BREUNIG M, Guter M, Babl S, Liebl R - Regensburg

3134 9:24 Recent progress in microrobots for ophthalmic therapies
ULLRICH F, Nelson B J - Zürich

3135 9:42 Collagen biomaterials for cornea regeneration - how does it work
GRIFFITH M, Reddy J, Liszka A, Lewis P N, Hayes S, Meek K M - Linköping

SIS 8:30 - 10:00 | RHODES 3

PO - Conjunctival tumors

Conjunctival neoplasms are rare tumours of benign or malignant nature, which are 1) often misdiagnosed; 2) associated with severe ocular morbidity when diagnosed too late and/or treated incorrectly; and c) associated with increasing mortality in some areas of the globe. Their diagnosis and treatment can be difficult requiring a multimodality approach. There has been much progress in our understanding of the pathogenesis of these tumours in recent years. In addition, major advances have occurred in treatment with the introduction of topical chemotherapy, adjunctive radiotherapy and microsurgical developments. This symposium will provide an overview of latest understanding of the epidemiology, pathology, imaging, TNM/AJCC clinical staging and treatment of these tumours. It will highlight the use of novel cell lines that will hopefully advance our understanding of some conjunctival malignancies. Finally, it will provide the opportunity for a panel discussion where specific clinical problems can be addressed.

COUPLAND S, CAUJOLLE JP

3141 8:30 Overview of the epidemiology and pathology of conjunctival tumours
LOEFFLER K U - Bonn

3142 8:48 Diagnostic modalities of conjunctival tumours
BLASI M A - L’Aquila

3143 9:06 Treatment of conjunctival tumours
CAUJOLLE J P - Nice

3144 9:24 Cell lines of conjunctival tumours and their potential use in research
JAGER M J, Cao J - Leiden

3145 9:42 Update on the 8th Edition TNM staging system for conjunctival tumours
COUPLAND S - Liverpool
EUPO 2016
Friday, Oct 7 - First morning session

8:30 - 10:00 | RHODES 4
EUPO session 1 - Neuro-ophthalmology
Common Optic Neuropathies in Adults: Diagnosis, Treatment and Prognosis
EUPO Programme, see pages 134-135.

8:30 - 10:00 | GALLIENI 1+2
LC - Ocular damage from ambient optical radiation

The first speaker provides an overview of the ambient exposure of ocular tissues to optical radiation. The second speaker will review current knowledge on the association between sun exposure and cataract. The third speaker will review the evidence for apoptosis as a damage mechanism in ultraviolet radiation damage to the lens. The fourth speaker will review the possibility that near-infrared radiation exposure from remote controls and sensors contributes to cataract formation. Finally, the fifth speaker will provide an update on the possible threat to the retina caused by the ongoing conversion from incandescent sources to LED-sources for illumination.

SODERBERG P, WEGENER A

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3161</td>
<td>8:30</td>
<td>Ambient exposure of the ocular tissues to optical radiation</td>
<td>SODERBERG P, Yu Z, Talebzadeh N, Malmquist L, Sandberg Melin C, Galichanin K - Uppsala</td>
</tr>
<tr>
<td>3162</td>
<td>8:48</td>
<td>Update on epidemiological evidence for an association between sun exposure and cataract</td>
<td>WEGENER A, Meyer L - Bonn</td>
</tr>
<tr>
<td>3163</td>
<td>9:06</td>
<td>Evidence for apoptosis in the lens after in vivo exposure to ultraviolet radiation</td>
<td>TALEBIZADEH N, Yu Z, Kronschläger M, Galichanin K, Söderberg P - Uppsala</td>
</tr>
<tr>
<td>3164</td>
<td>9:24</td>
<td>Is the increasing exposure of the eye to near-infrared radiation from remote controls and sensing a threat to the lens?</td>
<td>YU Z, Schülmeister K, Talebzadeh N, Kronschläger M, Söderberg P - Uppsala</td>
</tr>
<tr>
<td>3165</td>
<td>9:42</td>
<td>Is conversion of indoor illumination to LED-sources a threat to the retina?</td>
<td>BEHAR-COHEN F - Paris</td>
</tr>
</tbody>
</table>
**ACB - Stem cells and cell therapy advances in ophthalmology**

The anatomical and biological properties of stem cells in the eye have been the topic of in-depth research over the last few decades. Enormous advances in the cell and tissue isolation and cultivation techniques, as well as molecular characterization of the different cell populations have been achieved, next to the major advances made in the bioscaffolds’ engineering for cell delivery and treatment of eye diseases. Advances in the cell and gene therapy have reached culmination with the human cornea being at the top and holding great promise in treating eye disorders. The eye is indeed a golden mine for stem cells. This session will include lectures from European experts in the field with high international recognition and large collaborative networks.

**PETROVSKI G, MOE M**

**3171** 8:30 Challenges in the clinical applications of cornea limbal stem cells  
FERRARI S - Venice

**3172** 8:52 Regulating gene expression towards solving ocular surface diseases  

**3173** 9:14 Advances in corneal endothelium engineering for future transplantation applications  
SHAHDADFAR A - Oslo

**3174** 9:36 The future of stem cell and cell therapy in ophthalmology  
Ferrari S, Moore T, Shahdadfar A, PETROVSKI G - Szeged

**MBGE - Grand rounds in ophthalmic genetics**

This SIS will provide a forum to discuss clinical and molecular cases with peers and leaders from the field of ophthalmic genetics. The format is simple and is comparable to that of the Grand Rounds in departments of ophthalmology around the World. Both SIS organisers will be present, together with other leaders in the field of ophthalmic genetics. Because of the format of the SIS, there will be no formal speakers set in stone from the outset, as all EVER participants will be free to submit cases during the meeting prior to this session. As such, the format will be similar to the FAN Club meeting. Nevertheless, we have indicated speakers who have declared their interest in presenting.

**LEROY B, HAMEL C**

**3181** 8:30 Cases  
AUDO I - Paris

**3182** 8:48 Cases  
HAMEL C - Montpellier

**3183** 9:06 Cases  
LISKOVA P - Prague

**3184** 9:24 Cases  
HOLDER G - London

**3185** 9:42 Cases  
LEROY B - Ghent
**Summary:**
Primary inherited optic neuropathies are a group of blinding genetic disorders in which optic atrophy secondary to loss of retinal ganglion cells is a key clinical feature. The commonest causes worldwide are mutation in mitochondrial DNA (causing Leber’s Hereditary Optic Neuropathy) and mutation in the nuclear gene, OPA1 (causing Autosomal Dominant Optic Atrophy: ADOA). 60-75% of patients with autosomal dominant optic atrophy have mutations in the OPA1 gene. The OPA1 protein is targeted to the mitochondria and is involved in regulation of mitochondrial fusion. A better understanding of mitochondrial function, including dynamics, is revealing that functional and structural changes in mitochondrial morphology are important factors in diseases of ageing in the eye and visual system. Key proteins have been discovered which control the balance of mitochondrial fusion and fission and have a range of other functions, such as controlling maintenance of mitochondrial DNA, cell death, autophagy, mitochondrial metabolism and redox signalling. A decline in mitochondrial function plays a role in the ageing process and increases the incidence of age-related disorders. Mitochondrial optic neuropathies are “orphan” diseases but with the advent of recent trials of novel therapies in patients with the mitochondrial optic neuropathy, Leber’s hereditary optic neuropathy, there is the first glimmer of hope for the treatment of this group of patients.

**Award presentation of the EVER Certificate of Honour**

**Biography Marcela VOTRUBA:**
Marcela Votruba is a Professor in Ophthalmology at Cardiff University and a Consultant in Ophthalmology at The University Hospital of Wales. She was awarded an Open Scholarship to The Queen’s College, Oxford (1981-1984) to read Physiological Sciences and obtained her BM BCh at Green College, Oxford (1987). After Primary FRCS (1989) she trained in ophthalmology at The Royal London Hospital, St Bartholomew’s Hospital, London, Bristol Eye Hospital and Moorfields Eye Hospital, London. She obtained a PhD (1999) at UCL in ophthalmic genetics, supervised by Professor Shomi Bhattacharya and Professor Tony Moore, using linkage analysis and positional cloning to identify the OPA1 gene, causing dominant optic atrophy. She has held Wellcome Trust and MRC Clinician Scientist Fellowships and is a former Consultant at Moorfields Eye Hospital and a Visiting Research Scholar at the National Eye Institute, National Institutes of Health, USA. Her research focuses on ophthalmic genetics and mitochondrial diseases. She is particularly interested in the role of mitochondria in optic neuropathy and retinal degeneration. Her Mitochondria & Vision Lab in The Cardiff School of Optometry & Vision Institute focuses on in vitro and in vivo approaches to modelling mitochondrial dysfunction leading to retinal ganglion cell loss and on genes and proteins involved in the regulation of mitochondrial morphology, with a strong emerging interest in novel therapies. She runs a genetic eye disease clinic and a retinal clinic at the Cardiff Eye Unit, University Hospital, Wales. Since 2014 she has been the Head of the School of Optometry & Vision Sciences at Cardiff University, Wales, UK.
### ARVO@EVER - Animals in ocular oncology

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>Introduction and overview on animal models used in ocular oncology</td>
<td>JAGER M J - Leiden</td>
</tr>
<tr>
<td>11:12</td>
<td>Use of the chick embryo model in uveal melanoma</td>
<td>KALIRAI H - Liverpool</td>
</tr>
<tr>
<td>11:24</td>
<td>Uveal melanoma patient-derived xenografts</td>
<td>DECAUDIN D - Paris</td>
</tr>
<tr>
<td>11:36</td>
<td>Use of the zebrafish model in uveal melanoma</td>
<td>MIONE M - Karlsruhe</td>
</tr>
<tr>
<td>11:48</td>
<td>Orthopedic xenograft mice model of retinoblastoma</td>
<td>CASSOUX N - Paris</td>
</tr>
<tr>
<td>12:00</td>
<td>Intraocular lymphoma models</td>
<td>FRENKEL S - Jerusalem</td>
</tr>
<tr>
<td>12:12</td>
<td>Summary and future directions</td>
<td>COUPLAND S - Liverpool</td>
</tr>
</tbody>
</table>

### RV - FP session - AMD & miscellaneous

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>The immunohistochemical identification and localization of homocysteine in the human retina with the features of age related macular degeneration</td>
<td>OZIMEK M , Choragiewicz T , Junemann A , Rejdak R - Lublin</td>
</tr>
<tr>
<td>11:24</td>
<td>Characterization, structural analysis, evolution of AMD drusenoid deposits “L”, Lipid type and “P”, Protein-cellular type, with multimodal imaging and morphology-structural software</td>
<td>GONZALEZ C - Toulouse</td>
</tr>
<tr>
<td>11:54</td>
<td>Frequency doubling technology perimetry and retinal fiber layer correlation in type 2diabetics without retinopathy</td>
<td>ALDAHAM S , Martin-Ridaura M D C , Puell M C - Madrid</td>
</tr>
<tr>
<td>12:00</td>
<td>Correlation between choroidal and retinal thickness in diabetic patients without diabetic retinopathy</td>
<td>CARDIGOS J , Proenca R , Vicente A , Marques N , Cunha J P , Abegao Pinto L , Ferreira J - Lisbon</td>
</tr>
</tbody>
</table>
Friday, Oct 7 - Second morning session

11:00 - 12:30 | RHODES 2
COS - FP session - Corneal transplantation from the lab to the OR

GICQUEL J, FUCHSLUGER T

3331 11:00 How to make better, safer and easier endothelial controls of long-term stored corneas with Specular Microscopy?  
         GARCIN T, Bernard A, Calyaka E, Herbebin P, Hor G, He Z, Gain P, Thuret G - Saint Etienne

3332 11:12 Effect of biochemical cues on proliferation, phenotype and migration of human corneal stromal cells  
         FERNANDEZ-PEREZ J, Ahearne M - Dublin

3333 11:24 Influence of material compliance on human corneal stromal cell behaviour  
         KELLY C, Ahearne M - Dublin

3334 11:36 Involvement of abnormally-activated CD44+ cells migrating from the iris to the center of the cornea in Fuchs Endothelial Corneal Dystrophy  
         HE Z, Thuret G, Jun A S, Muraine M, Kallay L, Toubeau D, Pereira S, Bergandi F, Gain P - Saint-Etienne

3335 11:48 Alterations in proliferative activity in the corneal endothelial periphery after transcorneal freezing  
         CORRELL M, Crouzet E, Cabrerizo J, Dornonville de la Cour M, Gain P, He Z, Heegaard S, Kiiigaard J, Thuret G - Glostrup

11:00 - 12:30 | RHODES 3
PO - Controversies in posterior uveal melanoma

The management of malignant melanoma of the posterior uvea (ciliary body and choroid) is still controversial in some points. This controversy has evolved because the peculiar and often unpredictable behavior of this tumor is poorly understood. This SIS meeting discusses some of the controversial issues, with emphasis on the debate.

MOURIAUX F, CASSOUX N

3341 11:00 Fine needle aspiration biopsy or not?  
         CASSOUX N - Paris

3342 11:22 Endoresection or not?  
         BECHRakis N E - Innsbruck

3343 11:44 Cytogenetic or molecular analysis for prognosis?  
         JAGER M J - Leiden

3344 12:06 Follow-up: which one and for whom?  
         DAMATO B - San Francisco
EUPO session 2 - Neuro-ophthalmology
Systematic Approach to the Ocular Motor System

EUPO Programme, see pages 134-135.

**EUROPEAN UNIVERSITY PROFESSORS OF OPHTHALMOLOGY**

**EUROPEAN UNIVERSITY PROFESSORS OF OPHTHALMOLOGY 2016**

**Friday, Oct 7 - Second morning session**

11:00 - 12:30 | RHODES 4
EUPO session 2 - Neuro-ophthalmology
Systematic Approach to the Ocular Motor System

**EUPO Programme, see pages 134-135.**

11:00 - 12:30 | GALLIENI 1+2
PO/IM - Cytology of atypical inflammation or tumors

Diagnostic challenges in unsolved cases of inflammation or masses in the vitreous, retina or choroid.

An inflammation can obscure or mask a malignant process. Some tumors start very indolent and mimic uveitis and present in the immunology clinic. In these difficult presentations it is important to detect the atypical components and act quickly following the modern techniques to exclude or confirm malignancies. In this SIS the atypical presentations which are suspicious for malignancies will be highlighted. A retinal or choroidal lymphoma with vitreous seeding is a typical diagnostic challenge. An atypical flat choroidal melanoma can be obscured by bleeding or inflammation. Paraneoplastic processes can mimic real neoplasms or inflammation and their typical clinical aspect will be explained. For challenging cases a biopsy can be necessary. The technical aspects of vitreous biopsies, handling and will be explained, highlighting the newer techniques. Even in very small samples it is nowadays possible to perform genetic analysis to confirm the diagnosis and add prognostic factors.

**VAN GINDERDEUREN R, VAN CALSTER J**

**3361** 11:00 Latest diagnostic possibilities in unsolved uveitis, suspicious for malignancy
NERI P, Arapi I, Pirani V, Giovannini A, Mariotti C - Agugliano

**3362** 11:18 How to recognize a masquerade syndrome? What is the differential diagnosis?
VAN CALSTER J - Leuven

**3363** 11:36 How to perform a vitreal, retinal or choroidal biopsy? What justifies an invasive technique?
VAN CALSTER J - Leuven

**3364** 11:54 Innovative pathology techniques for small tissue samples or cytology of vitreous biopsies
VAN GINDERDEUREN R - Leuven

**3365** 12:12 Applied genetic testing in ocular tumors
COUPLAND S - Liverpool
November 4, 11:00 - 12:30 | Gallieni 4
IM - FP session - Novelties in diagnosis and treatment in ocular immunology

**BODAGHI B, WILLERMAIN F**

**3371** 11:00 Diagnosis and management of cytomegalovirus anterior uveitis/endothelitis in immunocompetent patients in 2 European referral centers

**3372** 11:12 Presentation and management of cytomegalovirus retinitis in immunocompromised children
DENIER C, Robert M, Adjadj E, Michel S, Aymard P A, Bremond-Gignac D - Paris

**3373** 11:24 Validation of an antiretinal antibody detection strategy for the diagnosis of autoimmune retinopathies
DRAGANOVA D, Debaugnies F, Postelmans L, Caspers L, Willermain F, Corazza F - Brussels

**3374** 11:36 Evaluation of Tumor Necrosis Factor inhibitor therapy in Susac syndrome

**3375** 11:48 In vitro evaluation of anti HSV-1 siRNAs and in vivo evaluation of electroporation to transfect siRNAs on murine cornea

---

Radiation cataracts are a field of recent interest, following accumulating evidence in the literature that the lens is more radiosensitive than previously thought. Indeed the International Commission for Radiation Protection recently revised its judgement regarding the threshold for lens effects and occupational dose limits, with the new recommendations now incorporated into the EU Basic Safety Standard. It is intended that this session will highlight research gaps including mechanistic needs, and how also other research fields could contribute to radiation cataract research. Speakers will examine recent developments in our mechanistic understanding of radiation cataract initiation and development, including evidence for low dose radiation effects. In addition, speakers will explore the radiation protection aspects and the need for collaborative ‘molecular epidemiology’ research to fully answer the remaining questions as to how low dose ionising radiation exposure causes cataracts.

**AINSBURY L, WEGENER A**

**3381** 11:00 Investigating the effect of low dose ionising radiation on epithelial progenitor cell niches

**3382** 11:30 Lifetime Study in mice: 24 months follow up after low doses of ionizing radiation with Scheimpflug imaging and OCT

**3383** 12:00 Epidemiological needs to support lens mechanistic research
AUVINEN A - Tampere
Retinal detachment may occur in different conditions as in pseudophakic, myopic, diabetic eyes. Prevention of retinal detachment will firstly discussed. Then, the characteristics in each condition will be detailed in order to apply the best strategy for the management of our patients. Finally, retinal detachment associated with tumor cases will be discussed.

POURNARAS J, LE MERY

POURNARAS J , LE MERY

13:30 - 15:00 | RHODES 1

G - EVER Obergurgl optic nerve meeting symposium: the ageing optic nerve

The theme of the 5th Obergurgl Optic Nerve Meeting in Dec. 2015 was “The ageing optic nerve” (Organizers: Jonathan Crowston, Melbourne; Franz Grus, Mainz; Keith Martin, Cambridge). The program featured leading researchers from ophthalmology, neuroscience and related fields. Speakers discussed the influence of oxidative stress, mitochondria, glia and autoimmunity on optic nerve health, as well as their ability to protect against degeneration or to slow it down. The emphasis was on ageing and its role in disease pathogenesis and treatment approaches.

The conference brought together clinicians and basic scientists from different fields and highlighted translational research providing a platform for networking and stimulating discussions.

GRUS F, CROWSTON J, MARTIN K

13:30 - 15:00 | HERMES

RV - Retinal detachment

Retinal detachment may occur in different conditions as in pseudophakic, myopic, diabetic eyes. Prevention of retinal detachment will firstly discussed. Then, the characteristics in each condition will be detailed in order to apply the best strategy for the management of our patients. Finally, retinal detachment associated with tumor cases will be discussed.

POURNARAS J, LE MERY

POURNARAS J , LE MERY

13:30 - 15:00 | RHODES 1

G - EVER Obergurgl optic nerve meeting symposium: the ageing optic nerve

The theme of the 5th Obergurgl Optic Nerve Meeting in Dec. 2015 was “The ageing optic nerve” (Organizers: Jonathan Crowston, Melbourne; Franz Grus, Mainz; Keith Martin, Cambridge). The program featured leading researchers from ophthalmology, neuroscience and related fields. Speakers discussed the influence of oxidative stress, mitochondria, glia and autoimmunity on optic nerve health, as well as their ability to protect against degeneration or to slow it down. The emphasis was on ageing and its role in disease pathogenesis and treatment approaches.

The conference brought together clinicians and basic scientists from different fields and highlighted translational research providing a platform for networking and stimulating discussions.

GRUS F, CROWSTON J, MARTIN K
### COS/RV - Emerging solutions in ophthalmology

This SIS cross-sectional thematizes cutting-edge developments to approach unmet needs in ophthalmology.

**FUCHSLUGER T, STEFANSSON E**

| 3531 | 13:30 | Presence of proteinase inhibitor-9 and granzyme B in healthy and pathological human corneas  
JIRSOVA K, Reinstein Merjava S, Chudickova M, Holan V - Prague |
| 3532 | 13:48 | Transduction of corneal endothelial cells with AAV2 vectors  
GRUENERT A - Erlangen |
| 3533 | 14:06 | Agonistic β2 receptor autoantibodies in ocular hypertension and open-angle glaucoma  
HOHBERGER B - Erlangen |
| 3534 | 14:24 | Automated intravitreal injection system for the efficient treatment of AMD  
ULLRICH F - Zürich |
| 3535 | 14:42 | Ocular drug delivery with cyclodextrin nanoparticles: Anterior segment advantages and posterior segm  
STEFANSSON E - Reykjavik |

### PO - Topical and intravitreal pharmacotherapy in ocular oncology

In ocular oncology, a great variety of therapeutic agents are used for topical chemotherapy of the conjunctival as well as for intravitreal specific chemotherapy. In addition, numerous anti-VEGF drugs are administrated in order to prevent or to treat irradiation induced side effects. The aim of this SIS is to bring together experts in ocular oncology in order to present a comprehensive overview of this subject.

**ZOGRAFOS L, DESJARDINS L**

| 3541 | 13:30 | Topical chemotherapy for pigmented and epithelial tumors of the conjunctiva  
DESJARDINS L - Paris |
| 3542 | 13:45 | Neovascular glaucoma. Prevention and treatment with intravitreal anti-VEGF’s in ocular oncology  
SCHALENBOURG A - Lausanne |
| 3543 | 14:00 | Irradiation induced maculopathy. Pathogenesis and therapeutic approach with anti-VEGF’s  
ZOGRAFOS L - Lausanne |
| 3544 | 14:15 | Intravitreal pharmacotherapy of CME related to conservative management of uveal melanomas  
BECHRakis N E - Innsbruck |
| 3545 | 14:30 | Intravitreal chemotherapy for intraocular lymphomas  
CASSOUX N - Paris |
| 3546 | 14:45 | Retinal toxicity following intra-vitreal injections of melphalan  
MUNIER F, Gaillard M C, Stathopoulos C, Beck-Popovic M - Lausanne |
EUPO 2016
Friday, Oct 7 - First afternoon session

13:30 - 15:00 | RHODES 4
EUPO session 3 - Neuro-ophthalmology
Uncommon but Important Causes of Visual Loss

EUPO Programme, see pages 134-135.

13:30 - 15:00 | GALLIENI 1+2
EOVS - FP session - Electrophysiology - protocols & applications

CASTELO-BRANCO M, KRASTEL H

3561  ✗  13:30  Flash adaptometry in congenital stationary night blindness
KRASTEL H, Zyganow M, Mai M, Schlichtenbrede F - Neckargemünd

3562  13:42  Comparison of perceptual eye positions among patients with different degrees of
anisometropia
ZENG J, Yang C, Yang X, Yan L - Guangzhou

3563  13:54  Retinal microcysts associated with optic atrophy in children - visual electrophysiology
studies

3564  ✗  14:06  Comparison of multifocal pattern ERG responses to luminance and chromatic
contrast stimulations
CHARLIER J - Perenchies

3565  14:18  A new electroretinogram function that can move the centre of the multifocal
hexagonal stimulus array
SUZUKI N, Yamane K - Numazu

3566  rf  14:30  Analysis of macular sensitivity using multifocal electroretinogram and
microperimetry in Central Serous Chorioretinopathy patients after half-dose
photodynamic therapy
Falcão-Reis F, Penas S - Porto

3567  rf  14:36  Systematic assessment of clinical methods to diagnose and monitor diabetic retinal
neuropathy
JENKINS K S, Rowan A, Layton C - Brisbane
IM - How to publish your scientific work?

Scientific writing is not an easy task. This sessions aims is to equip you with the basic knowledge and skills to transform your ideas and findings into a research article. It further will give you insights into the role as author, editor and reviewer in the publication process.

Who should attend?:
This session provides all individuals (at all levels) interested in scientific publishing an opportunity to deepen their knowledge.

What can you expect?:
The panelists will offer practical advices in the process of writing up. In addition, the personal view from an authors and editors perspective will be given in a vivid discussion with the participants.

PLEYER U

3571 13:30  What do we need as author, editor and publisher?
DUA H S - Nottingham

3572 13:52  Essentials of a good article
STEFANSSON E - Reykjavik

3573 14:14  How to keep your work published?
KIVELÄ T - Helsinki

3574 14:36  The review process - Reviewer friend or foe?
PLEYER U - Berlin

FP

MBGE - FP session - MBGE

BUJAKOWSKA K, SCHWARZ N

3581 13:30  Molecular study of the MFRP gene in patients with posterior microphthalmia (MCOP) supports its role in autosomal recessive MCOP pathogenesis

3582 13:42  Phenotype of maculopathy in primary hyperoxaluria type 1

3583 13:54  Molecular mechanisms of X-linked retinitis pigmentosa
ZHANG X, Shu X - Glasgow

3584 14:06  Gene transfer of prolyl hydroxylase domain 2 inhibits hypoxia-inducible angiogenesis in a model of choroidal neovascularization

3585 14:18  Autophagy is affected by Mitf in mouse primary RPE cells
GARCIA LLORCA A, Ogmundsdsottir M H, Steingrimson E, Eysteinson T - Reykjavik

3586 14:30  Splice-site mutation in the Bmpr1b gene of the mouse causes optic nerve head dysgenesis and retinal gliosis
GRAW J, Yan X, Amarie O V, Puk O, Sabrautzki S, Klaften M, Thiele F, Fuchs H, Hrabe de Angelis M - Neuherberg
Borrurat F., Bremond-Gignac D.

**F001**

**rf**
Automated evaluation of peripapillary choroidal thickness in nonarteritic anterior ischemic optic neuropathy


**F002**

Optical coherence tomography in patients with amyotrophic lateral sclerosis


**F003**

Retinal nerve fiber layer atrophy in patients with multiple sclerosis: Longitudinal 5 years study


**F004**

Assessment of visual function and structural retinal changes in Zen meditators


**F005**

Reduction in peripapillary retinal thickness after Thalidomide Treatment in Patients with POEMS Syndrome

*Hirotakay, Toshiyuki O., Masayas K., Takayuki B., Shuichi Y.* - Chiba

**F006**

Visual dysfunction and retinal changes in patients with multiple sclerosis

*Rodrigo M.J., Obis J., Cipres Alastuey M., Vilades E., Garcia-Martín E.* - Zaragoza

**F007**

Effects of current treatments in progressive retinal nerve fiber layer loss in multiple sclerosis patients

*Satue M., Rodrigo M.J., Obis J., Cipres Alastuey M., Vilades E., Garcia-Martín E.* - Zaragoza

**F008**

Evaluation of progressive visual dysfunction and degeneration of the retinal nerve fiber layer and macular thickness in patients with Parkinson disease.

*Satue M., Rodrigo M.J., Obis J., Cipres Alastuey M., Vilades E., Garcia-Martín E.* - Zaragoza

**F009**

Visual dysfunction and its correlation with retinal changes in patients with Alzheimer’s disease

*Vilades E., Garcia-Martín E., Satue M., Rodrigo M.J., Obis J., Cipres Alastuey M.* - Zaragoza

**F010**

Visual dysfunction and its correlation with retinal changes in patients with Parkinson disease

*Vilades E., Garcia-Martín E., Satue M., Rodrigo M.J., Obis J., Cipres Alastuey M.* - Zaragoza

**F011**

Optical Coherence Tomography to distinguish parkinson disease versus supranuclear progressive palsy


**F012**

Analysis of retinal and choroidal thickness in the macular area in patients with Parkinson’s disease using swept-source optical coherence tomography

*Obis J., Cipres Alastuey M., Vilades E., Garcia-Martín E., Satue M., Rodrigo M.J.* - Zaragoza

**F013**

Analysis of the peripapillary retinal nerve fiber layer and choroidal thickness in patients with Parkinson’s disease using swept-source optical coherence tomography

*Obis J., Cipres Alastuey M., Vilades E., Garcia-Martín E., Satue M., Rodrigo M.J.* - Zaragoza

**F014**

Macular thickness and retinal layer measurements in multiple sclerosis patients using new Swept-Source Optical coherence tomography Triton device

*Cipres Alastuey M., Vilades Palomar E., Garcia Martin E., Satué M., Rodrigo M.J., Obis Alfaro J.* - Zaragoza
15:00 - 16:00 | POSTER AREA
NSPH - Neuro-ophthalmology/Strabismology/Paediatric/History
F001 - F047

F015 Retinal nerve fiber layer measurements in multiple sclerosis patients using new Swept-Source Optical coherence tomography Triton device
CIPRES ALASTUEY M, Vilades Palomar E, Garcia Martin E, Satué M, Rodrigo M J, Obis Alfaro J - Zaragoza

F016 Normative values for optical coherence tomography parameters in children and inter-examiner agreement of choroidal thickness measurements
ERKAN TURAN K, Taylan Sekeroglu H, Baytaroglu A, Bezcı F, Karahan S - Ankara

F017 Early changes in mild Alzheimer’s disease in the neuroretinal rim segmentation

F018 Maculopapillary analysis in the posterior pole in patients with mild Alzheimer’s disease

F019 Visual outcomes of fractionated radiotherapy in optic nerve sheath meningioma
KHEIR V, Borruat F X - Lausanne

F020 Papilledema secondary to internal jugular veins thrombosis in a peritoneal dialysis patient
BRAÇA J, Loureiro M, Barros P, Gomes A M, Meira D - Vila Nova de Gaia

F022 MonPack One and multiple sclerosis
RODRIGO M J, Obis J, Cipres Alastuey M, Vilades E, Garcia-Martin E, Satué M - Zaragoza

F023 Wave-amplitude differences between corneal and conjunctival electrodes for multifocal electoretinogram
MUNOZ - NEGRETE F J, Rebolleda G, Garcia Garcia A - Madrid

F024 Treatment of visual impairment in patients with Leber’s Hereditary Optic Neuropathy (LHON) using Idenbenone (Raxone®)
METZ G, Hasham S, Catarino C, Klopkost T - Liestal

F025 Clinical and radiological evidence of meningioma growth due to gestational or exogenous hormones: 2 cases

F026 Pupillary reaction according to a balance autonomic nervous organ of vision in healthy children
BUSHUYEVA N, Dukhayer S, Slobodianyk S - Odessa

F027 Paraneoplastic retinopathy and optic neuropathy with Waldenström Macroglobulinemia
OZTURK N, Havelange V, Draganova D, Bosch A - Bruxelles

F028 Eye position under general anesthesia in orthophoric children

F029 Learning curves for strabismus surgery in two ophthalmologists
MOOSANG K - Chuncheon

F030 Surgical Effect of Medial Rectus Posterior pulley fixation in Esotropia greater at near fixation
CHOI HY, Jeon H - Busan
15:00 - 16:00 | POSTER AREA
NSPH - Neuro-ophthalmology/Strabismology/Paediatric/History
F001 - F047

**F031** Strabismus in Children with Periventricular leukomalacia: MRI correlation
CHOI HY, Jeon H - Busan

**F032** Normal Range of Eye Movement and Its Relationship to Age

**F033** Surgical treatment of pediatric strabismus (PS): series of 148 patients
RAHMANIA N, Van Rompay T, Morfeq H, Promelle V, Milazzo S - Amiens

**F034** Long term results of concomitant strabismus treatment based on operation preliminary modeling using three-dimensional biomechanical eye model
BUSHUYEVA N, Romanenko D - Odessa

**F035** Accommodation and fusion in patients with constant and intermittent exotropia
BOYCHUK I, Aloui T - Odessa

**F036** Early childhood blindness – etiologies and comorbidity
LOFGREN S, De Verdier K, Ek U, Ferneli E - Stockholm

**F037** Symmetric tarsal show is crucial in creating upper eyelid symmetry
DE GROOT V - Edegem

**F038** Orbital cellulitis in a child with sickle cell anemia

**F039** ROP laser treatment based on fluorescein angiography classification

**F040** Normative values of retinal vessel oximetry in healthy children against adults
WAIZEL M, Kazerounian S, Türksever C, Todorova M G - Basel

**F041** Evaluation of monotherapy of intravitreal Bevacizumab in retinopathy of prematurity stage 3 plus
SHIRZADEH S - Mashhad

**F042** Phakic intraocular lens (Verisyse) implantation for correction of high anisometropia in pediatric patients
AUTRATA R, Krejcirova I, Griscikova L - Brno

**F043** Excimer laser correction for myopic anisometropic amblyopia in pediatric patients- Long term results
AUTRATA R, Krejcirova I, Griscikova L - Brno

**F044** Comparaison of the Plusoptix A12 and the 2WIN with the Retinomax K-plus 3 in a pediatric population
BOUVIER R, Heripret A, Promelle V, Milazzo S - Amiens

**F045** Rupture of Descemet's membrane associated with forceps delivery

**F046** Congenital aniridia: an epidemiological approach on 105 patients
SALVIAT F, Robert M, Michel S, Bremond-Gignac D - Paris

**F047** Does macular pigment optical density really matter in children?
ERKAN TURAN K, Cankaya A B, Taylan Sekeroglu H, Inam O, Karahan S - Ankara
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>F048</td>
<td>Unexplained vision loss with intra-ocular silicone oil tamponade in situ; a case series</td>
<td>DE LAEY JJ, BAILLIF S, SILVester A, Cazabon S - West Kirby</td>
</tr>
<tr>
<td>F049</td>
<td>Macular hole angle as a surgery prognostic factor</td>
<td>ROCHA DE SOUSA A, Silva M I, Morais A S, Falcao M, Falcao-Reis F - Porto</td>
</tr>
<tr>
<td>F050</td>
<td>Novel clinical method for preventing condensation in noncontact wide-angle viewing systems</td>
<td>KWON S, Choi D, Park I, Lee J P - Anyang-Si</td>
</tr>
<tr>
<td>F051</td>
<td>Retinal toxicity by intravitreal liquid perfluorocarbon</td>
<td>MONTERO MORENO J A, Ruiz-Moreno J M, Fernandez-Munoz M, Amat-Peral P - Valladolid</td>
</tr>
<tr>
<td>F052</td>
<td>Late reopening of successfully treated macular holes after combined phaco-vitrectomy ILM peel and gas</td>
<td>PONOMARENKO M, Lochhead J - Cowes</td>
</tr>
<tr>
<td>F053</td>
<td>Silicone oil tamponade in the treatment of persistent macular holes</td>
<td>GRAJEWSKI L, Carstens J, Krause L - Dessau</td>
</tr>
<tr>
<td>F054</td>
<td>Unusual presentation of an intraocular foreign body with double – perforation and retention in lateral rectus muscle</td>
<td>PONOMARENKO M, Lochhead J - Cowes</td>
</tr>
<tr>
<td>F055</td>
<td>Correlation between intraocular pressure and bottle heights during vitrectomy</td>
<td>MOOSANG K - Chuncheon</td>
</tr>
<tr>
<td>F058</td>
<td>Static retinal vessel analysis in routine optometric practice</td>
<td>FRENCH C, Heitmar R - Birmingham</td>
</tr>
<tr>
<td>F059</td>
<td>Trial study to automatically distinguish small haemorrhages in early diabetic retinopathy from image artefacts</td>
<td>SUZUKI N, Yamane K - Numazu</td>
</tr>
<tr>
<td>F060</td>
<td>Age macular degeneration: clinical, biological, morphologic, structural biomarkers for neovascular complication</td>
<td>GONZALEZ C - Toulouse</td>
</tr>
<tr>
<td>F061</td>
<td>Age macular degeneration: clinical, biological, morphologic, structural biomarkers for atrophy complication</td>
<td>GONZALEZ C - Toulouse</td>
</tr>
<tr>
<td>F062</td>
<td>Retinal astrocytic hamartomas: 2 cases of atypical clinical presentation</td>
<td>BOUTELEUX V, Tick S, El Chehab H, Mendes M, Agard E, Russo A, Dot C - Lyon</td>
</tr>
<tr>
<td>F064</td>
<td>En-face Imaging of epiretinal membrane using swept source optical coherence tomography</td>
<td>KIM J T, Chung H - Seoul</td>
</tr>
</tbody>
</table>
**15:00 - 16:00 | POSTER AREA**

**RV - Retina/Vitreous**

**F048 - F114**

**F065**

Visualization of neovascular changes by swept source OCT angiography

SZAFLIK J P , Szaflik M - Warszaw

**F066**

En face OCT of uncomplicated angioid streaks

PERESTRELO S - Porto

**F067**

Outer retinal reflectivity on En-face OCT as a new tool to detect early stage hydroxychloroquine maculopathy

VIOTTE A , Bigan G , Flores M , Girard C , Delbosc B , Saleh M - Besancon

**F068**

Modern diagnostic methods used in macular telangiectasia

ROMANOWSKA DIXON B , Karska Basta I , Lesniak A - Krakow

**F069**

Ganglion cell-inner plexiform layer thickness and visual improvement after vitrectomy for rhegmatogenous retinal detachment

LEE JY , Kim DY , Kim JY - Jeju-si Jeju-do

**F070**

Spectral domain optical coherence tomography for detecting retinal arterial macroaneurysm


**F071**

Enhanced visualization of retinal vasculature in fundus images through image processing

KIMYT , Choi S H - Seoul

**F072**

The effect of center shift on the measurement of macular thickness: A spectral domain optical coherence tomography study

KIM JY , SHIN K S , Lim H B , Shin I H - Daejeon

**F073**

Tomographic analysis of the retinal layers in diabetic macular edema treated with dexamethasone intravitreal implant

MEDEIROS PINTO J , Prates Canelas J , Rosa R , Coelho C , Vaz-Pereira S - Lisbon

**F074**

Deep learning approach for diabetic retinopathy screening

COLAS E , Besse A , Orgogozo A , Schmauch B , Meric N , Besse E - Paris

**F075**

Iluvien monotherapy for diabetic macular oedema in vitrectomised and non-vitrectomised eyes: one year data


**F076**

Frequency doubling technology perimetry and retinal fiber layer correlation in type 2 diabetes without retinopathy

ALDAHAM S , Martin-Ridaura M D C , Puell M C - Madrid

**F077**

Diabetic maculopathy screening in England: are we seeing too much?

BEGUM S , Macgregor C , Meredith P , Cansfield J , Meredith S - Portsmouth

**F078**

Correlation between choroidal and retinal thickness in diabetic patients without diabetic retinopathy


**F079**

SD-OCT for study of retinal layers segmentation in patients under Hydroxychloroquine treatment


**F080**

Vitreous and serum VEGF levels after intravitreal injection of bevacizumab, ranibizumab and triamcinolone acetonide in patients with proliferative diabetic retinopathy

SOZEN-DELIL F I , Cekic O , Haklar G - Istanbul
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>F081</td>
<td>The change of Ganglion cell layer and Inner plexiform layer thickness in Type 2 DM with non-proliferative diabetic retinopathy</td>
<td>CHOI C, Mun S J - Iksan-si</td>
</tr>
<tr>
<td>F082</td>
<td>Improvement of diabetic macular edema after micropulse laser therapy</td>
<td>EL MATRI L, Falfoul Y, Chebibi Z, Kortli M, El Matri K, Chebil A - Tunis</td>
</tr>
<tr>
<td>F083</td>
<td>Novel OCT prognostic indicators in diabetic macular oedema</td>
<td>MANN R, Begum S, Mourtzoukos S - Portsmouth</td>
</tr>
<tr>
<td>F084</td>
<td>Macular thickness in diabetic eyes without clinical macular edema</td>
<td>GARCIA ZAMORA M, Montero Moreno J A, Gonzalez Uruena C, Francis Caballero E, Fernandez-Munoz M - Valladolid</td>
</tr>
<tr>
<td>F086</td>
<td>Peripheral vessel leakage in diabetic retinopathy using Wide field retinal angiography</td>
<td>MAAMOURI R, Bouraoui R, Fedra K, Hassairi A, El Matri L - Tunis</td>
</tr>
<tr>
<td>F087</td>
<td>The predictive value of retinal fixation for the visual outcome after anti-VEGF treatment of diabetic macular oedema with center involvement</td>
<td>STÆHR JAKOBSEN N, Ancher Larsen D, Bek T - Aarhus C</td>
</tr>
<tr>
<td>F088</td>
<td>Selective Retina Therapy (SRT) for diabetes macular edema in Korean patients: 12-months results</td>
<td>PARK Y G, Roh Y J - Seoul</td>
</tr>
<tr>
<td>F089</td>
<td>Comparison of efficacy of intravitreal ranibizumab and aflibercept in eyes with diabetic macular edema</td>
<td>OSHITARI T, Shimizu N, Tatsumi T, Takatsuna Y, Arai M, Sato E, Yamamoto S - Chiba</td>
</tr>
<tr>
<td>F090</td>
<td>Factors influencing intravitrealBevacizumaband triamcinolone treatment in patients with diabetic macular edema</td>
<td>LEE M Y - Uijeongbu-Ši</td>
</tr>
<tr>
<td>F091</td>
<td>Incidence of retinal vein occlusions (RVO) in patients treated with oral anticoagulants or antiplatelet drugs for cardioembolic or atherothrombotic prevention</td>
<td>FRUSCHELLI M, Fazio S, Capozzoli M, Chimenti G, Hadjistilianou T, Sicuranza A, Apire L, Puccetti L - Siena</td>
</tr>
<tr>
<td>F092</td>
<td>Analysis of SD-OCT prognostic factors in macular edema associated with retinal vein occlusion</td>
<td>BOURAOUI R, Bouladi M, Dhoub N, Mghaieth F, Limaiem R, Chaker N, El Matri L - Tunis</td>
</tr>
<tr>
<td>F093</td>
<td>Correlation of foveal bulge on SD-OCT and visual acuity in resolved macular edema associated with branch retinal vein occlusion</td>
<td>BOURAOUI R, Dhoub N, Bouladi M, Zerei N, Maamouri R, Chaker N, El Matri L - Tunis</td>
</tr>
<tr>
<td>F095</td>
<td>Treatment outcome of switching from ranibizumab to aflibercept in patients with central retinal vein occlusion</td>
<td>KONIDARIS V, Gorgoli K, Burgula S, Deane J, Banerjee S, Empeslidis T - Leicester</td>
</tr>
</tbody>
</table>
F096  Relationship between visual outcomes and initial optical coherence tomographic findings in macular edema secondary to branch retinal vein occlusion after bevacizumab treatment
KWONY H, Kim ST, Ahn H - Busan

F097  Characteristics of retinal vein occlusion (RVO) patients with macular edema who lasted remission more than 6 months after single injection of intravitreal bevacizumab.
LEE MY - Uljeongbu-Si

F098  The 1 year outcome of intravitreal dexamethasone implant for macular edema secondary to central retinal vein occlusion
KIM HW, Chung IY, Lee JE, Kim K - Busan

F100  Changes in choroidal thickness after ranibizumab and aflibercept therapy for treatment-naïve wet age-related macular degeneration
KANG HG, Kim JS, Lee JH, Kim YI, Lee SH - Daegu

F101  Impact of intravitreal bevacizumab injections on perceived quality of life in a cohort of patients with exudative age related macular degeneration. Real life results at 4 years
MONTERO MORENO JA, Arnaiz C, Martinez-Perez L, De la Fuente A, Gonzalez Uruena C - Valladolid

F102  Prevalence and incidence of epimacular membranes in patients with wet AMD

F103  Spontaneous anatomical improvement on OCT findings in patients with neovascular age-related macular degeneration without anti-VEGF treatment.
KIM KH, Yang SJ - Gangneung-siGangwon-do

F104  Comparison between Aflibercept, Ranibizumab intravitreal injection on Neovascular Age-related macular degeneration patients
KWONY H, Min JS, Ahn H - Busan

F105  Licence to save - A UK survey of anti-VEGF use for the eye in 2015

F106  The long-term effect of intravitreal bevacizumab injection in central serous chorioretinopathy
MUN SJ, Choi C, Jeong JG - Jeonju

F107  Spironolactone in the treatment of nonresolving central serous chorioretinopathy: A comparative analysis
LEE JY, Kim DY, Kim JY - Jeju-siJeju-do

F108  Retinal microangiopathy as primary manifestation of systemic lupus erythematosus

F109  Ophthalmic findings before carotid endarterectomy in the ipsilateral and contralateral eye

F110  Short-term efficacy of intravitreal aflibercept depending on subtypes of polypoidal choroidal vasculopathy: polypoidal choroidal neovascularization or idiopathic choroidal vasculopathy
SAGONG M, Jeong S - Daegu
RV - Retina/Vitreous
F048 - F114

15:00 - 16:00 | POSTER AREA

F111  Vitreous and serum Hsp 70 levels in rhegmatogenous retinal detachment
SOZEN-DELIL F I, Cekic O, Haklar G - Istanbul

F112  Assessment of choroidal thickness and retinal nerve fiber layer thickness before and after G training using swept-source optical coherence tomography

F113  Itraconazole inhibits laser-induced choroidal neovascularization in rats by suppressing VEGFR2 expression

F114  A case of bilateral central serous chorioretinopathy secondary to Cobimetinib treatment
Friday, Oct 7 - Second afternoon session

16:00 - 17:30 | RHODES 4
EUPO session 4 - Neuro-ophthalmology
Recognizing the Emergencies: From Symptom to Diagnosis

EUPO Programme, see pages 134-135.
16:00 - 16:30
Section Business Meetings

- ACB .................. Gallieni 4
- COS .................. Rhodes 2
- EOVS .................. Rhodes 1
- G ...................... Rhodes 1
- IM ...................... Gallieni 1+2
- LC ...................... Gallieni 5
- MBGE .................. Gallieni 1+2
- NSPH .................. Rhodes 2
- PBP ................... Rhodes 3
- PO .................... Rhodes 3
- RV ..................... Hermes

**Agenda**

1. Report of the chair of section
2. Report of the programme secretary
3. Next year’s meeting:
   - nomination of the 2017 section programme secretary (different from the section chair)
   - proposals of 2017 Special Interest Symposia (SIS)
   - proposals of 2017 Courses
   - proposals for 2018 Keynote speakers
4. Comment on the EVER activities
5. Other business

In addition to the agenda, the sections COS and G will nominate at least 2 candidates for section chair 2017 - 2021
**EVER 2016**

Friday, Oct 7 - Second afternoon session

---

**16:30 - 18:00 | HERMES**

**FAN Club**

Cases with retinal imaging are presented and discussed with a panel. Each case presentation lasts for 10 minutes with 5 minutes for discussion. This session is open to all EVER delegates. Presenters at this session are welcome to bring a powerpoint presentation of a single interesting case on a USB memory key and load it up in the speakers room.

www.fan-int.org

---

**16:30 - 18:00 | RHODES 1**

**G - Implications of neuro-glial interactions in neurodegenerative diseases**

Retinal neurons rely on oxygen and nutrient supply as well as on the removal of toxic neurotransmitters and metabolites from the interstitial space. The maintenance of this homeostasis depends on tightly regulated neuro-glial interactions. Increasing evidence indicates that neurodegenerative conditions and optic nerve diseases are associated with dysfunctional glial cells leading to neuronal damage. However, the mechanisms that promote and maintain neuro-glial energy exchange are poorly understood. The proposed symposium seeks to create a multidisciplinary discussion on the importance of neuro-glial interaction and its regulation in the pathogenesis of optic nerve, retinal and brain neurodegenerative diseases.

**KOLKO M, WAAGEPETERSEN H**

<table>
<thead>
<tr>
<th>Item</th>
<th>Time</th>
<th>Title</th>
</tr>
</thead>
</table>
| 3621 | 16:20 | Is glutamate dehydrogenase in astrocytes one of the keys to control brain glutamate homeostasis?  
WAAGEPETERSEN H - Copenhagen |
| 3622 | 16:42 | Is neurodegenerative retinal diseases the result of disturbed energy metabolism in Müller cells?  
KOLKO M - Roskilde |
| 3623 | 17:04 | Current neuroprotective strategies in glaucoma – implications of neuro-glial interactions  
CORDEIRO M F - London |
| 3624 | 17:26 | Optic nerve energy metabolism: the role of astrocyte glycogen  
RANSOM B - Seattle |
**COS - Corneal neovascularization and immune privilege**

This SIS provides an overview of current developments in corneal neovascularization, anti-VEGF approaches and molecular mechanisms of the corneal immune privilege.

**HORI J, CHEN L, ZHANG H**

**3631** 16:20 New insights into corneal lymphangiogenesis  
**CHEN L - Berkeley**

**3632** 16:38 MIRNA-126 regulation in corneal neovascularization  
**ZHANG H -**

**3633** 16:56 Identifying VEGF-independent factors for targeted antiangiogenic therapy in the cornea  

**3634** 17:14 Molecular mechanisms of immune privilege of the cornea - as a potential of Immune checkpoint therapy  
**HORI J - Tokyo**

**3635** 17:32 Corneal neovascularization: clinical aspects and the role of the immune system  
**BONINI S - Rome**

---

**PO: OOG Session 1**

**KIVELÄT, HADJISTILIANOUT**

**3641** 16:30 Late intraocular relapses in retinoblastoma  
**HADJISTILIANOUT, Borri M, Defrancesco S, Munier F, Galluzzi P, Bracco S, Galimberti D, Menicacci F, Coriofani G - Sienna**

**3642** 16:42 Management of unilateral retinoblastoma with buphthalmia  
**ANGI M, Lumbroso Le Rouic L, Levy C, Desjardins L, Cassoux N - Milan**

**3643** 16:54 Intraarterial and intravitreal chemotherapy in the combined treatment in children with group C and D intraocular retinoblastoma  
**SAAKYAN S - Moscow**

**3644** 17:06 New challenges in retinoblastoma treatment  

**3645** 17:18 Clinical and morphometric investigation of retinopathy in children with retinoblastoma treated with chemotherapy  
**SAAKYAN S - Moscow**

**3646** 17:24 Congenital Malignant Ciliary Body Medullopithelioma in Two newborns  
**HADJISTILIANOUT, Mittica P, Bagaglia S, Fruschelli M, Menicacci C, Fusco F, Defrancesco S, Borri M, Galluzzi P - Sienna**

**3647** 17:30 Unravelling the potential of secreted frizzled related protein 3 as a vascular marker  
**MADIGAN M, Gu R, Gilan P, Eamegdoool S - Sydney**
OPA is defined as the difference between systolic and diastolic intraocular pressure (IOP) and represents the pulsatile wave front produced by the varying amount of blood in the eye during the cardiac cycle. It is an important parameter in ocular blood flow and has been shown to vary be able to provide information concerning the autonomic nervous system input. Furthermore, it can be influenced by the structural properties of the eye, such as corneal thickness, and ocular rigidity, as well as with systemic variables like heart rate, blood pressure, and left ventricular ejection fraction.

The concept of this course is to provide the audience with a oriented review of the current data on OPA, its physiological meaning and how we measure it. The strenghts and caveats of the measurement of this parameter will be discussed as well as the potential of translating this information into clinical practice.

**ABEGAO PINTO L, MARQUES-NEVES C**

- **3661** 16:20 Fundamental principals and applied biophysics
  - MARQUES-NEVES C - Lisbon

- **3662** 16:42 OPA analysis - oscillatory and autonomic influence
  - SCHMIDL D - Vienna

- **3663** 17:04 Physiology and clinical relevance of this parameter
  - ABEGAO PINTO L - Lisbon

- **3664** 17:26 Use of OPA in ocular blood flow studies

---

**IM - FP session - New insights in imaging in ocular immunology**

**HERBORT CP, NERI P**

- **3671** 16:30 EDI-OCT is less suited for close monitoring of primary stromal choroiditis when compared to Indocyanine green angiography
  - HERBORT C P, Balci O, Gasc A, Jeannin B - Lausanne

- **3672** 16:42 Analysis of choroidal folds in Acute Vogt-Koyanagi-Harada disease using high-penetration optical coherence tomography
  - NAKAI K, Tsuboi K - Osaka

- **3673** 16:54 Comparison of retinal and choroidal involvement in sarcoidosis chorioretinitis
  - EL AMEEN A, Herbort C P - Evian

- **3674** 17:06 Contribution of dual fluorescein and indocyanine green angiography to the appraisal of posterior involvement in birdshot retinochoroiditis and Vogt-Koyanagi-Harada disease
  - BALCI O, Jeannin B, Herbort C P - Istanbul
Severe allergic conjunctivitis in children may be severe causing loss of quality of life and visual impairment. Vernal keratoconjunctivitis and atopic keratoconjunctivitis are rare diseases but must be distinguished because of their evolution. Imaging of these diseases and systemic treatment are reviewed and developed. An overview of the innovating diagnosis, new imaging techniques and treatment are summarized for a better comprehension of severe allergic ocular surface diseases.

**BREMOND-GIGNAC D, FAUQUERT J**

**3681** 16:20 Atopic and vernal keratoconjunctivitis: differences and similarities  
**BREMOND-GIGNAC D - Paris**

**3682** 16:50 Imaging of allergic keratoconjunctivitis  
**CHIAMBARETTA F - Clermont Ferrand**

**3683** 17:20 Non-ocular treatments in ocular allergy  
**DELGADO L - Porto**
18:00 - 18:30 | HERMES
EVER General Assembly

1. President’s address by Aki Kawasaki
2. Minutes of the General Assembly 2015
3. Report of the Secretary General, Catherine Creuzot
4. Report of the Programme Secretary, Marcela Votruba
5. Report of the Treasurer, Steffen Heegaard:
   - approval of the accounts 2015
   - discharge to the directors
   - approval budget for 2016
6. Results of the elections
7. Presentation of the board 2017
8. Future congresses
9. Miscellanea
10. Handover of chain of office
### NSPH/RV - The first ones in ophthalmology

This symposium will provide fascinating new insights into the first described case of some ophthalmological diseases and some of the great innovators and pioneers in diagnostic and therapeutic advances in Ophthalmology. This particular look to the history of our specialty begins with a paleopathological study of traumatic and infectious evidences of what seems to be the first documented case of orbital cellulitis in one the most complete and best preserved ancient hominid skulls ever found. The practice of Ophthalmology has a rich history that spans a lot of centuries. Since the first use of plants or surgery in the civilizations of the Fertile Crescent, the important discoveries have been generally simple, and one is apt to wonder why they were not made earlier. Then, we explore the beginnings of two important diagnostic imaging techniques: fluorescein angiography and ultrasonography. Finally, we include another example of historical interest: Charles-Michel Billard, the founder of Neonatology and an international figure in the field of Ophthalmology.

**GRZYBOWSKI A, ASCASO F**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4111</td>
<td>Homo heidelbergensis: the oldest case of odontogenic orbital cellulitis?</td>
<td>ASCASO F, Adiego M I - Zaragoza</td>
</tr>
<tr>
<td>4112</td>
<td>The first cataract surgery</td>
<td>GRZYBOWSKI A - Olsztyn</td>
</tr>
<tr>
<td>4113</td>
<td>The first steps in retinal angiography</td>
<td>DE LAEY J - J - Gent</td>
</tr>
<tr>
<td>4114</td>
<td>The firsts in ophthalmic echography</td>
<td>KIVELÄT - Helsinki</td>
</tr>
<tr>
<td>4115</td>
<td>Charles-Michel Billard (1800-1832), the founder of neonatology and ophthalmology</td>
<td>FRANCESCHETTI A - Meyrin</td>
</tr>
</tbody>
</table>

### COS - Keratoconus diagnosis and treatment in the clinical practice

The applicability of treatment options for keratoconus and the prognosis of functional outcome and freezing of progression is mainly determined by the stage/severity of the disease. In early stages contact lenses are a viable option for visual rehabilitation, whereas progressed stages may require specialized rigid gas permeable contact lenses or keratoplasty. New options such as crosslinking and intracorneal ring segments aim to retard or even stop progression. However, they require a minimum of residual stromal thickness. Therefore, screening and early diagnosis of keratoconus is key in order to timely react with therapeutic options. Corneal topography and tomography as well as the assessment of corneal biomechanical properties are established tools for diagnosis of early keratoconus and a variety of indices are available assisting the ophthalmologist in keratoconus diagnosis. We will discuss the topographic, tomographic and biomechanical features of keratoconus, how keratoconus indices could assist clinical diagnosis and how keratoconus can be distinguished from other corneal conditions. In addition, we show the application of corneal tomography in the monitoring of corneal stabilization after crosslinking.

**SZENTMARY N, ZSOLT NAGY Z**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4121</td>
<td>Central keratoconus and bilateral asymmetry of keratoconus</td>
<td>LANGENBUCHER A, Szentmáry N, Eppig T - Homburg</td>
</tr>
<tr>
<td>4122</td>
<td>Interpretation of keratoconus indices</td>
<td>EPPIG T, Spira-Éppig C, Szentmáry N, Langenbacher A - Homburg/Saar</td>
</tr>
<tr>
<td>4123</td>
<td>Keratoconus, keratoglobus, keratotorus and pellucid marginal degeneration</td>
<td>SZENTMÁRY N - Homburg/Saar</td>
</tr>
<tr>
<td>4124</td>
<td>Relevance of the posterior corneal surface for detection of early keratoconus and post-LASIK keratectasia</td>
<td>WYLEGALA E - Katowice</td>
</tr>
<tr>
<td>4125</td>
<td>Corneal tomographical changes following crosslinking</td>
<td>ZSOLT NAGY Z - Budapest</td>
</tr>
</tbody>
</table>
Acanthamoeba keratitis, infectious crystalline keratopathy, fungal keratitis and atypical mycobacterial keratitis have emerged as important types of infectious keratitis. These corneal infections have often been associated with contact lens wear, with corneal surgery such as radial keratotomy or penetrating keratoplasty and with the uncontrolled use of topical steroids. The clinical setting of each of these infections is important in alerting the clinician to the possible diagnosis. There have been improvements in rapid diagnostic techniques for such infections in the last years. Treatment has also improved, but remains a difficult problem, especially for Acanthamoeba. In this course, we’ll give you an overview of recent developments in the clinical and histopathologic methods for diagnosis and treatment options of these corneal infections. We will also see how new techniques such as Amniotic Membrane Transplantation and Crosslinking can help the clinician, when facing severe cases.

GICQUEL JJ, BREMOND-GIGNAC D

**4131** 8:30  New breakthrough in severe corneal infections: GMA, cross linking
GICQUEL J - Saint Jean d’Angély

**4132** 9:00  Specificities of corneal infectious diseases in children
BREMOND-GIGNAC D - Paris

**4133** 9:30  Prevention of Herpes and Zoster keratitis
LABETOLLE M, Rousseau A - Le Kremlin Bicêtre

**HEEGAARD S, CASSOUX N**

**4141** 8:30  BAP1 germline mutations in uveal melanoma patients without family history of eye cancer

**4142** 8:42  Chromosomal aberration predict uveal melanoma mutation status
KILIC E, Yavuzyiligitoglu S, Drabarek W, Obukasim A, Brands T, Eussen B, De Klein A - Rotterdam

**4143** 8:54  Inflammatory Cell Infiltrates in Metastatic Uveal Melanoma
KRISHNAY, McCarthy C, Kalirai H, Coupland S - Liverpool

**4144** 9:06  Histomorphological changes of uveal melanoma (UM) following proton beam therapy (PBR)
QURESHI S, Hussain R, Kalirai H, Heimann H, Coupland S - Liverpool

**4145** 9:12  UM Cure 2020 - A Consortium of European experts in Uveal Melanoma to identify new therapies for patients with metastatic disease

9:18  Business meeting
## EUPO session 5 - Strabismus

**Paralytic Strabismus: Diagnosis, Evaluation and When to Treat**

EUPO Programme, see pages 134-135.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30</td>
<td>EUPO 5</td>
<td>EUPO session 5 - Strabismus</td>
<td></td>
</tr>
<tr>
<td>8:30</td>
<td>GALLIENI 1+2</td>
<td>FRO: Belgian Fund for Research in Ophthalmology 1</td>
<td></td>
</tr>
<tr>
<td>8:30</td>
<td>TASSIGNON MJ , CASPERS L</td>
<td>Neuroinflammation as fuel for axonal regeneration: unravelling the underlying molecular players</td>
<td>ANDRIES L - Leuven</td>
</tr>
<tr>
<td>8:42</td>
<td>BARBOSA BREDA J - Porto</td>
<td>Metabolomic profile of surgical glaucoma patients</td>
<td></td>
</tr>
<tr>
<td>8:54</td>
<td>BECKERS A - Leuven</td>
<td>The interplay between dendrite and axon regeneration in central nervous system repair: which way to grow?</td>
<td></td>
</tr>
<tr>
<td>9:06</td>
<td>BEHAEGEL J - Brussels</td>
<td>Enhanced donor selection in the treatment of LSCD using advanced imaging techniques</td>
<td></td>
</tr>
<tr>
<td>9:18</td>
<td>DEVOLDERE J - Ghent</td>
<td>Intravitreal injection of mRNA containing nanoparticles to introduce sustained expression of neurotrophic factors in Müller celles</td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td>HAAGDORENS M - Edegem</td>
<td>Tissue engineering in Ophthalmology: Regenerating the anterior cornea using synthetic collagen-mimicking nanoscaffolds and Limbal Epithelial Stem Cells</td>
<td></td>
</tr>
<tr>
<td>9:42</td>
<td>MASSET M - Bruxelles</td>
<td>Role ofTonEBP inthe inflammatory response of ARPE-19cells subjected to hyperosmolar stress</td>
<td></td>
</tr>
<tr>
<td>9:54</td>
<td>MATTHYSSEN S - Edegem</td>
<td>3D printed recombinant human collagen scaffolds for corneal tissue engineering: an in vivo study of biocompatibility</td>
<td></td>
</tr>
</tbody>
</table>
The cataract surgeon and the anterior interface

TASSIGNON MJ - Antwerpen

Summary:
Performing a posterior capsulorhexis on a routine basis related to the implantation of the bag-in-the-lens IOL has opened new frontiers in helping understanding the Berger space and its relation with the vitreous. It is only recent that this space could be observed life during surgery thanks to new OCT devices. This observation may open new understandings on the pathogenesis of vitreo-retinal complications after cataract surgery.

Award presentation of the EVER Certificate of Honour

Biography Marie-José TASSIGNON:

Marie-José Tassignon is born in 1952 in the French speaking part of Belgium. She was raised in French by her father and in Dutch by her mother. She completed her studies of medical doctor at the Free University of Brussels. She defended her PhD thesis in Leiden, The Netherlands, in 1990 and was appointed Chief of the Department of Ophthalmology of the Antwerp University Hospital and Chair of the Department of Ophthalmology of the Faculty of Medicine of the University of Antwerp in 1991. In 2007 she became Medical Director of the Antwerp University Hospital after having been Vice-Dean of the Faculty of Medicine of the University of Antwerp from 2003 to 2008. She is full professor at the University of Antwerp since 2003 and closely implicated in the national trainees educational program.

She was president and past-president of the European Society of Cataract and Refractive Surgeons (ESCRS) from 2004 until 2007 and was president and past-president of the European Board of Ophthalmology (EBO) from 2007 until 2008. She is member of 18 international societies in ophthalmology and was board member in 5 out of them. She was elected chair “L” of the International Academy of Ophthalmology (AOI) in 2007 and was elected chair “V” of the European Academy of Ophthalmology in 2008. She became Alumni of Pretoria University of South Africa in 2008 and full member of the Ukraine Academy of Medicine in 2012. She became member of the Royal Academy of Medicine of Belgium in 2009. She became boardmember of the International Council of Ophthalmology in 2016.

Seven patents have been approved out of which the patent of the original lens design called the bag-in-the-lens implantation technique and the caliper ring to perform a calibrated anterior capsulorhexis. This lens has been commercialized in Belgium in 2004 and is currently on its way to be accepted worldwide as technique to eradicate posterior capsule opacification. This technique has attracted quite some international ophthalmic surgeons as well as pediatric cataract surgeons to Antwerp since it eradicates the occurrence of PCO in all patients regardless the age of surgery. It is also very attractive for vitreo-retinal surgeons because it keeps the visual axis free and is also attractive for complex optics intraocular lenses since it allows customized IOL centration.

Marie-José Tassignon was awarded the Kritzinger award in 2003; the Binkhorts medal at ESCRs in 2011; the Norman Galloway award, Nottingham University, United Kingdom in 2014, the Academia Ophthalmologica Internationalis lecturer 2015; the Peter Eustace medal 2015 by European Board of Ophthalmology for excellence in education; the Montgomery lecture at the Royal College of Surgeons delivered by the Irish Council of Ophthalmology in 2015; the Tadeusz Krzawicz award at WOC 2016 and the Moroccan Ophthalmological award in 2016. She was honorary guest at the 27th International Congress of German Ophthalmic Surgeons, DOC in Nürnberg and guest professor at Michigan Eye Kellogg’s University in 2013 and at Harvard Massachusetts Eye and Ear in 2014. She received three best paper awards at ASCRS and five best video awards at videorefractive, ESCRs and WOC.

Marie-José Tassignon is author of 248 publications and of 23 chapters of 21 books but she is primarily mother of two children and grandmother of three grandchildren to date.
EUPO session 6 - Strabismus
Case Presentations I: Odd and Unusual Things in Strabismus
Amblyopia, Nystagmus and Secondary Strabismus

EUPO Programme, see pages 134-135.
<table>
<thead>
<tr>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Taking a roller coaster ride with autophagy markers p62 and LC3</td>
<td>Koskela A, Reinisalo M, Kaarniranta K - Kuopio</td>
</tr>
<tr>
<td>Possible association with obesity-related loci and outcome of wet AMD</td>
<td>Kaarniranta K, Helisalmi S, Birling A, Saavalainen L, Tolppola O, Vajanto V, Usitupa M, Paterno J J - Kuopio</td>
</tr>
<tr>
<td>HuR/ELAVL1 expression in the human cataractous lens</td>
<td>Amadio M, Marchesi N, Govoni S, Pascale A, Petrovski G - Pavia</td>
</tr>
<tr>
<td>SMA+perivascular cells evaluation in VEGF induced blood-retinal barrier breakdown in rabbit model</td>
<td>Grillo-Antonelli S, Mauro V, Cimbolini N, Feraille L, Elena P P - La Gaude</td>
</tr>
<tr>
<td>Blepharospams treated with eyelid suspension : long terme follow up and outcomes</td>
<td>Lathier T, Robert P Y, Adenis J P - Limoges</td>
</tr>
<tr>
<td>Unexpected orbital swelling after injection of hydrogel self inflating expanders</td>
<td>Grivet D, Ronin C, Boutet C, Thuret G, Gain P - Saint-Etienne</td>
</tr>
<tr>
<td>Surgical outcome of minimal resection with full thickness rotating suture technique for lower lid epiblepharon</td>
<td>Jeong H C, Sohn E J, Kwon Y H, AHN H - Busan</td>
</tr>
<tr>
<td>The digital slide scanner applied to the ocular anatomopathology</td>
<td>Kaspi M, Grivet D, Forest F, Douchet C, Dumollard J M, Peoc'h M, Thuret G, Gain P - Saint-Priest en Jarez</td>
</tr>
<tr>
<td>Comparison of the retinal measurements of standard and neurological SD-OCT applications in MS patients</td>
<td>Paterno J J, Kaarniranta K - Kuopio</td>
</tr>
<tr>
<td>Fate of donor sclera used to lengthen extraocular muscle in a rabbit model of strabismus surgery</td>
<td>Conde C, Lindström M, Pedrosa Domellöf F - Umeå</td>
</tr>
<tr>
<td>A new method of exophthalmometry</td>
<td>Afanasyeva D, Gushchina M, Borzenok S - Moscow</td>
</tr>
<tr>
<td>Poster</td>
<td>Title</td>
</tr>
<tr>
<td>--------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>S017</td>
<td>Thickness of chorioretinal complex in the fovea in teenagers with myopia</td>
</tr>
<tr>
<td>S018</td>
<td>An investigation of the correlation between functional and structural changes in tilted and non-tilted high myopic eyes</td>
</tr>
<tr>
<td>S019</td>
<td>Reflectometric analysis of normal and ex-premature foveal microstructure in SD-OCT images - a comparison to image analysis using directional OCT and manual segmentation</td>
</tr>
<tr>
<td>S020</td>
<td>Comparative analysis of the morphometric parameters of the macular area of the retina in patients with refractive, axial, mixed and combined types of myopia</td>
</tr>
<tr>
<td>S021</td>
<td>Manufacturing of an ocular prosthesis based on the 3D printed anophthalmic socket</td>
</tr>
</tbody>
</table>
10:50 - 12:00 | POSTER AREA

COS - Cornea/Ocular Surface

S022 - S064

GICQUEL J, FUCHSLUGER

S022

Surface chemistry of the interactions of cationic nanoemulsions with human meibum films

DAULL P, YOKOI N, NENCHEVA Y, GEORGIJEV G A - Evry

S023

Peter’s anomaly in twins: a rare incidence with novel associations

ALZAHARNI S, KHAYAT H, TAYYIB A, ALSULAMI R, ALKHAHTANI A, ALMARZOKI H - Jeddah

S024

Severe ocular manifestations of rosacea in adult

HASSEI MI A, LIMAEM R, KORTTL M, MAAMOURI R, EL MATTI L - Tunis

S025

Pollen count compared with severity of symptoms and signs of dry eye disease in Norway

EIDET J R, TASHAYEV B, CHEN X, RAEDER S, BADIAN R, UTHEIM Ö, FOSTAD I G, DARTT D A, UTHEIM T P - Oslo

S026

Graft functionality after DSAEK surgeries in Denmark from 2006 to 2009

CORRELL M, STORMLY HANSEN M, HOVLYKKE M, JHORTDAL J, OLSN JULIAN H - Glostrup

S027

Erroneous measurement of the intraocular pressure with the goldmann aplanation tonometry in fuchs endothelial corneal dystrophy


S028

Peripheral refraction and retinal contour after FS-LASIK and orthokeratology

TARUTTA E, KHODZHABEKYAN N, KHANDZHAYAN A, MILASH S - Moscow

S029

A new approach of presbyopia over a myopic population: PresbyLASIK using the myopic SUPRACOR Algorithm (preliminary results about 12 eyes)


S030

Clinical evaluation of oculus keratograph corneal topographer in normal population

EHSAEI A, YAZDANI N, Ostadimoghadam H, SHAHKARAMI L - Mashhad

S031

The prospects of using the radiation for the assessment of corneal and scleral hydration

IOMDINA E N, SELIVERSTOV S, SIANOSYAN A, TEPLYAKOVA K, RUSOVA A, GOFTSMA N - Moscow

S032

Comparison of MyoRing implantation with corneal collagen cross-linking in different combination for keratoconus treatment

KAZAKBAEVA G, BIKBOV M, USUBOV E - Ufa

S033

The evaluation of intrastromal MyoRing implantation with corneal collagen cross-linking in keratoconus treatment

KAZAKBAEVA G, BIKBOV M, USUBOV E - Ufa

S034

Assessment of postoperative corneal healing after epithelium-off cross-linking with a regenerating agent in progressive keratoconus patients

KYMIONIS G, SCHMETTERER L, GARHOFER G, SCHMIDL D, CHIAMBARETTA F, GROUIN J M, GUMUS K - Athens

S035

Three years outcomes of small incision lenticule extraction: mild to moderate myopia vs. high myopia

KIM J R - Seoul

S036

Electrospun polymer nanofibers as substrate/carrier for engineering of human corneal epithelium

MOMTAZI L, SHAHDAFAR A, ZELLTHIME H, NILSSEN O, EIDET J R - Oslo

S037

Novel molecular design of culture substrates with amino acids

MOMTAZI L, SHAHDAFAR A, ZELLTHIME H, NILSSEN O, EIDET J R - Oslo
S038  DNA damage in human limbal epithelial cells expanded ex vivo  
LORENZO CORRALES Y, Haug Berg K, Noer A, R. Collins A, Nicolaissen B - Oslo

S039  The effect of culture medium and carrier on explant culture of human limbal epithelium: a comparison of ultrastructure, keratin profile and gene expression  
Pathak M, Olsdorff K, Drolsum L, Moe M C, Katerina J, Nicolaissen B, NOER A - Oslo

S040  The effect of silica nanoparticle exposure on cultured human keratocytes  
YIM B, Park J, Park CY - Goyang-si,Gyeonggi-do

S041  Development of novel electrospun scaffolds for corneal tissue engineering  
KADOR K, Ahearne M - Dublin

S042  Ex-vivo porcine corneal storage using an innovative bioreactor  

S043  OCT spectralis for terrien marginal degeneration diagnosis  

S044  AS-OCT utility for corneal lacerations in pediatric patients  

S045  Terrien marginal degeneration presenting with corneal perforation  

S046  Possible misdiagnosis of patients with ocular trauma in a Danish emergency room without ophthalmic assistance. A retrospective cohort study of 1824 patients  
JAKOBSEN T M, Møller F, Storr-Paulsen T - Vejle

S047  Corneal perforation during laser assisted blepharoplasty  
LEE S, Moon D, Kang H - Daegu

S048  Management of acute corneal hydrops in keratoconus with pre-Descemet's membrane sutures  
BREHON A, Stephan S, Nguyen Kim P, Cochereau I, Gabison E - Saint-Priest en Jarez

S049  Potential of High resolution Gabor-Domain optical coherence microscopy for early diagnosis of corneal disease  

S050  Corneal imaging and densitometry measurements to monitor fuchs progression and treatments outcomes  
ALZahrani K, Carley F, Brahma A, Morley D, Hillarby M C - Manchester

S051  Evaluation of the eyelid disorders in the daily ophthalmic practice in 9 European Countries: The MEIBUM* survey  

S052  Semi-fluorinated alkanes for topical delivery of Cyclosporine  
AGARWALL P, Scherer D, Günther B, Rupenthal I - Auckland
10:50 - 12:00 | POSTER AREA

**COS - Cornea/Ocular Surface**

**S022 - S064**

- **S053** Effects of TRPM8 and TRPV1 agonists on the neural activity of corneal cold thermoreceptors in tear-deficient guinea pigs
  QUIRCE S, Luna C, Acosta M C, Kovacs I, Belmonte C, Gallar J - San Juan de Alicante

- **S054** Cacicol® – neurotrophic keratopathy in systematic review
  MRUKWA KOMINEK E, Rokicki D - Katowice

- **S055** Regression of corneal neovascularization associated with corneal epithelial defect after treatment with regenerating agents (Cacicol®)

- **S056** Management and treatment of contact lens keratitis

- **S057** Topical N-acetylcysteine on patients with refractory filamentary keratitis
  KOH J W, Yang Y R - Gwangju

- **S058** Comparison of autologous platelet-rich plasma with autologous serum eye drop in corneal epithelial disorder
  SHIRZADEH S - Mashhad

- **S059** Free living amoebae (FLA) keratitis

- **S060** Case of conjunctival amyloidosis with repeated subconjunctival hemorrhages
  ANDOH T - Chiba

- **S061** Osmoprotective activity of alpha-lipoic acid and taurine on hyperosmolar stress in cultured human corneal and conjunctival epithelial cells
  SUAREZT, Soria J, Chatard-Baptiste C - Derio

- **S062** Taurine exerts antioxidant and osmoprotecting activity: an in vitro and in vivo study
  BUOCOLO C, Fidilio A, Platania C B M, Geraci F, Drago F - Catania

- **S063** The effect of silica nanoparticles on human corneal epithelial cells
  PARK J, Yim B, Park CY, Chang M W - Goyang-si/Gyeonggi-do

- **S064** Subgroup analysis of two phase III studies of 0.1% cyclosporine A cationic emulsion (CsA CE) in patients with dry eye disease
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors and Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>S065</td>
<td>Macular OCT features in eyes with VKH disease</td>
<td>DIWO E, Stoykova V, Massamba N, Le Hoang P, Bodaghi B - Paris</td>
</tr>
<tr>
<td>S068</td>
<td>Ocular manifestations in dengue fever</td>
<td>REMOND A L, Butel N, Fardeau C, Errera M H, Le Hoang P, Bodaghi B - Paris</td>
</tr>
<tr>
<td>S069</td>
<td>Evaluation of choroidal changes in patients with ocular toxoplasmosis using spectral domain optical coherence tomography</td>
<td>AKPOLA T C, Murat M, Celebi N - Istanbul</td>
</tr>
<tr>
<td>S070</td>
<td>Ocular candidiasis in intravenous drug misusers</td>
<td>LAM D, Belazzougui R, Fardeau C, Toutou V, Le Hoang P, EdelY, Bodaghi B - Paris</td>
</tr>
<tr>
<td>S072</td>
<td>Modern aspects of demodex blepharitis treatment</td>
<td>Rykov S, PETRENKO O, Shargorodskaya I - Kyiv</td>
</tr>
<tr>
<td>S073</td>
<td>Unilateral painful external ophthalmoplegia as the first manifestation of combined anterior and posterior scleritis</td>
<td>ESTEBAN O, Ascaso J, Idoate A, Sanchez J I, Berniolles J, Bartolomé I, Cristóbal J A - Zaragoza</td>
</tr>
</tbody>
</table>
**LC - Lens and Cataract**

S074 - S086

**LÖFGREN S, ERCAL N**

**S074**
Comparison of several transport activities of lens epithelial cells from cataract and healthy dog

*OCHIAI H - Sagamihara Kanagawa*

**S075**
Exposure to subthreshold dose of UVR-B induces apoptosis in the lens epithelial cells and does not in the lens fiber cells

*GALICHANIN K, Yu Z, Talebizadeh N, Burmakin M, Söderberg P - Uppsala*

**S076**
Prevention and reversal of selenite-induced cataracts by N-acetylcysteine amide in Wistar rats

*Maddirala Y, Tobwala S, Karacal H, ERCALL N - Rolla*

**S077**
A dual therapeutic approach for the reversal of cataracts

*Beltz J, Pfaff A, ERCALL N - Rolla*

**S078**
Human anterior lens epithelium in presenile cataract- scanning and transmission electron microscopy study

*ANDJELIC S, Drašlar K, Hvala A, Hawlina M - Ljubljana*

**S079**
Composition of phacoemulsificated human lenses analyzed by infrared spectroscopy

*CHANIECKI P, Miszczyk J, Rekas M, Paluszkiewicz C - Krakow*

**S080**
Ocular tolerance in rabbits of intracameral administration of Mydrane, a fixed combination of tropicamide, phenylephrine, and lidocaine for cataract surgery

*OLMIERE C, Viaud-Quentric K - Clermont-Ferrand*

**S081**
Weill-Marchesani syndrome: displaced lens, displaced pupil, displaced diagnosis

*HUSSAIN N, Jeyabaladevan S, Macapagal M, Tumbocon J - Kingston upon ThamesSurrey*

**S082**
Comparison of visual and refractive outcomes after implantation of a new diffractive trifocal toric lens, a trifocal lens and a monofocal toric lens

*MARECHAL M, Delbarre M, Berenguí M, Rambaud C, Benisty D, Charpentier S, Timsit A, Froussart-Maille F - Clamart*

**S083**
Clinical features of cataract extraction with negative power intraocular lens implantation in high myopia patients

*CHOI J B, SHIN W B, Kim M K - Seoul*

**S084**
Implantable Collamer Lens to treat high myopia : efficiency and safety

*CHARPENTIER S, Graber M, Rambaud C, Monin J, Berenguí M, Delbarre M, Sendon D, Marechal M, Timsit A, Froussart-Maille F - Clamart*

**S085**
Outbreak of fungal endophthalmitis following cataract surgery

*MOON D, Lee S, You Y, Lee D - Daegu*

**S086**
Eleven year review of risk factors and visual outcomes of patients with posterior capsule rupture (PCR) as a complication of cataract surgery at a district general hospital

*BEGUM S, Penwarden A, Saunders D, Balendra S I, Schulz C, Hunter M - Portsmouth*
S087  
**JAGER MJ, VAN GINDERDEUREN R**  
BAP1 germline mutations in uveal melanoma patients without family history of eye cancer


**S088**  
DNA methylation patterns in Uveal Melanoma derived FFPE samples correlate with survival

NESS C, Grüner CC, Meza Zepeida L, Moe MC, Noer A - Oslo

**S089**  
Electroporation enhances chemosensitivity of uveal melanoma cells


**S090**  
Uveal melanoma clonogenic response to proton beam irradiation

ROMANOWSKA DIXON B, Jasinska K, Michalik M, Madeja Z, Urbanska K, Elas M - Krakow

**S091**  
Histomorphological changes of uveal melanoma (UM) following proton beam therapy (PBR)

Qureshi S, Hussain R, Kalirai H, Heimann H, Coupland S - Liverpool

**S092**  
UM Cure 2020 - A consortium of European experts in uveal melanoma to identify new therapies for patients with metastatic disease


**S093**  
Choroidal nevi classification using swept source optical coherence tomography and infrared reflectance patterns at different wavelengths


**S094**  
Wide-field autofluorescence and scanning laser ophthalmoscopy: a tool for differential diagnosis of intraocular tumors

Espositi G, Denaro R, Hadjistilianou T, Chimenti G, Esposito PL - Siena

**S095**  
Transpalpebral near-infrared LED transillumination for anteriorly located intraocular tumors imaging

Zadorozhnyy O, Korol A, Kustryn T, Nasinnyk I, Pasyechnikova N - Odessa

**S096**  
The role of anterior segment optical coherence tomography (AS-OCT) and ultrasound biomicroscopy (UBM) in conjunctival nevi

Lauwers N, Janssens K, Mertens M, De Keizer RJW, De Groot V - Edegem

**S097**  
Clinical and morphometric investigation of retinopathy in children with retinoblastoma treated with chemotherapy

Sakayan S - Moscow

**S098**  
Congenital malignant ciliary body medullegenepithelioma in two newborns


**S099**  
Proton beam radiotherapy (PBR) for the treatment of retinal capillary haemangioblastoma


**S100**  
Management strategies in vasoactive proliferative tumor of the retina

Tunc M - Ankara

**S101**  
Intravitreal bevacizumab as an adjuvant treatment of choroidal metastasis

Costa J, Braga J, Neves F, Meira D, Ribeiro L - Vila Nova de Gaia
10:50 - 12:00 | POSTER AREA

PO - Pathology/Oncology
S087 - S110

S102
Primary intraocular lymphoma and flow cytometry analysis of the vitreous – a case report
ROMANOWSKA DIXON B, Karska Basta I, Kubicka-Trzaska A - Krakow

S103    rf
Sequential bilateral optic nerve infiltration as the sole manifestation of relapsed T-cell lymphoblastic lymphoma: a case report.

S104    rf
Clinical and instrumental diagnostics in patients with orbital metastasis
SAAKYAN S - Moscow

S105
An analysis of IgG4-related ocular disease among idiopathic orbital inflammations and mucosa- associated lymphoid tissue lymphoma
Sohn E J, Roh M S, Kwon Y H, AHN H - Busan

S106
Orbital mucocele: Orbital Masquerading Syndrome
TUNC M - Ankara

S107
First cases of ocular dirofilariasis caused by drofilaria repens in Belgium
SMETS M, De Potter P - Bruxelles

S108    rf
Grading iris color of post-mortem human eyes
MADIGAN M, Cionaca V, Sitiwin E, Ton H T - Sydney

S109
Histopathological findings after pars plana vitrectomy with a new hypersonic vitrector

S110
Application of laser radiation exposed Chlorpromazine for the treatment of pseudotumours induced in rabbit eyes
POPA CHERECHEANU A, Tozar T, Geamanu A, Iancu R, Duta S, Pirvulescu R - Bucharest
### Women 4 EVER

Women 4 EVER wishes to assist women in developing tools for career advancement and to foster gender equality in ophthalmology and visual science. We encourage mentorship, collaboration, and communication. In this informal and open session, we invite all interested members of EVER to come and meet colleagues, share experiences and ask for advice. It is also a venue where ideas about gender-based studies in ophthalmology may be developed.

**CREUZOT C**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Details</th>
</tr>
</thead>
</table>
| 13:00 | Combined family life and ophthalmic oncology career  
*VAN GINDERDEUREN R, Leuven* |
| 13:30 | Combining immunology, ophthalmology and personal life in Finland  
*KAUPPINEN A, Kuopio* |
| 14:00 | Discussion |

### COS - Pseudophakic and phakic toric implants – from preoperative examination

Toric intraocular lenses (tIOL) are either implanted in the capsular bag in a regular cataract surgery or used as phakic or pseudophakic add-on tIOL in a refractive surgery procedure for correcting spherocylindrical refraction or for fine-tuning of refraction after cataract surgery. First, detailed clinical and instrument assisted diagnostics have to be performed for a proper indication as well as for calculating tIOL power. In this SIS we will discuss the diagnostic modalities such as corneal tomography and guide how to interpret the instrument data and how to derive a proper indication from clinical and instrument-based exams. In a next step, different options for calculating phakic and pseudophakic tIOL are shown and the calculation scheme is applied to clinical examples. In addition, we present an overview on WEB calculation platforms. In a next step, the peri- and intraoperative details of tIOL surgery is shown from axis marking to a proper positioning of the lens in the eye and axis alignment. In a last step, we show how to monitor the patient in the follow-up period and give advice for troubleshooting and how to deal with potential complications such as re-adjustment of the cylinder axis after rotation of the tIOL.

**LANGENBUCHER A, SZENTMARY N, EPPIG T**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Details</th>
</tr>
</thead>
</table>
| 4421  | 13:00  
*Spectrum of indications, patient selection, options for astigmatic corrections, pre- and postoperative patient care*  
*SZENTMARY N - Homburg/Saar* |
| 4422  | 13:18  
*Instrument assisted diagnostics – biometry, topography and wave-front analysis*  
*EPPIG T, Spira-Eppig C, Szentmáry N, Langenbucher A - Homburg/Saar* |
| 4423  | 13:36  
*How to calculate pseudophakic and phakic toric implants?*  
*LANGENBUCHER A, Szentmány N, Eppig T - Homburg* |
| 4424  | 13:54  
*Intraoperative optical coherence tomography (iOCT) assisted positioning of toric lens implants*  
*WYLEGALA E - Katowice* |
| 4425  | 14:12  
*Surgical aspects of toric lens implantation and complication management*  
*BARRAQUER R I - Barcelona* |
COS - Maximising success in deep anterior lamellar keratoplasty

The most popular technique for deep anterior lamellar keratoplasty (DALK) is the 'big bubble' (BB) technique wherein air is injected in the cornea to create a bubble that separates Descemet's membrane (DM) from the stroma. An attempt to create a BB often results in the cornea being filled with numerous small bubbles without the formation of a BB. Manual dissection is then required to complete the procedure. The goal of this course is to present an update on this popular surgical procedure and give tips and tricks from trained surgeons.

DUA HS, GICQUEL JJ

**4431** 13:00  Know your bubbles
DUA H S - Nottingham

**4432** 13:30  What to do when no bubbles? and post operative pitfalls
GICQUEL J - Poitiers

**4433** 14:00  Surgical tips through clips
SAID D - Nottingham

PO: OOG Session 3

ZOGRAFOS L, DESJARDINS L

**4441** 13:00  Long-term visual acuity preservation after proton therapy for peri- and parapapillary melanoma patients treated at the Paul Scherrer Institute

**4442** 13:12  Outcomes after proton beam therapy for large choroidal melanomas in 492 patients
BENSOUSSAN E, Bailiiff S, Maschi C, Caujolle J P, Thariat J - Nice

**4443** 13:24  Dry eye syndrome following proton therapy of ocular melanomas
MASCHI C, Sara L, Peyrichon M L, Bailiff S, Herault J, Thariat J, Caujolle J P - Nice

**4444** 13:36  Proton beam radiotherapy (PBR) for the treatment of retinal capillary haemangioblastoma
HUSSAIN R, Hassan S, Ho V, Kacperak A, Errington D, Heimann H - Liverpool

**4445** 13:42  Case report of a choroidal ganglioneuroma
VAN GINDERDEUREN R, Missotten G - Leuven

**4446** 13:54  Choroidal metastasis from thyroid cancer: a case series
MAMUNUR R, Kivelä T - Helsinki

**4447** 14:06  Management strategies in vasoactive proliferative tumor of the retina
TUNC M - Ankara
EUPO session 7 - Strabismus
Nonparalytic Esodeviations and Exodeviations
Case Presentations II: Odd and Unusual Things in Strabismus

EUPO Programme, see pages 134-135.

13:00 - 14:30 | GALLIENI 1+2
FRO: Belgian Fund for Research in Ophthalmology 2

<table>
<thead>
<tr>
<th>Number</th>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>4461</td>
<td>13:00</td>
<td>AON therapy for restoration of defective splicing in genes mutated in hereditary blindness</td>
<td>NAESENS S - Gent</td>
</tr>
<tr>
<td>4462</td>
<td>13:12</td>
<td>Exploring strategies to overcome the inner limiting membrane as a barrier for non-viral retinal gene therapy after intravitreal injection</td>
<td>PEYNSHAERT K - Ghent</td>
</tr>
<tr>
<td>4463</td>
<td>13:24</td>
<td>Copy number variation analysis and whole exome sequencing of three unique Belgian keratoconus families</td>
<td>VALGAEREN H - Edegem</td>
</tr>
<tr>
<td>4464</td>
<td>13:36</td>
<td>Regenerating the ocular surface using standardized, xeno-free, tissue-engineered conjunctival grafts for conjunctival reconstruction</td>
<td>VANACKER S - Antwerpen</td>
</tr>
<tr>
<td>4465</td>
<td>13:48</td>
<td>Targeting specific pathways to enhance human corneal endothelial proliferation in vitro</td>
<td>VAN DEN BOGERD B - Edegem</td>
</tr>
<tr>
<td>4466</td>
<td>14:00</td>
<td>Automated retinal vessel analysis to improve the detection and management of ophthalmic and systemic diseases</td>
<td>VAN KEER K - Leuven</td>
</tr>
<tr>
<td>4467</td>
<td>14:12</td>
<td>Hidden genetic variation in retinal dystrophies – exploring the contribution of copy number variations</td>
<td>VAN SCHIL K - Ghent</td>
</tr>
<tr>
<td>4468</td>
<td>14:24</td>
<td>Confocal and optical coherence bleb imaging pre-and after filtering surgery</td>
<td>WILLEKENS K - Leuven</td>
</tr>
</tbody>
</table>
14:30 - 15:00 | HERMES
Prize Award Ceremony & Closing Remarks

Chair: Andrew Dick, President EVER 2017

Introduction of the Award Ceremony by Marcela Votruba, Programme Secretary
- Travel awards presentation by the section chairs
- Poster prize presentations by the section chairs

Presentation and report of the scientific sections meetings

Conclusion of the congress by the President 2016 Aki Kawasaki
Friday 7 October 2016 in Rhodes 4

08:30  Common Optic Neuropathies in Adults: Diagnosis, Treatment and Prognosis
   Antonella BOSCHI, Valerie PURVIN
   08:30  Idiopathic (demyelinating) optic neuritis  PURVIN V
   08:50  Non-arteritic anterior ischemic optic neuropathy  SAARELA V
   09:10  Compressive optic neuropathy: pituitary adenoma  BOSCHI A
   09:30  Leber hereditary optic neuropathy  YU WAI MAN P
   09:50  Discussion
   10:00  Break

10:30  Case Presentations I: Odd and Unusual Things in Neuro-ophthalmology
   Valerie PURVIN, Ville SAARELA

11:00  Systematic Approach to the Ocular Motor System
   François-Xavier BORRUAT, Caroline TILIKETE
   11:00  Central disorders of ocular motility  BORRUAT FX
   11:25  Central disorders of ocular stability  TILIKETE C
   11:50  Myasthenia  LEE M
   12:15  Discussion
   12:30  Lunch

13:30  Uncommon but Important Causes of Visual Loss
   Fiona BREMNER, Graham HOLDER
   13:30  Inatrogenic visual loss: toxicities  PURVIN V
   13:50  Acquired autoimmune retinopathies  HOLDER G
   14:10  Posterior reversible encephalopathy syndrome (PRES)  KAWASAKI A
   14:30  Neuromyelitis optica (NMO) and spectrum disorders  BREMNER F
   14:50  Discussion
   15:00  Break

16:00  Recognizing the Emergencies: From Symptom to Diagnosis
   Catherine VIGNAL CLERMONT, Michael LEE
   16:00  Transient monocular visual loss: carotid embolus vs giant cell arteritis  VIGNAL CLERMONT C
   16:20  Diagnosis and management of giant cell arteritis  LEE M
   16:40  Acute diplopia: third nerve palsy  BREMNER F
   17:00  Acute anisocoria: aneurysm vs Horner syndrome  KAWASAKI A
   17:20  Discussion

17:30  Case Presentations II: Odd and Unusual Things in Neuro-ophthalmology
   Patrick YU WAI MAN, Aki KAWASAKI

18:00 End
Neuro-ophthalmology and Strabismus

Saturday 8 October 2016 in Rhodes 4

08:30 Paralytic Strabismus: Diagnosis, Evaluation and When to Treat
   Oliver EHRT, Heimo STEFFEN
   - 08:30 Acquired cranial nerve palsies       STEFFEN H
   - 08:55 Congenital cranial dysinnervation disorders   KAESER PF
   - 09:20 Surgical indications and management of paralytic strabismus   EHRT O
   - 09:45 Discussion

10:00 Break

10:30 Case Presentations I: Odd and Unusual Things in Strabismus
   Dominique BREMOND GIGNAC, Cameron PARSA
   - 11:00 Amblyopia, Nystagmus and Secondary Strabismus
     Jan Tjeerd DE FABER, Pierre-François KAESER
     - 11:00 Amblyopia: physiologic basis and management   PARSA C
     - 11:20 Screening strategies for amblyopia              BREMOND GIGNAC D
     - 11:40 Infantile nystagmus                            KAESER PF
     - 12:00 Secondary and iatrogenic strabismus            DE FABER JT
     - 12:20 Discussion
     - 12:30 Lunch

13:30 Nonparalytic Esodeviations and Exodeviations
   Rosario GOMEZ de LIANO, Marcel TEN TUSSCHER
   - 13:30 Esotropia: Considerations in Infants and Adults   TEN TUSSCHER M
   - 13:55 Exodeviations                                  GOMEZ DE LIANO R
   - 14:20 Nonsurgical management of strabismus            DE FABER JT
   - 14:45 Discussion

15:00 Case Presentations II: Odd and Unusual Things in Strabismus
   Dominique BREMOND GIGNAC, Cameron PARSA
   - 15:00 End
XXth EVER CONGRESS
EVER 2017 NICE
SEPTEMBER 27-30
www.ever.be
Awardees of the EVERf Research Fellowships 2016

• Dr Mahajan DEEPTI, India
  host institute: Vision Lab, Cardiff Centre for Vision Sciences, Cardiff University, UK

• Dr Narine ADZHEMIAN, Russia
  host institute: Medical University of Vienna, Austria
SAVE THE DATE

www.soe2017.org

REGISTER and SUBMIT ABSTRACTS NOW!

EB Diploma Examination 2017

Applications open October 2016

Venue:
Le Palais des Congrès de Paris

Website: ebo-online.org
The Obergurgl Optic Nerve Meeting
Focus Area -
Boosting optic nerve function
December 13-15
2016
www.optic-nerve-online.com

Organisation:
Jonathan Crowston
Professor of Ophthalmology, University of Melbourne

Franz Grus
Professor of Experimental Ophthalmology, Johannes Gutenberg University, Mainz

Keith Martin
Professor of Ophthalmology, University of Cambridge

Austria - Obergurgl
Hotel Edelweiss & Gurgl
February 5 – 8, 2017
Brisbane Convention and Exhibition Centre
Brisbane, Australia

Bridging disciplines and disparities: Connecting eye research with health outcomes

The sixth ARVO-Asia meeting will explore the latest in basic, translational and clinical research through symposia, plenary, paper and poster sessions and special interest groups.

We discuss how we can build bridges that ensure our discoveries translate into effective prevention, diagnosis and treatments for patients with eye disease.

Chair: Mark H.B. Radford, MD, PhD

Co-chairs:
Justine R. Smith, FRANZCO, PhD, FARVO
Peter J. McCluskey, MD, FRANZCO

Early registration closes Dec. 12, 2016
Abstract submission: July 12 – Sept. 20, 2016
Online program available: Dec. 13, 2016

arvo.org/arvoasia
ARVO 2017
MAY 7 – 11 | BALTIMORE
GLOBAL CONNECTIONS IN VISION RESEARCH

Important Dates

- **Abstract submission**
  October 14 – December 2, 2016

- **Early meeting registration**
  Opens September 19, 2016

Travel grants are available. Apply when submitting your abstract.
For further information and easy ordering please go to our website
www.karger.com/ophthalmology
Raxone is the first and only approved medication for Leber’s Hereditary Optic Neuropathy (LHON)

- LHON is a severe, progressive mitochondrial disease causing irreversible vision loss
- Raxone demonstrated:
  - Clinically relevant recovery (CRR) of vision in 30% of patients
  - Clinically relevant stabilisation (CRS) in 50% of patients
- Raxone has a safety and tolerability profile similar to placebo

References: 1. Raxone SmPC. September 2015. 2. Raxone EPAR. September 2015; from prospective studies and case collection (RHODOS, EAP, Table 12 EPAR).

To hear what Raxone can do for your Leber’s patients, visit Santhera at booth 101 or go to www.santhera.com
<table>
<thead>
<tr>
<th>Name</th>
<th>Poster Numbers</th>
<th>Oral Presentations</th>
<th>Poster Session Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABEGAO PINTO</td>
<td>L: 1325, 3124, 3663</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ABU EL ASRAR</td>
<td>A: 1335, 2332</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AFANASYEVA</td>
<td>D: 1375, S016</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AGARWAL</td>
<td>P: S052</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AHMED</td>
<td>F: 2722</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AHN</td>
<td>H: S010, S105</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AKPOLAT</td>
<td>C: 2331, S069, T097</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALA-KAUHALUOMA</td>
<td>M: F109</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALDAHAM</td>
<td>S: 3326, F076</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALGHAMDI</td>
<td>A: 1555</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALI ALJASIM</td>
<td>L: T043, T044</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALLEN</td>
<td>C: 2333</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALMENARA MICHELENA</td>
<td>C: F108, S066</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALMOALLEM</td>
<td>B: 3581</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALVAREZ</td>
<td>L: T075</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALZAHARI</td>
<td>K: S050</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALZAHARI</td>
<td>S: 1145, S023</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AMADIO</td>
<td>M: S006</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AMBRESIN</td>
<td>A: 3115</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ANDJELIC</td>
<td>S: S078</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ANDOH</td>
<td>T: S060</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ANDRE</td>
<td>H: 3584</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ANDRIES</td>
<td>L: 4161</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ANDROUDI</td>
<td>S: 1132</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ANGI</td>
<td>M: 3642</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ANISIMOV</td>
<td>S: 2674</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ANTOUN</td>
<td>J: 3371</td>
<td></td>
<td></td>
</tr>
<tr>
<td>APTEL</td>
<td>F: 3122, T029</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ARCINIEGAS</td>
<td>C: 2121</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ARDAN</td>
<td>T: T106</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ARJAMAA</td>
<td>O: 1371</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ARNOULD</td>
<td>L: 1376</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ARSENIJEVIC</td>
<td>Y: 1512</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ASCASO</td>
<td>F: 2711, 4111, F070, F094</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ATILLA</td>
<td>H: 2663, 2741</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AUDO</td>
<td>I: 3181</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AUTRATA</td>
<td>R: F042, F043</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AUVINEN</td>
<td>A: 3383</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BAE, JH</td>
<td>F113</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BALCI, Ö</td>
<td>3674</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BALDESCHI</td>
<td>L: 2632</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BALENTRA</td>
<td>S: 1162</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BARBONI</td>
<td>P: 2363</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BARBOSA BREA</td>
<td>J: 4162, T017</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BARRAQUER</td>
<td>J: 2353</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BARRAQUER, RI</td>
<td>4425</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BATSON</td>
<td>J: 1341</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BAUDIN</td>
<td>F: 2681</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BECHRakis</td>
<td>NE: 2732, 3342, 3544</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BECKERS</td>
<td>A: 4163</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BEGUM</td>
<td>S: 2338, F077, S086</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BEHAEGEL</td>
<td>J: 4164</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BEHAR-COHEN</td>
<td>F: 3165</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BEK, T</td>
<td>1115</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BENSOUSSAN</td>
<td>E: 4442</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BERNIOLLES</td>
<td>J: S027, S043</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BERROD</td>
<td>J: 1562, 3513</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BEUERMAN</td>
<td>R: 1172, 2772</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BITOUN</td>
<td>P: 1523</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BJORKOY</td>
<td>G: 2173</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BLASI, MA</td>
<td>3142</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BLOOM</td>
<td>P: 2724</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BOBAT</td>
<td>H: T025</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BODAGHI</td>
<td>B: 1535</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BONINI</td>
<td>S: 3635</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BONO, V</td>
<td>T023</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BOSCHI</td>
<td>A: 2633</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BOULADI, M</td>
<td>T008, T009</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BOURAOUI, R</td>
<td>F092, F093</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BOURNE</td>
<td>R: 1361</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BOUTELEUX</td>
<td>V: F062</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BOUVIER</td>
<td>R: F044</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BOYA, P</td>
<td>3521</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BOYCHUK, I</td>
<td>F035, S017</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BRAGA, J</td>
<td>F021</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BRANDL, C</td>
<td>T081</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BREHON, A</td>
<td>S013, S048</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BREMONT-GIGNAC</td>
<td>D: 2662, 2744, 3681, 4132</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BREUNIG, M</td>
<td>3133</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BRISCOE, D</td>
<td>2654</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BRON, A</td>
<td>1521, 2616</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BRUNNER, S</td>
<td>2112</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BUCOLO, C</td>
<td>S062</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BUELENS, T</td>
<td>3374</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BUJAKOWSKA, K</td>
<td>2762</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BUSHUYEVA, N</td>
<td>F026, F034, S020</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BUZNYK, O</td>
<td>1143</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CALONGE, M</td>
<td>2771</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CALVAS, P</td>
<td>2661</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CANDI, A</td>
<td>T104</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CARDIGOS, J</td>
<td>3327, F078, T015</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CARELLI, V</td>
<td>1552, 2364, 2424, 2426</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
CARRASQUILLO, KG: 2373
CARVALHO, B: S011
CASSOUX, N: 2341, 2344, 3315, 3341, 3545
CASTELO-BRANCO, M: 2645
CAUJOLLE, JP: 3143
CELLINI, M: T006
CHANIECKI, P: S079
CHARLIER, J: 3564
CHARPENTIER, S: S084
CHEN, L: 3631
CHIAMBARETTA, F: 2743, 2834
CHIQUET, C: 2354
CHOI, C: F081
CHOI, H: F030, F031
CHOI, JB: S083
CIPRÈS ALASTUEY, M: F014, F015
COLAS, E: 2337, F074
CONDE, C: S015
CORDEIRO SOUSA, D: 2685, T045, T086
CORDEIRO, MF: 3623
CORRELL, M: 1146, 3335, S026
COSCAS, F: 3111
COSCAS, G: 3114
COSTA, J: S101
COSTA, L: 1347, 3328, F079, T024, T102
COUPLAND, S: 3145, 3317, 4145, S092
COUVRER, E: S049
CRAWLEY, L: 2723
CREUZOT, C: 1363
CRISÓSTOMO, S: T016
CROUZET, E: 1141, S042
CTORI, I: T079
CVEKL, A: 2351
CZAK, W: 2673
DABASIA, P: T027
DALGAARD, LM: 1522
DALKE, C: 3382
DAMATO, B: 3344
DANIELSON, P: 2734
DAULL, P: 2677, S022
DAVIS, B: 2323
DE BOEVER, P: 2683
DE GROEF, L: 1344
DE GROOT, V: F037
DE LAEY, J: 4113
DE ZAEYTIJD, J: T069
DESJARDINS, L: 2343, 3541, 3644
DEVOLDERE, J: 1544, 4165
DICK, A: 1131, 1136
DIWO, E: S065
DOAN, S: 2374, S051
DOBROWOLSKI, D: 2134, 2136
DOGAN, M: 2385, T107
DRAGANOVA, D: 3373
DUA, HS: 1576, 3571, 4431
DUCH, S: 2124
DYSLI, C: 2623
EHSAEI, A: S018, S030
EIDET, JR: 2676, S025
EL AMEEN, A: 3673, T034
EL MATRI, L: F082, T068
EPPIG, T: 4122, 4422
ERCAL, N: 2782, S076, S077
ERDURMUS, M: T098
ERKAN TURAN, K: F016, F047
ESPOSTI, G: S094
ESTEBAN, O: S073, T066
EYSTEINSSON, T: 2382
FENOLAND, JR: 1528, T042
FERNÁNDEZ-NAVARRO, J: 1543
FERNÁNDEZ-PÉREZ, J: 3332
FERRARI, S: 3171
FIOLENTZIS, M: S089
FITZKE, FW: 2164
FRANCESCHETTI, A: 4115
FRENCH, C: 2686, F058
FRENKEL, S: 3316
FRUSCHELLI, M: 3325, F091
FUCHSLUGER, T: 3132
FUNKE, S: 3525
GABRIELLE, P: 1546
GALICHANIN, K: S075
GALLEGOS, B: 2322
GARCÍA LLORCA, A: 3585, T076
GARCIA MARTIN, E: F003, F004
GARCIA-FEJOO, J: 1322, 3123
GARCIA-ZAMORA, M: F084
GARCIA, M: T073
GARcin, T: 3331
GARHÖFER, G: 2145
GAZZARD, G: 2721
GEORGIAKIS, T: 1511
GIANNACCARE, G: T020
GICQUEL, J: 4131, 4432
GLITZENBERG, C: 2113
GOCHO, K: 2682
GOH, M: T082
GOMES ALVES DA CONCEIÇÃO, R: T050
GONZALEZ, C: 3323, F060, F061
GRABSKA-LIBEREK, I: T040
<table>
<thead>
<tr>
<th>Author</th>
<th>ID</th>
</tr>
</thead>
<tbody>
<tr>
<td>GRAEFF, E.</td>
<td>2755</td>
</tr>
<tr>
<td>GRAJEWSKI, L.</td>
<td>F053</td>
</tr>
<tr>
<td>GRAW, J.</td>
<td>3586</td>
</tr>
<tr>
<td>GREENWOOD, J.</td>
<td>2211</td>
</tr>
<tr>
<td>GRIFFITH, M.</td>
<td>3135</td>
</tr>
<tr>
<td>GRILLO-ANTONELLI, S.</td>
<td>S007</td>
</tr>
<tr>
<td>GRIVET, D.</td>
<td>S009</td>
</tr>
<tr>
<td>GRUENERT, A.</td>
<td>3532</td>
</tr>
<tr>
<td>GRZYBOWSKI, A.</td>
<td>1154, 2641, 2713, 4112</td>
</tr>
<tr>
<td>GUAGLIANO, R.</td>
<td>F039</td>
</tr>
<tr>
<td>GUPTA, V.</td>
<td>1531</td>
</tr>
<tr>
<td>HAAGDORENS, M.</td>
<td>4166</td>
</tr>
<tr>
<td>HAAVISTO, A.</td>
<td>T083</td>
</tr>
<tr>
<td>HADJISTILIANOU, T.</td>
<td>3641, 3646, S098</td>
</tr>
<tr>
<td>HAIKONEN, S.</td>
<td>T090</td>
</tr>
<tr>
<td>HAMEL, C.</td>
<td>3182</td>
</tr>
<tr>
<td>HARDARSON, S.</td>
<td>2383</td>
</tr>
<tr>
<td>HASSAIRI, A.</td>
<td>1142, 2675, F063, S024</td>
</tr>
<tr>
<td>HAWRAMI, A.</td>
<td>2336, F075</td>
</tr>
<tr>
<td>HE, Z.</td>
<td>3334</td>
</tr>
<tr>
<td>HEEGAARD, S.</td>
<td>2653</td>
</tr>
<tr>
<td>HEISTERKAMP, A.</td>
<td>1575</td>
</tr>
<tr>
<td>HEITMAR, R.</td>
<td>T089</td>
</tr>
<tr>
<td>HENDERSON, R.</td>
<td>2763</td>
</tr>
<tr>
<td>HENGERER, F.</td>
<td>2184</td>
</tr>
<tr>
<td>HEO, DW.</td>
<td>T061</td>
</tr>
<tr>
<td>HERBORG, A.</td>
<td>T091</td>
</tr>
<tr>
<td>HERBORT, CP.</td>
<td>1135, 1334, 1533, 3671</td>
</tr>
<tr>
<td>HERMANN, P.</td>
<td>2624</td>
</tr>
<tr>
<td>HERRERO-VANRELL, R.</td>
<td>2142</td>
</tr>
<tr>
<td>HIROTAKA, Y.</td>
<td>F005</td>
</tr>
<tr>
<td>HOFFART, L.</td>
<td>1144</td>
</tr>
<tr>
<td>HOHBERGER, B.</td>
<td>3533</td>
</tr>
<tr>
<td>HOLDER, G.</td>
<td>2163, 3184</td>
</tr>
<tr>
<td>HOLOPAINEN, J.</td>
<td>1173, 2773</td>
</tr>
<tr>
<td>Hori, J.</td>
<td>3634</td>
</tr>
<tr>
<td>HORWITZ, A.</td>
<td>1168, T031</td>
</tr>
<tr>
<td>HOUILLIER, C.</td>
<td>2614</td>
</tr>
<tr>
<td>HU, T.</td>
<td>2387, T093</td>
</tr>
<tr>
<td>HUANG, O.</td>
<td>1166, T018</td>
</tr>
<tr>
<td>HUDSON, C.</td>
<td>1112</td>
</tr>
<tr>
<td>HUNJTENS, B.</td>
<td>T074</td>
</tr>
<tr>
<td>HUSSAIN, N.</td>
<td>S081</td>
</tr>
<tr>
<td>HUSSAIN, R.</td>
<td>1561, 4444, S099</td>
</tr>
<tr>
<td>IDOATE, A.</td>
<td>F045</td>
</tr>
<tr>
<td>ILHAN, B.</td>
<td>T011</td>
</tr>
<tr>
<td>IOMDINA, EN.</td>
<td>1343, S031, T037</td>
</tr>
<tr>
<td>IRION, L.</td>
<td>S109</td>
</tr>
<tr>
<td>IRRICH, K.</td>
<td>1351, 1352, 1353</td>
</tr>
<tr>
<td>ISIK, M.</td>
<td>T010</td>
</tr>
<tr>
<td>IYER, J.</td>
<td>T038</td>
</tr>
<tr>
<td>JACKSON, TL.</td>
<td>1541</td>
</tr>
<tr>
<td>JAGER, MJ.</td>
<td>3144, 3311, 3343</td>
</tr>
<tr>
<td>JAKOBS, TM.</td>
<td>S046</td>
</tr>
<tr>
<td>JAMES TE</td>
<td>2433</td>
</tr>
<tr>
<td>JANISZEWSKA, D.</td>
<td>2133</td>
</tr>
<tr>
<td>JENKINS, KS.</td>
<td>3567, T013</td>
</tr>
<tr>
<td>JEPPESEN, SK.</td>
<td>T094</td>
</tr>
<tr>
<td>JIRSOVA, K.</td>
<td>3531</td>
</tr>
<tr>
<td>JÖHANNESSON, G.</td>
<td>2731</td>
</tr>
<tr>
<td>KAARNIRANTA, K.</td>
<td>2174</td>
</tr>
<tr>
<td>KADOR, K.</td>
<td>S041</td>
</tr>
<tr>
<td>KADZIAUSKIENE, A.</td>
<td>T059</td>
</tr>
<tr>
<td>KALIRAI, H.</td>
<td>3312</td>
</tr>
<tr>
<td>KALOGEROU, M.</td>
<td>T054</td>
</tr>
<tr>
<td>KANAWATI, S.</td>
<td>F057</td>
</tr>
<tr>
<td>KANG, H.</td>
<td>F100</td>
</tr>
<tr>
<td>KANG, S.</td>
<td>S004, T100</td>
</tr>
<tr>
<td>KANNAN, R.</td>
<td>2172</td>
</tr>
<tr>
<td>KASPI, M.</td>
<td>S012</td>
</tr>
<tr>
<td>KAUPPINEN, A.</td>
<td>1374</td>
</tr>
<tr>
<td>KAYA, S.</td>
<td>2432</td>
</tr>
<tr>
<td>KAZAKBAEVA, G.</td>
<td>S032, S033</td>
</tr>
<tr>
<td>KELLY, C.</td>
<td>3333</td>
</tr>
<tr>
<td>KESSEL, L.</td>
<td>2784</td>
</tr>
<tr>
<td>KELESTYN, P.</td>
<td>2615</td>
</tr>
<tr>
<td>KHAIROLALLAH, M.</td>
<td>1333, 1532</td>
</tr>
<tr>
<td>KHAN, A.</td>
<td>3324</td>
</tr>
<tr>
<td>KHATIB, T.</td>
<td>1165, T049</td>
</tr>
<tr>
<td>KHAYAT, H.</td>
<td>2756, S103</td>
</tr>
<tr>
<td>KHEIR, V.</td>
<td>1556, F019</td>
</tr>
<tr>
<td>KIJC, E.</td>
<td>4142</td>
</tr>
<tr>
<td>KIM, DY.</td>
<td>F112</td>
</tr>
<tr>
<td>KIM, HW.</td>
<td>F098</td>
</tr>
<tr>
<td>KIM, JR.</td>
<td>S035</td>
</tr>
<tr>
<td>KIM, JT.</td>
<td>F064</td>
</tr>
<tr>
<td>KIM, JY.</td>
<td>F107</td>
</tr>
<tr>
<td>KIM, K.</td>
<td>F103</td>
</tr>
<tr>
<td>KIM, Y.</td>
<td>1161</td>
</tr>
<tr>
<td>KIM, YT.</td>
<td>F071</td>
</tr>
<tr>
<td>KIM, YY.</td>
<td>T060</td>
</tr>
<tr>
<td>KINOSHITA, S.</td>
<td>2511</td>
</tr>
<tr>
<td>KIVELÀ, T.</td>
<td>2342, 3573, 4114</td>
</tr>
<tr>
<td>KLEYMAN, A.</td>
<td>T032</td>
</tr>
<tr>
<td>KLOPSTOCK, T.</td>
<td>2421, 2425</td>
</tr>
<tr>
<td>KNOP, E.</td>
<td>2371</td>
</tr>
<tr>
<td>KOH, J.</td>
<td>S057</td>
</tr>
<tr>
<td>KOLK, M.</td>
<td>3622</td>
</tr>
<tr>
<td>KOMPPELLA, UB.</td>
<td>2144, 3131</td>
</tr>
<tr>
<td>KONIDARIS, V.</td>
<td>F095</td>
</tr>
<tr>
<td>KOSKELA, A.</td>
<td>S001, S002</td>
</tr>
<tr>
<td>KOUASAL, B.</td>
<td>T070</td>
</tr>
<tr>
<td>KRASTEL, H.</td>
<td>3561, T005</td>
</tr>
<tr>
<td>KRISHNA, Y.</td>
<td>4143</td>
</tr>
<tr>
<td>KUBIC, A.</td>
<td>T010</td>
</tr>
<tr>
<td>KUDRATAVAITE, O.</td>
<td>2381</td>
</tr>
<tr>
<td>KUGELBERG, M.</td>
<td>1152</td>
</tr>
<tr>
<td>KWOK, J.</td>
<td>3522</td>
</tr>
<tr>
<td>Author Name</td>
<td>ID(s)</td>
</tr>
<tr>
<td>--------------------</td>
<td>--------</td>
</tr>
<tr>
<td>Kwon, S</td>
<td>F050</td>
</tr>
<tr>
<td>Kwon, YH</td>
<td>F096, F104</td>
</tr>
<tr>
<td>Kyminonis, G</td>
<td>S034</td>
</tr>
<tr>
<td>Labbe, A</td>
<td>T039</td>
</tr>
<tr>
<td>Labetoulle, M</td>
<td>1153, 4133, S071</td>
</tr>
<tr>
<td>Lagali, N</td>
<td>3633</td>
</tr>
<tr>
<td>Lagreze, WD</td>
<td>2422</td>
</tr>
<tr>
<td>Lam, D</td>
<td>S070</td>
</tr>
<tr>
<td>Langenbucher, A</td>
<td>4121, 4423</td>
</tr>
<tr>
<td>Lathiere, T</td>
<td>S008</td>
</tr>
<tr>
<td>Lauwers, N</td>
<td>2751, S096</td>
</tr>
<tr>
<td>Lazreg, S</td>
<td>2672, 2742, 2832</td>
</tr>
<tr>
<td>Le Mer, Y</td>
<td>3514</td>
</tr>
<tr>
<td>Leal, I</td>
<td>1164, T041, T046</td>
</tr>
<tr>
<td>Lee, JE</td>
<td>T087</td>
</tr>
<tr>
<td>Lee, JY</td>
<td>F069</td>
</tr>
<tr>
<td>Lee, MY</td>
<td>F090, F097</td>
</tr>
<tr>
<td>Lee, SH</td>
<td>S047</td>
</tr>
<tr>
<td>Lee, Y</td>
<td>T085</td>
</tr>
<tr>
<td>Lemaître, S</td>
<td>2753</td>
</tr>
<tr>
<td>Lenaers, G</td>
<td>2361</td>
</tr>
<tr>
<td>Leonardi, A</td>
<td>S064</td>
</tr>
<tr>
<td>Leroy, BP</td>
<td>1412, 1514, 2162, 2611, 3185</td>
</tr>
<tr>
<td>Liasis, A</td>
<td>1124</td>
</tr>
<tr>
<td>Liinamaa, J</td>
<td>1554</td>
</tr>
<tr>
<td>Lisikova, P</td>
<td>2764, 3183, T071</td>
</tr>
<tr>
<td>Lockwood, A</td>
<td>T047</td>
</tr>
<tr>
<td>Loeffler, K</td>
<td>3141</td>
</tr>
<tr>
<td>Lofgren, S</td>
<td>F036</td>
</tr>
<tr>
<td>Lorenzo Corrales, Y</td>
<td>S038</td>
</tr>
<tr>
<td>Loshkareva, A</td>
<td>2671</td>
</tr>
<tr>
<td>Ludgate, M</td>
<td>2631</td>
</tr>
<tr>
<td>Luhmann, U</td>
<td>3523</td>
</tr>
<tr>
<td>Lumbroso, B</td>
<td>3112</td>
</tr>
<tr>
<td>Lytvynchuk, L</td>
<td>1584, 2115</td>
</tr>
<tr>
<td>Maamouri, R</td>
<td>F085, F086</td>
</tr>
<tr>
<td>Maclaren, R</td>
<td>1711</td>
</tr>
<tr>
<td>Madigan, M</td>
<td>2758, 3647, S108</td>
</tr>
<tr>
<td>Makley, L</td>
<td>2785</td>
</tr>
<tr>
<td>Mammadzada, P</td>
<td>T096</td>
</tr>
<tr>
<td>Mamunur, R</td>
<td>4446</td>
</tr>
<tr>
<td>Manns, R</td>
<td>F083</td>
</tr>
<tr>
<td>Manoli, P</td>
<td>F028</td>
</tr>
<tr>
<td>Marcelis, W</td>
<td>F025</td>
</tr>
<tr>
<td>Marechal, M</td>
<td>S082</td>
</tr>
<tr>
<td>Marques-Neves, C</td>
<td>3661</td>
</tr>
<tr>
<td>Martinez, M</td>
<td>F038, F114</td>
</tr>
<tr>
<td>Martinozzi, A</td>
<td>2362</td>
</tr>
<tr>
<td>Maschi, C</td>
<td>4443</td>
</tr>
<tr>
<td>Masset, M</td>
<td>4167</td>
</tr>
<tr>
<td>MatthysSEN, S</td>
<td>4168</td>
</tr>
<tr>
<td>Mauget-Faysse, M</td>
<td>2684</td>
</tr>
<tr>
<td>Medeiros Pinto, J</td>
<td>2154, 2335, F073</td>
</tr>
<tr>
<td>Mekki, MB</td>
<td>2375</td>
</tr>
<tr>
<td>Mendez, M</td>
<td>T064</td>
</tr>
<tr>
<td>Merayo-Lloves, J</td>
<td>2431</td>
</tr>
<tr>
<td>Messmer, EM</td>
<td>2833</td>
</tr>
<tr>
<td>Metz, G</td>
<td>F024</td>
</tr>
<tr>
<td>Michael, R</td>
<td>2182</td>
</tr>
<tr>
<td>MichalewskA, Z</td>
<td>2111, 2153</td>
</tr>
<tr>
<td>Milla, E</td>
<td>2123</td>
</tr>
<tr>
<td>Millan, M</td>
<td>2183</td>
</tr>
<tr>
<td>Miniewicz, J</td>
<td>2152</td>
</tr>
<tr>
<td>Mione, M</td>
<td>3314</td>
</tr>
<tr>
<td>Missotten, L</td>
<td>1611</td>
</tr>
<tr>
<td>Mohan, R</td>
<td>1513</td>
</tr>
<tr>
<td>Montazi, L</td>
<td>S036, S037</td>
</tr>
<tr>
<td>Montero Moreno, J</td>
<td>1542, F051, F101</td>
</tr>
<tr>
<td>Moon, D</td>
<td>S085</td>
</tr>
<tr>
<td>Moore, T</td>
<td>3172</td>
</tr>
<tr>
<td>Moosang, K</td>
<td>F029, F055</td>
</tr>
<tr>
<td>Moschos, M</td>
<td>1312</td>
</tr>
<tr>
<td>Moulin, A</td>
<td>2752</td>
</tr>
<tr>
<td>Mouriaux, F</td>
<td>2651</td>
</tr>
<tr>
<td>Mrukwa-Kominek, E</td>
<td>S054</td>
</tr>
<tr>
<td>Mun, S</td>
<td>F106</td>
</tr>
<tr>
<td>Munier, F</td>
<td>3546</td>
</tr>
<tr>
<td>Munoz-Negrete, FJ</td>
<td>1557, F001, F023, T035</td>
</tr>
<tr>
<td>Munoz, M</td>
<td>2122, T028</td>
</tr>
<tr>
<td>Naessens, S</td>
<td>4461</td>
</tr>
<tr>
<td>NagaoKA, T</td>
<td>1111</td>
</tr>
<tr>
<td>Nakai, K</td>
<td>3672</td>
</tr>
<tr>
<td>Nau, C</td>
<td>2372</td>
</tr>
<tr>
<td>Neri, P</td>
<td>1133, 1534, 2311, 3361</td>
</tr>
<tr>
<td>Ness, C</td>
<td>S088</td>
</tr>
<tr>
<td>Noer, A</td>
<td>S039</td>
</tr>
<tr>
<td>Normando, EM</td>
<td>2621</td>
</tr>
<tr>
<td>Nowinska, A</td>
<td>2131</td>
</tr>
<tr>
<td>Nubile, M</td>
<td>2312</td>
</tr>
<tr>
<td>Obis, J</td>
<td>F012, F013</td>
</tr>
<tr>
<td>ochiai, H</td>
<td>S074</td>
</tr>
<tr>
<td>Olafsdottir, OB</td>
<td>T095</td>
</tr>
<tr>
<td>Olmiere, C</td>
<td>S080</td>
</tr>
<tr>
<td>Osborne, N</td>
<td>2643, 2644</td>
</tr>
<tr>
<td>Oshitari, T</td>
<td>F089</td>
</tr>
<tr>
<td>Ozimek, M</td>
<td>3321</td>
</tr>
<tr>
<td>Ozturk, N</td>
<td>F027</td>
</tr>
<tr>
<td>Panfoli, I</td>
<td>T105</td>
</tr>
<tr>
<td>Papastefanou, V</td>
<td>S093</td>
</tr>
<tr>
<td>Pappas, G</td>
<td>1315</td>
</tr>
<tr>
<td>paraqan, L</td>
<td>2171</td>
</tr>
<tr>
<td>Park, J</td>
<td>S063</td>
</tr>
<tr>
<td>Park, YG</td>
<td>F088</td>
</tr>
<tr>
<td>Paterno, J</td>
<td>S003, S005, S014</td>
</tr>
<tr>
<td>Pazos, M</td>
<td>2321</td>
</tr>
<tr>
<td>Pabay, A</td>
<td>3524</td>
</tr>
<tr>
<td>Pedrosa, AC</td>
<td>3322</td>
</tr>
<tr>
<td>Perestrelo, S</td>
<td>F066</td>
</tr>
<tr>
<td>Name</td>
<td>Code(s)</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>------------------------------</td>
</tr>
<tr>
<td>Perez Navarro, I</td>
<td>S045, S056</td>
</tr>
<tr>
<td>Petrenko, O</td>
<td>S072</td>
</tr>
<tr>
<td>Petrovski, G</td>
<td>3174</td>
</tr>
<tr>
<td>Peynishaert, K</td>
<td>K: 1342, 4462</td>
</tr>
<tr>
<td>Pica, A</td>
<td>4441</td>
</tr>
<tr>
<td>Pierrson e, B</td>
<td>2181</td>
</tr>
<tr>
<td>Pientucha-Dutczak, M</td>
<td>T052</td>
</tr>
<tr>
<td>Pinna, A</td>
<td>S059</td>
</tr>
<tr>
<td>Pinto Proença, R</td>
<td>2334</td>
</tr>
<tr>
<td>Plainis, S</td>
<td>1311</td>
</tr>
<tr>
<td>Pleyer, U</td>
<td>U: 1134, 1151, 1332, 3574</td>
</tr>
<tr>
<td>Ponomarenko, M</td>
<td>F052, F054</td>
</tr>
<tr>
<td>Popa Cherecheanu, A</td>
<td>A: S110, T056</td>
</tr>
<tr>
<td>Pournaras, C</td>
<td>C: 1113, 2715, 3116, 3512</td>
</tr>
<tr>
<td>Pournaras, J</td>
<td>J: 1313, 3515</td>
</tr>
<tr>
<td>Prieto, P</td>
<td>2781</td>
</tr>
<tr>
<td>Pruente, C</td>
<td>2714</td>
</tr>
<tr>
<td>Qi, X</td>
<td>2352</td>
</tr>
<tr>
<td>Quinlan, R</td>
<td>R: 3381</td>
</tr>
<tr>
<td>Quince, S</td>
<td>S053</td>
</tr>
<tr>
<td>Qureshi, S</td>
<td>S4144, S091</td>
</tr>
<tr>
<td>Rahmania, N</td>
<td>N: F033</td>
</tr>
<tr>
<td>Ramireza, I</td>
<td>I: T030</td>
</tr>
<tr>
<td>Ransom, B</td>
<td>B: 3624</td>
</tr>
<tr>
<td>Rebolleda, G</td>
<td>G: F011, T058, T063</td>
</tr>
<tr>
<td>Remaut, K</td>
<td>K: 2143</td>
</tr>
<tr>
<td>Remond, A</td>
<td>A: S068</td>
</tr>
<tr>
<td>Ricouard, F</td>
<td>F102</td>
</tr>
<tr>
<td>Robson, A</td>
<td>A1123</td>
</tr>
<tr>
<td>Rocha de Sousa, A</td>
<td>A: 1563, 3566, F049, T007</td>
</tr>
<tr>
<td>Rodrigo, MJ</td>
<td>M: F006, F022</td>
</tr>
<tr>
<td>Roels, D</td>
<td>D: T012</td>
</tr>
<tr>
<td>Roemer, S</td>
<td>S: 1551</td>
</tr>
<tr>
<td>Rojas Lozano, MP</td>
<td>MP: F002</td>
</tr>
<tr>
<td>Romanowska Dixon, MB</td>
<td>MB: F068, S090, S102</td>
</tr>
<tr>
<td>Rouland, JF</td>
<td>JF: 1526, T033</td>
</tr>
<tr>
<td>Rousseau, A</td>
<td>A: 3375</td>
</tr>
<tr>
<td>Rozet, J</td>
<td>J: 2664</td>
</tr>
<tr>
<td>Ruiters, S</td>
<td>S: 1377, S021</td>
</tr>
<tr>
<td>Rupenthal, ID</td>
<td>ID: 2141</td>
</tr>
<tr>
<td>Saakyan, S</td>
<td>S: 2757, 3643, 3645, S097, S104</td>
</tr>
<tr>
<td>Sagong, M</td>
<td>M: F110</td>
</tr>
<tr>
<td>Saguett, P</td>
<td>P: T108</td>
</tr>
<tr>
<td>Saim, D</td>
<td>D: 4433</td>
</tr>
<tr>
<td>Saksonov, S</td>
<td>S: 2114</td>
</tr>
<tr>
<td>Salobrar-Garcia, E</td>
<td>E: F017, F018</td>
</tr>
<tr>
<td>Salvi, M</td>
<td>M: 2634</td>
</tr>
<tr>
<td>Salviat, F</td>
<td>F: F046</td>
</tr>
<tr>
<td>Sanchez Marin, Ji</td>
<td>Ji: F056, S044</td>
</tr>
<tr>
<td>Sandberg Melin, C</td>
<td>C: T062</td>
</tr>
<tr>
<td>Sapeta, S</td>
<td>S: 1572</td>
</tr>
<tr>
<td>Satue, M</td>
<td>M: F007, F008</td>
</tr>
<tr>
<td>Schalenbourg, A</td>
<td>A: 3542</td>
</tr>
<tr>
<td>Schmetterer, L</td>
<td>L: 1411, 2642</td>
</tr>
<tr>
<td>Schmidl, D</td>
<td>D: 1573, 3662</td>
</tr>
<tr>
<td>Schwarz, N</td>
<td>N: 2761</td>
</tr>
<tr>
<td>Scott, A</td>
<td>A: 1321</td>
</tr>
<tr>
<td>Sepetis, A</td>
<td>A: T077</td>
</tr>
<tr>
<td>Shahdadfar, A</td>
<td>A: 3173</td>
</tr>
<tr>
<td>Shalaby, A</td>
<td>A: F105</td>
</tr>
<tr>
<td>Shih, KC</td>
<td>KC: 1163</td>
</tr>
<tr>
<td>Shin, KS</td>
<td>KS: F072, S067</td>
</tr>
<tr>
<td>Shin, Y</td>
<td>Y: F032, T080</td>
</tr>
<tr>
<td>Shizadeh, S</td>
<td>S: F041, S058</td>
</tr>
<tr>
<td>Silvester, A</td>
<td>A: 2155, F048</td>
</tr>
<tr>
<td>SimcooK, P</td>
<td>P: 1314</td>
</tr>
<tr>
<td>Sjostrand, J</td>
<td>J: S019</td>
</tr>
<tr>
<td>SkalicK, P</td>
<td>P: T072</td>
</tr>
<tr>
<td>Skytt, D</td>
<td>D: 1372</td>
</tr>
<tr>
<td>Smedowski, A</td>
<td>A: 2132, T051</td>
</tr>
<tr>
<td>Smets, M</td>
<td>M: S107</td>
</tr>
<tr>
<td>Smith, R</td>
<td>R: 1122, 1125</td>
</tr>
<tr>
<td>Soderberg, P</td>
<td>P: 3161</td>
</tr>
<tr>
<td>Sonner, J</td>
<td>J: 2733</td>
</tr>
<tr>
<td>Soubrane, G</td>
<td>G: 3113</td>
</tr>
<tr>
<td>Souza Neves, F</td>
<td>F: 1545, T065</td>
</tr>
<tr>
<td>Souza, F</td>
<td>F: 2151</td>
</tr>
<tr>
<td>Sozen-Delil, Fi</td>
<td>Fi: 1565, F080, F111</td>
</tr>
<tr>
<td>Spileers, W</td>
<td>W: 2161</td>
</tr>
<tr>
<td>Stachs, O</td>
<td>O: 1574</td>
</tr>
<tr>
<td>Stuehr Jakobsen, N</td>
<td>N: F087</td>
</tr>
<tr>
<td>Stalmans, I</td>
<td>I: 3121</td>
</tr>
<tr>
<td>Stangos, A</td>
<td>A: 3511, T022</td>
</tr>
<tr>
<td>Stappler, T</td>
<td>T: 1316</td>
</tr>
<tr>
<td>Stefansson, E</td>
<td>E: 3535, 3572</td>
</tr>
<tr>
<td>Stone, D</td>
<td>D: T026</td>
</tr>
<tr>
<td>Strupait, R</td>
<td>R: T067</td>
</tr>
<tr>
<td>Suarez, S</td>
<td>S: 0661</td>
</tr>
<tr>
<td>Suleiman, E</td>
<td>E: T019</td>
</tr>
<tr>
<td>Sullivan, D</td>
<td>D: 2831</td>
</tr>
<tr>
<td>Sunaric Megevand, G</td>
<td>G: 1323, 1324</td>
</tr>
<tr>
<td>Suzuki, N</td>
<td>N: 2687, 3565, F059</td>
</tr>
<tr>
<td>Szaflik, JP</td>
<td>JP: F065, T053</td>
</tr>
<tr>
<td>Szentmary, N</td>
<td>N: 4123, 4421</td>
</tr>
<tr>
<td>TalebiZadeh, N</td>
<td>N: 3163</td>
</tr>
<tr>
<td>Tarutta, E</td>
<td>E: S028, T002</td>
</tr>
<tr>
<td>Tassinong, MJ</td>
<td>MJ: 2712, 4211</td>
</tr>
<tr>
<td>Thompson, D</td>
<td>D: 1121, 3563</td>
</tr>
<tr>
<td>Thuret, G</td>
<td>G: 2313</td>
</tr>
<tr>
<td>Timsit, A</td>
<td>A: S029</td>
</tr>
<tr>
<td>Tiranti, V</td>
<td>V: 2423</td>
</tr>
<tr>
<td>Toft-Kehler, AK</td>
<td>AK: T048</td>
</tr>
<tr>
<td>Toth, M</td>
<td>M: T021</td>
</tr>
<tr>
<td>Touitou, V</td>
<td>V: 2613</td>
</tr>
<tr>
<td>Tripoli, G</td>
<td>G: 1524</td>
</tr>
<tr>
<td>Tunc, M</td>
<td>M: 2652, 2754, 4447, S100, S106</td>
</tr>
<tr>
<td>Turck, N</td>
<td>N: 1345, 1346, T103</td>
</tr>
<tr>
<td>Turunen, J</td>
<td>J: 4141, S087</td>
</tr>
</tbody>
</table>
ULLRICH, F: 3134, 3534
UUSITALO, H: 1171, 2774
VALGAEREN, H: 4463
VAN CALSTER, J: 3362, 3363
VAN DEN BOGERD, B: 4465
VAN GINDERDEUREN, R: 3364, 4445
VAN KEER, K: 1167, 2384, 4466, T057
VAN SCHIL, K: 4467
VANACKER, S: 4464
VANDEWALLE, E: 1527, 3125, T036
VEGA-ESTRADA, A: 2185
VIDAL-SANZ, M: 2324
VIGNAL-CLERMONT, C: 1553
VILADES, E: F009, F010
VIOTTE, A: F067
VOHRA, R: 1373
VOTRUBA, M: 3211
WAAGEPETERSEN, H: 3621
WAIZEL, M: F040
WALPERT, M: 2622
WEGENER, A: 3162
WEI, X: T088
WERKMEISTER, R: 1114, 1571
WILLEKENS, K: 1566, 3664, 4468, T055
WILLERMAIN, F: 1331, 2612
WOZNIAK, P: 2386, T092
WYLEGALA, E: 2135, 4124, 4424
YAZGAN, S: T014
YEKTA, AA: T001, T084
YIM, B: S040
YU-WAI-MAN, P: 2365
YU, Z: 3164
ZADOROZHNYY, O: S095, T099
ZENG, J: 3562
ZHANG, H: 3632
ZHANG, K: 2783
ZHANG, X: 3583
ZOGRAFOS, L: 2345, 3117, 3543
ZSOLT NAGY, Z: 4125
All authors of abstracts are listed alphabetically.

One letter and three digit numbers refer to posters.

Four digit numbers refer to oral presentations.

The digit numbers marked in bold indicate a first author abstract.
All Authors

VASSEUR, V: 2684
VAVLA, M: 2362
VAZ-PEREIRA, S: 1545, 2335, F073
VÁZQUEZ-ALFAGEME, C: S093
VAZQUEZ, LE: 1524
VEGA-ESTRADA, A: 2185
VEGA, F: 2183
VEGA, Z: T028
VERMORGEN, K: 1527, T036
VERSTRAETEN, T: 1541
VERTICCHIO VERCHELIN, AC: F039
VIAUD-QUENTRIC, K: S080
VIBEK, J: 1522
VICENTE, A: 2334, 3327, F078
VIDAL-SANZ, M: 2324
VIEIRA, L: 3328, F079, T015
VIESTENZ, A: S089
VIGNAL CLERMONT, C: 1553
VIKATMAA, L: F109
VIKATMAA, P: F109
VILADES PALOMAR, E: F014, F015
VILADES, E: F003, F004, F006, F007, F008, F022, F009, F010
VILLADES, E: F012, F013
VILLEGAS-PEREZ, MP: 2324
VILLOTA, E: T073
VIOTTI, A: F067
VITOVSKA, O: 2114
VOHRA, R: 1372, 1373
VOKSANYAN, L: 3123
VOTRUBA, M: T071
VOTRUBA, MJAU: 3211
VUJORINEN, I: S003
WAAGEPETERSEN, H: 3621
WAGNER, H: 4441
WAIZEL, M: F040
WAJCZAK, A: T053
WALCZAK, M: 2622
WALRAEDT, S: 3582
WALSER, M: 4441
WANG, S: 2783
WARMOUTH, SF: 1341
WEBER, BH: T081
WEBER, DC: 4441
WEBSTER, A: 3581
WECHSLER, B: 1555
WEGENER, A: 3162
WEGER, M: 2893
WEI, X: T088
WELLMAN, J: 1514
WERKMEISTER, R: 1114, 1571
WERKMEISTER, RM: 2386, T092
WIDDOWSON, P: 1165, T049
WILLEKENS, K: 1167, T057, 1566, 3664, T055
WILLERMAIN, F: 3371, 3373, 3374, 1331, 2612
WILLIAMS, K: T074
WILSKA, R: 4141, S087
WITKOWSKA, KJ: 2386, T092
WOLFF, B: 2684
WONG, B: 1112
WONG, D: 1561
WONG, R: 3524
WONG, T: 1166, T018, T038
WOZNIAK, PA: 2386, T092
WU, J: 1561
WU, JJ: 3381
WURST, W: 3382
WYLEGALA, E: 2132, 4124, 4424
XEROUDAKI, M: 3633
XIE, Q: 2351

YAGI, N: 2181
YAGMUR, M: S051
YAHIAOUI, S: 2375
YAMAMOTO, S: F089
YAMANE, K: 2687, 3565, F059
YAN, L: 3562
YAN, X: 3566
YAN, Y: 2783
YANG, C: 3562
YANG, H: 2321
YANG, SJ: F103
YANG, X: 3562
YANG, YR: S057
YANG, Z: T038
YASIN, N: 2141
YAVUZYIGITOGLU, S: 4142
YAZDANI, N: S030, T001
YAZGAN, S: T014
YEKTA, AA: T001, T084
YEKTA, R: T001
YIM, B: S063, S040
YOKOI, N: 2677, S022
YOO, C: T060
YOU, Y: S085
YU-WAI-MAN, P: 2365
YU, M: S368
YU, Z: 3161, 3163, S075, 3164
YU, ZF: 1514
YUBERO, R: F017, F018
ZADOROZHNYY, O: S095, T099
ZAGORSKI, Z: S051
ZAMBARAKJI, H: 2336, F075
ZAMBRANO, I: S109
ZEITZ, C: T069
ZELL THIME, H: S036, S037
ZENG, J: 3562
ZENOUDA, A: T039
ZEPPA, L: T023, T023
ZEREI, N: F093
ZHANG, H: 3632
ZHANG, J: 1341
ZHANG, K: 2783
ZHANG, X: 3583
ZHANG, L: 2783
ZHAO, Y: 2351
ZHENG, D: 2351
ZHU, J: 2789
ZHRAVLEV, A: T019
ZIMMERMANN, A: F102
ZIMMERMANN, ME: T081
ZITZELSBERGER, H: 3382
ZOGRAFOS, L: 2752, 4441, 2345, 3117, 3543
ZSOLT NAGY, Z: 4125
ZYGANOW, M: 3561
### Authors by Country

<table>
<thead>
<tr>
<th>Country</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALGERIA</td>
<td>2</td>
</tr>
<tr>
<td>AUSTRALIA</td>
<td>3</td>
</tr>
<tr>
<td>AUSTRIA</td>
<td>9</td>
</tr>
<tr>
<td>BELGIUM</td>
<td>47</td>
</tr>
<tr>
<td>CANADA</td>
<td>1</td>
</tr>
<tr>
<td>CHINA</td>
<td>2</td>
</tr>
<tr>
<td>CYPRUS</td>
<td>1</td>
</tr>
<tr>
<td>CZECH REPUBLIC</td>
<td>6</td>
</tr>
<tr>
<td>DENMARK</td>
<td>16</td>
</tr>
<tr>
<td>FINLAND</td>
<td>15</td>
</tr>
<tr>
<td>FRANCE</td>
<td>77</td>
</tr>
<tr>
<td>GERMANY</td>
<td>23</td>
</tr>
<tr>
<td>GREECE</td>
<td>5</td>
</tr>
<tr>
<td>HONG KONG, CHINA</td>
<td>1</td>
</tr>
<tr>
<td>HUNGARY</td>
<td>2</td>
</tr>
<tr>
<td>ICELAND</td>
<td>5</td>
</tr>
<tr>
<td>INDIA</td>
<td>2</td>
</tr>
<tr>
<td>IRAN</td>
<td>3</td>
</tr>
<tr>
<td>IRELAND</td>
<td>3</td>
</tr>
<tr>
<td>ISRAEL</td>
<td>2</td>
</tr>
<tr>
<td>ITALY</td>
<td>24</td>
</tr>
<tr>
<td>JAPAN</td>
<td>9</td>
</tr>
<tr>
<td>LITHUANIA</td>
<td>2</td>
</tr>
<tr>
<td>NETHERLANDS, THE</td>
<td>3</td>
</tr>
<tr>
<td>NEW ZEALAND</td>
<td>2</td>
</tr>
<tr>
<td>NORWAY</td>
<td>8</td>
</tr>
<tr>
<td>POLAND</td>
<td>17</td>
</tr>
<tr>
<td>PORTUGAL</td>
<td>19</td>
</tr>
<tr>
<td>ROMANIA</td>
<td>1</td>
</tr>
<tr>
<td>RUSSIA</td>
<td>9</td>
</tr>
<tr>
<td>SAUDI ARABIA</td>
<td>4</td>
</tr>
<tr>
<td>SINGAPORE</td>
<td>6</td>
</tr>
<tr>
<td>SLOVENIA</td>
<td>1</td>
</tr>
<tr>
<td>SOUTH-KOREA</td>
<td>35</td>
</tr>
<tr>
<td>SPAIN</td>
<td>45</td>
</tr>
<tr>
<td>SWEDEN</td>
<td>15</td>
</tr>
<tr>
<td>SWITZERLAND</td>
<td>24</td>
</tr>
<tr>
<td>TAIWAN</td>
<td>1</td>
</tr>
<tr>
<td>TUNISIA</td>
<td>6</td>
</tr>
<tr>
<td>TURKEY</td>
<td>11</td>
</tr>
<tr>
<td>UKRAINE</td>
<td>7</td>
</tr>
<tr>
<td>UNITED KINGDOM</td>
<td>70</td>
</tr>
<tr>
<td>UNITED STATES</td>
<td>13</td>
</tr>
<tr>
<td>Time</td>
<td>Session/Activity</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>11:30 - 13:00</td>
<td>PBPRV - Retinal perfusion imaging</td>
</tr>
<tr>
<td>14:00 - 15:30</td>
<td>RV - Management of Aphakia</td>
</tr>
<tr>
<td></td>
<td>G - The ideal glaucoma rotation</td>
</tr>
<tr>
<td>15:40 - 16:00</td>
<td>Coffee break</td>
</tr>
<tr>
<td>16:00 - 16:30</td>
<td>EVER Past President lecture: Lessons from the Fascinating World of Bestrophinopathies - LEROY B</td>
</tr>
<tr>
<td>16:30 - 16:50</td>
<td>Coffee break</td>
</tr>
<tr>
<td>16:50 - 18:20</td>
<td>MBGERV - Advances in gene-based therapies for ocular disorders</td>
</tr>
<tr>
<td></td>
<td>G - FP session - New technologies in glaucoma</td>
</tr>
<tr>
<td></td>
<td>IM - Inflammatory versus non-inflammatory posterior segment diseases</td>
</tr>
<tr>
<td></td>
<td>RV - FP session - Surgery I</td>
</tr>
<tr>
<td></td>
<td>NSPH - FP session - Neuro-ophthalmology and paediatric ophthalmology</td>
</tr>
<tr>
<td></td>
<td>RV - FP session - Surgery II</td>
</tr>
<tr>
<td></td>
<td>PBP - High-resolution imaging of the anterior eye segment</td>
</tr>
<tr>
<td>18:35 - 19:00</td>
<td>European Ophthalmology Heritage Lecture: Magnificat - MISSOTTEN L</td>
</tr>
<tr>
<td>19:00 - 19:30</td>
<td>Keynote Lecture: Developing new treatments for inherited retinal degenerations - MACLAREN R</td>
</tr>
<tr>
<td>19:30 - 21:30</td>
<td>EVER Welcome Reception</td>
</tr>
<tr>
<td>08:30 - 10:00</td>
<td>RV - Diabetic retinopathy</td>
</tr>
<tr>
<td></td>
<td>G - You tube: different tubes for different glaucomias</td>
</tr>
<tr>
<td></td>
<td>DUCK S - MILLA E</td>
</tr>
<tr>
<td>10:00 - 10:20</td>
<td>Coffee break</td>
</tr>
<tr>
<td>10:20 - 10:50</td>
<td>EVER Acta Lecture: The pathogenic role of LR1G in ocular neovascularisation: From discovery to targeted therapy - GREENWOOD J</td>
</tr>
<tr>
<td>11:00 - 12:30</td>
<td>IM - OCT in inflammatory ocular diseases: beneath and beyond the retina</td>
</tr>
<tr>
<td></td>
<td>G - Mathematical modelling in glaucoma</td>
</tr>
<tr>
<td></td>
<td>VIDAL-SANZ M - CORDEIRO MF</td>
</tr>
<tr>
<td></td>
<td>RV - FP session - Diabetes</td>
</tr>
<tr>
<td></td>
<td>SOUBRANE G - COSCAS F</td>
</tr>
<tr>
<td></td>
<td>PO VR - Mistakes in the diagnosis of fundus tumors</td>
</tr>
<tr>
<td></td>
<td>DESJARDINS L - ZOGRAFOS L</td>
</tr>
<tr>
<td></td>
<td>LC - FP session - Lens and cataract</td>
</tr>
<tr>
<td></td>
<td>ZHANG K - MAKLEY L</td>
</tr>
<tr>
<td></td>
<td>NSPH - Hot topic in ocular surface in children</td>
</tr>
<tr>
<td></td>
<td>BOSCH-1A - BALDENSCH L</td>
</tr>
<tr>
<td></td>
<td>LC - Lens and IOL optics and accommodation</td>
</tr>
<tr>
<td></td>
<td>OSBORNE N - GARHOFER G</td>
</tr>
<tr>
<td>13:40 - 14:40</td>
<td>Industry-sponsored lunchtime symposium: Demodec: innocent or guilty in blepharitis? - JAMSTE</td>
</tr>
<tr>
<td>14:30 - 16:00</td>
<td>Keynote Lecture: Medical science and clinical research in corneal regenerative medicine - KNOSITAS</td>
</tr>
<tr>
<td>16:00 - 17:00</td>
<td>Poster session 1: Electrophysiology, Physiological Optics, Vision Sciences</td>
</tr>
<tr>
<td></td>
<td>Glaucoma</td>
</tr>
<tr>
<td></td>
<td>Molecular Biology / Genetics / Epidemiology</td>
</tr>
<tr>
<td></td>
<td>Physiology / Biochemistry / Pharmacology</td>
</tr>
<tr>
<td>17:00 - 18:30</td>
<td>RV - Controversies in vitreoretinal practice</td>
</tr>
<tr>
<td></td>
<td>G - Laser - the force reawakens. New concepts in established technology</td>
</tr>
<tr>
<td></td>
<td>CRAWLEY L - BLOOM F</td>
</tr>
<tr>
<td></td>
<td>G - YOS for EVER - young ophthalmologist scientists</td>
</tr>
<tr>
<td></td>
<td>JÖHANNESSEN G</td>
</tr>
<tr>
<td></td>
<td>NSPH - Hot topic in ocular surface in children</td>
</tr>
<tr>
<td></td>
<td>BREMONT-GNAC D - ATILLA H</td>
</tr>
<tr>
<td></td>
<td>PO - FP session</td>
</tr>
<tr>
<td></td>
<td>MGBE/NSPH - Syndromic retinopathies</td>
</tr>
<tr>
<td></td>
<td>LISKOVA P</td>
</tr>
<tr>
<td>18:30 - 20:00</td>
<td>Modern understanding of dry eye</td>
</tr>
<tr>
<td></td>
<td>SULLIVAN DA</td>
</tr>
<tr>
<td>HERMES</td>
<td>RHODES 1</td>
</tr>
<tr>
<td>--------</td>
<td>---------</td>
</tr>
<tr>
<td><strong>Friday, October 7, 2016</strong></td>
<td></td>
</tr>
<tr>
<td><strong>08:30 - 10:00</strong></td>
<td><strong>RV</strong> - Confrontation of OCT-angiography and fluorescence angiography</td>
</tr>
<tr>
<td><strong>10:10 - 10:40</strong></td>
<td>Keynote Lecture: <strong>OPA1 gene and mitochondrial optic neuropathy: disease mechanisms and potential therapies</strong> - <strong>VOTRUBA M</strong></td>
</tr>
<tr>
<td><strong>10:40 - 11:00</strong></td>
<td><strong>Coffee break</strong></td>
</tr>
<tr>
<td><strong>11:00 - 12:30</strong></td>
<td><strong>ARVO III</strong> - Animals in ocularg oncology</td>
</tr>
<tr>
<td><strong>12:30 - 13:30</strong></td>
<td></td>
</tr>
<tr>
<td><strong>13:30 - 15:00</strong></td>
<td><strong>RV</strong> - Retinal detachment</td>
</tr>
<tr>
<td><strong>15:00 - 16:00</strong></td>
<td><strong>Poster session 2: Neuro-ophthalmology / Strabismology / Paediatric/Ophthalmology</strong></td>
</tr>
<tr>
<td><strong>16:00 - 16:30</strong></td>
<td><strong>Business meeting RV</strong></td>
</tr>
<tr>
<td><strong>16:30 - 18:00</strong></td>
<td><strong>FAN Club Case presentations</strong></td>
</tr>
<tr>
<td><strong>18:00 - 18:30</strong></td>
<td><strong>EVER General Assembly</strong></td>
</tr>
</tbody>
</table>

| **Saturday, October 8, 2016** | | | | | | | |
| **08:30 - 10:00** | **NSPHRV - The first ones in ophthalmology** | **COS** - Keratoconus diagnosis and treatment in the clinical practice | **COS** - Corneal infectious diseases | **OOG Session 2 & Business Meeting** | **EUPO 5** Strabismus | | | **FR0 - Belgian Fund for Research in Ophthalmology - part 1** |
| **10:00 - 10:20** | **Coffee break** | | | | | | | |
| **10:20 - 10:50** | Ophthalmic Research Lecture: The cataract surgeon and the anterior interface - **TASSIGNON M-J** | | | | **EUPO 6** Strabismus | | **EUPO 6** Strabismus | **FR0 - Belgian Fund for Research in Ophthalmology - part 1** |
| **10:50 - 12:00** | **Poster session 3: Anatomy / Cell Biology / Cornea / Ocular Surface / Immunology / Microbiology** | | | | | | | **FR0 - Belgian Fund for Research in Ophthalmology - part 2** |
| **12:00 - 13:00** | **Lunchtime** | | | | | | | |
| **13:00 - 14:30** | **Women 4 EVER** | **COS** - Pseudophakic and phakic toric implants - from preoperative examination | **COS** - Maximising success in deep anterior lamellar keratoplasty | **OOG Session 3** | **EUPO 7** Strabismus | | | **FR0 - Belgian Fund for Research in Ophthalmology - part 2** |
| **14:30 - 15:00** | **Prize Award Ceremony & Closing Remarks** | | | | | | | |
EVER would like to thank all of its past and present sponsors. We would especially like to thank the following companies, many of which are our long-term supporters, for their generous sponsorship in 2016. Thanks to their kind support, EVER can continue to encourage research and dissemination of knowledge concerning the eye and vision by means of meetings, publications, and exchange of information.

EVER 2016 - programme book